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61. Abstract
Aims: We assessed the frequencies of C4A and C4B null alleles, and of low 
IgG subclass levels in the general population (II, III, IV) and in healthy 
blood donors without sinus problems (II). In a series of case-control studies, 
we tested whether genetic defi ciencies of C4, (C4 nulls, in studies I, II, III, 
IV), low IgG subclass levels (II, III), IgG1 and IgG3 allotypes (Gm, III), 
or HLA-A*, -B*, and DRB1* gene polymorphisms (I, III) are associated 
with recurrent herpetic gingivostomatitis (I), severe chronic or frequently 
recurrent rhinosinusitis (II), acute purulent rhinosinusitis (II), genital herpes 
patients with HSV-2 infection having at least 10 yearly recurrences for 
longer than 1 year aft er the fi rst clinical episode (III), or with severe chronic 
periodontitis (IV). We further aimed to assess whether any immunologic 
parameters found in the study patients associate with any complications 
of the diseases studied, or with any associated comorbidities (I, II, III). At 
the same time, we compared the applicability of a new polymerase chain 
reaction (PCR)-based quantitative analysis of C4A and C4B genes with the 
traditional C4A and C4B protein allotyping (II, III, IV).
Main methods: We recruited, with strict clinical disease criteria, consecutive 
patients and control subjects from the Division of Infectious Diseases 
(I, II, III), Vihti Health Care Center (II), from the dental offi  ces of three 
periodontists (IV), Vita Laboratories Ltd (II, III, IV), and Finnish Red 
Cross Transfusion Service (II). In the studies, aft er exclusion, 3 patients with 
herpetic gingivostomatitis (I), 48 patients with severe chronic or recurrent 
rhinosinusitis (II), 50 patients with acute purulent rhinosinusitis (II), 52 
patients with frequently recurrent genital HSV-2 infection (III), 37 patients 
with severe adult periodontitis (IV), 100 blood donors (II), and 150 subjects 
coming for health survey before accepting a new occupational post (II, III, 
IV) were included. Immunoglobulins (II, III), type-specifi c anti-HSV-2 IgG 
(I, III) and IgG subclass antibodies against glycoprotein G (III), IgG1 and 
IgG3 allotyping (III), levels of C3, C4, and complement classical pathway 
hemolytic activity (I, II, III, IV), C4 immunophenotyping (I, II, III, IV), C4 
real-time PCR-genotyping (II, III, IV), and HLA-A*, -B*, -DR*-typing (I, 
III) were performed.
Results: Patients with the rare chronic recurrent intraoral HSV-1 infection 
had HLA-A*, -B*, -C*, and -DRB1* homozygosity, together with total genetic 
defi ciency of complement component C4A or C4B. 
In chronic or recurrent rhinosinusitis patients (n = 48), low IgA, IgG, 
7IgG1, IgG2, IgG3, and IgG4 were all more common than in the general 
population (n = 150) and in those without known episodes of purulent 
rhinosinusitis (n = 48) combined. We searched for clinically relevant 
diff erences between patients with chronic or recurrent rhinosinusitis and 
those with non-recurrent uncomplicated acute purulent rhinosinusitis (n = 
50). According to stepwise logistic regression analysis, nasal polyposis (odds 
ratio, OR 10.64 [95% confi dence interval, CI 2.5-45.7] P = 0.001), bronchial 
asthma (8.87 [2.3-34.9] 0.002), C4A null alleles (5.84 [1.4-24.9] 0.017), and 
low levels of IgG4 together with either IgG1 or IgG2 (15.25 [1.4-166.8] 0.026) 
were more common in those with treatment-resistant rhinosinusitis than 
in acute rhinosinusitis patients. 
Compared with herpes simplex seronegative control subjects (n = 70), 
G3mg,G1ma/a(x), a haplotype that encodes the heavy chains of IgG3 and 
IgG1, was more frequent in the patients (P = 0.047). Th is haplotype has 
previously been associated with low IgG3 levels and with highly effi  cient 
immune evasion from IgG1 by HSV. Th e G3mg,G1ma/a(x) haplotype is thus a 
new genetic polymorphism associated with active genital herpes infection. 
Compared with the control subjects, low total IgG1 (4.9 [2.0-12.5] 0.001) 
and IgG3 (3.6 [1.7-7.8] 0.001), unlike anti-HSV-2 antibodies, were associated 
with frequent recurrences. Th e strongest statistical signifi cance was reached 
in the frequencies of low IgG or IgG3 or both between patients and HSV-
seronegative control subjects (7.9 [3.3-19.2] < 0.001). Low IgG1 was more 
common when all infected persons (patients and seropositive control 
subjects) were compared with seronegative subjects (4.0 [1.1-13.9] 0.030). 
C4 nulls were negatively associated with herpetic neuralgias (0.2 [0.06-0.81] 
0.022) and prolonged or chronic neuralgias (0.2 [0.05-0.57] 0.004). Certain 
HLA haplotypes and alleles were found more frequently in herpes patients 
and in control subjects. 
In severe chronic adult periodontitis, plasma levels of C3 were higher, 
and CH50 was lower in patients than in control subjects. Partial C4 gene 
defi ciencies were more frequent in patients than in control subjects (2.4 
[1.1-5.5] 0.032).
Conclusions: Both C4 nulls and low IgG subclass levels are common in 
the general population. C4 null alleles or low immunoglobulin G subclass 
levels or both were associated with recalcitrant mucosal infections. Changes 
in complement levels may refl ect chronic, recurring infl ammation. C4A 
defi ciencies are associated with chronic or recurrent rhinosinusitis, potentially 
through their eff ect on immune defense and infl ammation control. Isolated 
low IgG subclass levels had limited value in the assessment of patients with 
rhinosinusitis. 
HLA homozygosity, HLA alleles, the G3mg,G1ma/a(x) haplotype, and low 
plasma levels of ADCC-mediating IgG1 and IgG3 antibodies may predispose 
to recurrent herpes infections. C4 nulls are associated with protection from 
8herpetic neuralgias, potentially through reduced infl ammation. 
C4 defi ciencies are associated with predisposition to chronic periodontitis. 
Th e new real time PCR C4 genotyping test complemented the traditional 
C4 allotyping method. 
Partly, these fi ndings in patients may be explained by the immune 
evasion mechanisms employed by the causative microbes. C4 nulls may 
also regulate the degree of mucosal infl ammation. Since low IgG subclass 
levels are common in the adult population, our fi ndings directly infl uence the 
interpretation of subclass levels in the clinic. Th e found new immunogenetic 
polymorphisms associated with frequent mucosal infections may also 
infl uence, for example, vaccine development.
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3. Abbreviations
For clarity, those abbreviations used only in tables, clarifi ed in their footnotes, 
have not been included. When the name of a molecule listed below has been 
written in italics, it refers to the name of the corresponding gene (or gene 
region) according to the HUGO nomenclature. Some molecules and genes 
with commonly used abbreviations have not been abbreviated in the text. 
Th en, only for the fi rst time the term is used in the text, its abbreviation 
may follow in parenthesis.
ADCC antibody-dependent cellular cytotoxicity
AP alternative pathway of complement
APC antigen-presenting cell
ARS acute/intermittent (presumed bacterial) rhinosinusitis
BCR B cell receptor
BF factor B gene
C complement factor (e.g. C4 and C5)
C4bp C4b-binding protein
CH50 complement classical pathway hemolytic activity
CDR complementarity-determining region of an immunoglobulin heavy
 chain
CP  classical pathway of complement
CRS chronic rhinosinusitis
CRRS chronic or recurrent rhinosinusitis
CVID common variable immunodefi ciency
DC dendritic cell
f complement factor (e.g. fB)
FcR Fc receptor
GC germinal center
Gm immunoglobulin G heavy chain gene allotype
HIGM hyper-IgM syndrome
HLA human leukocyte antigen
HSV herpes simplex virus
IFN interferon
Ig immunoglobulin
IGH immunoglobulin heavy chain gene
Km allotypic allele of immunoglobulin light chain gene
LP lectin pathway of complement
LPS lipopolysaccharide
LT lymphotoxin
11
LTA lymphotoxin-α gene
MHC major histocompatibility complex
NK natural killer 
PAMP  pathogen-associated molecular pattern
PCR polymerase chain reaction
S-IgA secretory IgA
sIg surface immunoglobulin
SLE systemic lupus erythematosus
SCD immunoglobulin G subclass defi ciency
TCR T cell receptor
TD thymus-dependent
Th  T helper cell
TI thymus-independent
TLR Toll-like receptor
TNF tumor necrosis factor
TP terminal pathway of complement
VDJ recombined variable, diversity, and joining genes
vFcR viral Fc receptor
VH variable immunoglobulin heavy chain gene
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4. Introduction
To survive the harsh pressures of the environment, human beings like other 
organisms must be capable of defending themselves. Physical barriers, 
such as the skin and mucosal surfaces, tolerate harmless, non-invading, 
commensal organisms. Th ese aid us by competing with the more virulent 
microbes, and by keeping our mucosal surfaces alert and intact. Microbes 
around us act as friends or foes, whereas the immune system has to be able 
to recognize the diff erence.
At species level, the changing outside challenges have lead to the evolution 
of adaptive immunity. A highly developed immune system protects us from 
intrusion of extrinsic substances and organisms such as bacteria, viruses, 
fungi, and parasites. Th e adaptive arm of immunity is organized around T- 
and B-lymphocytes. Each lymphocyte displays a single type of receptor with 
unique specifi city. Human lymphocyte populations are large and diverse. Th is 
greatly heightens the probability of an individual lymphocyte to encounter 
a matching antigen. Aft er a non-self, off ending structure is found, clonal 
activation, proliferation, selection, and maturation of the adaptive immune 
response takes place. Th is will enable a quicker, concerted response during a 
rechallenge by the same or a closely related organism. Even so, it takes three 
to fi ve days for suffi  cient number of clones to be produced and to diff erentiate 
into eff ector cells.
Th e innate arm of immunity, by scanning for nonself structures 
and pathogen-associated molecular patterns (PAMP), is able to sense 
and instantly attack various microbes. Innate immunity also alerts and 
orchestrates multiple, less rapidly acting eff ector arms of immunity. Yet, 
during an individual’s life-span, innate immunity is incapable of adjusting 
to any major changes in the environment.
Gene mutations, duplications, and recombination events in germ line 
cells aid species to adapt their immunity. Structurally and functionally 
related genes governing the production of related proteins with specialized 
functions may emerge. Genomic changes are then handed down to further 
generations. Some of the best known examples are the immunoglobulin (Ig), 
major histocompatibility complex (MHC), complement, and immune-type 
receptor genes.
Within a chromosome, duplicated genes may be tightly linked and form 
relatively stable combinations called conserved haplotypes. Products of closely 
related genes within a haplotype, so called isotypes, enable diff erentiated 
functions within the immune system. Well known examples of isotypes are Ig 
subclasses such as IgG1 and IgG3, and complement component C4 isotypes 
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C4A and C4B. Th e genes of these isotypes may further go through series of 
mutations, resulting in polymorphisms. Between individuals, structurally 
slightly diff erent proteins with highly similar functions may then be encoded 
by the same gene. Th ese protein allotypes are commonly found in Igs (e.g. 
Gm1a and Gm1f) and in complement proteins (e.g. C4A3 and C4A1). 
Within the genome, deletions may occur and mutated non-expressed 
genes may arise. Clinically, this may manifest as an immunodefi ciency in an 
individual with severely impaired immune function. Over 90% of all adult 
primary immunodefi ciencies are caused by humoral immunodefi ciencies 
that lead to missing or very low levels of Igs or complement components. 
Depending on the genes aff ected and the types of mutations, changes in the 
eff ector protein levels and in the repertoire of available isotypes may ensue. 
For example, individuals normally have four copies of complement factor 
C4 (C4) genes in their genome, two of each isotype (C4A, C4B). Having 
only one gene copy (“C4 null allele” or “partial C4 defi ciency”) of either 
isotype may fail to aff ect the level of total C4 plasma concentration, but may 
lead to decreased levels of circulating isotype-specifi c C4. Activation of the 
immune system may also be excessive and cause hyper-infl ammation, such 
as seen in autoimmune diseases and in the systemic infl ammatory response 
syndrome during sepsis, sometimes associated with C4A null alleles. To avoid 
deleterious eff ects to the host, infl ammation has to be tightly regulated. Mild 
genetic defects and regulatory disturbances of the immune system, leading 
to lower eff ector protein levels, may thus be either harmful or benefi cial to 
the host.
Aft er the emergence of higher organisms, microbes have acquired means 
to evade the immunity of potential hosts. Microbes causing chronic or 
recurrent infections need to evade from the rapidly acting eff ector arms 
of the host’s immunity. Th eir ability to evade from diff erent isotypes and 
allotypes of complement factors and antibodies varies. In the clinical practice 
of infectious diseases, otherwise immunocompetent patients suff ering 
from a narrow spectrum of recurrent or chronic infections are commonly 
encountered. Hypothetically, this could be caused by multiple, subtle, and 
common defects in subjects’ immune system. Whether this predisposes the 
host to specifi c pathogens or clinical infectious syndromes is poorly known. 
Although subtly low levels of Igs and partial or total defi ciencies of some 
complement components are very common in the general population, the 
clinical consequences caused by these have rarely been studied.
Th e aim of this study was to explore whether common subtle immunologic 
defects such as C4 nulls, or low Ig class or subclass levels are associated 
with recurrent or chronic infections, or their complications. Since mucosal 
surfaces are exposed to frequent attacks by potentially pathogenic organisms, 
we decided to recruit patients who suff er from severe and complicated forms 
of common, usually mild or infrequent mucosal infections.
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5. Review of the literature
5.1 Complement system 
Th e eff ector mechanisms of innate immunity do not require previous contact 
with an antigen and are activated immediately. Major participants of innate 
immunity are epithelia, cytokines, chemokines, complement, antimicrobial 
peptides, phagocytes, natural killer (NK) cells, and Toll-like receptors. 
Together, they also help the adaptive immunity to diff erentiate self from 
non-self structures. Th is is accomplished by the use of germ line-encoded 
molecules recognizing PAMPs363.
In order to sense a wider repertoire of PAMP, complement has evolved 
into three distinct pathways: the alternative pathway (AP), the lectin pathway 
(LP), and the classical pathway (CP)378. Complement consists of at least 34 
circulating factors produced by diff erent cellular sources, and of at least 
14 diff erent complement receptors on various cell types (Tables 1.1 and 
1.2)150, 302. Additional collectins (surfactant protein A [SP-A] and D [SP-
D]), pentraxins (serum amyloid protein [SAP]), and galectins interact with 
complement. All three pathways are activated in a sequential manner, with 
the activation of one component leading to the activation of the next (Fig. 
1.1). Direct B-cell receptor and thrombin activation, as well as bypass-
pathways have also been described155, 324. During activation, several factors 
are cleaved. Th e resulting fragments are designated lowercase suffi  xes such as 
C3a and C3b. With the exception of C2, the smaller fragment is designated 
“a” and the larger “b”. Further fragments are designated consecutive lower 
case letters alphabetically (“C3d”), and inactivated products are marked by 
i (“iC3b”)378. Th e three pathways converge at the level of complement factor 
C3 (C3), which is the central protein of complement (Fig. 1.1)378.
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Figure 1.1 Complement pathways. 
Some of the smaller fragments released during activation are not shown. For 
abbreviations, functions, and ligands of individual molecules see Tables 1 and 2.
Complement has three main, partly overlapping physiologic activities. It 
readily defends us from invading organisms by opsonization, chemotaxis, 
activation of leukocytes, lysis of bacteria and cells, and formation of 
antimicrobial peptides (Table 1.3)378, 379. It also interacts with adaptive 
immunity: it augments antibody responses and enhances immunologic 
memory. Complement achieves this through CP and C3 activation, which 
also leads to disposal of immune complexes and apoptotic cells as part of the 
“scavenger” system (Tables 1.1 and 1.3)68, 301. Complement enhances B cell 
immunity mainly via complement receptors CD21 and CD35 (Table 1.2)68.
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1HC = hepatocytes, MNP = mononuclear phagocytes, EpiC = epithelial cells, EndoC = 
endothelial cells, AC = adipocytes, FB = fi broblasts, KC = keratinocytes, MB = myoblasts, GEC 
= gastrointestinal epithelial cells, GUC = genitourinary cells, SI = small intestine, T = testis, H 
= heart, L = lung, Plac= placenta, NP = neutrophils, AlvC = alveolar cells, AstroC = astrocytes, 
Kd = kidney, PMN = polymorphonuclear cells, PC = pneumocytes, MΦ = macrophages, MC 
= monocytes, TC = platelets, GC = glial cells, Mast = mast cells, Ery = erythrocytes, Eos = 
eosinophils, GlomP = glomerular podocytes, FDC = follicular dendritic cells, NK = natural killer 
cells, BP = basophils, LPC = liver parenchymal cells, SMC = smooth muscle cells, DC = dendritic 
cells, MesC = mesangial cells, RC = reticulocytes. 2RCA = regulator of complement activation. CP 
= classical pathway, AP = alternative pathway, MAC = membrane attack complex. Modifi ed from 
refs.150, 300.
Table 1.3 Complement functions
FUNCTION COMPLEMENT FACTORS AND 
MECHANISMS
Host defense against infection
Opsonization Covalently bound fragments of C3 and C4
Chemotaxis and leukocyte activation Anaphylatoxins C5a, C3a, C4a, and their 
leukocyte receptors
Generation of antimicrobial peptides C3a, C3a-desArg
Lysis of bacteria and cells Membrane-attack complex (C5b-C9)
Interface between adaptive and innate immunity
Regulation of antibody responses
Foreign antigen recognition
Self-antigen recognition
1. C3b and C4b bound to immune complexes 
and to antigen engage CD21-CD19-CD81 
coreceptor on B1 cells and enhance positive 
selection of B1 cells
2. Coligation of BCR and CD21-CD19-CD81 
coreceptor by C3- or C4- coated self-antigen 
induces anergy or apoptosis in bone marrow and 
at transitional stage
3. Antigen coupled to C3d activates naive mature 
follicular B cells through BCR and CD21-
CD19-CD81 coligation; with T cell help leads to 
activation and expansion of B cells
4. GC-formation initiated by activated B cells in 
FDC-organized splenic follicles; engaged CR on 
GC enhance BCR signaling
Enhancement of B cell memory Post-GC B cells require complement and antigen 
selection for the effi  cient maintenance of long-
term memory B cells
Regulation of T cell immunity Priming of CD4+ and CD8+ T cells by 
fragments of C3
Disposal of waste
Clearance of immune complexes from tissues C1q; covalently bound fragments of C3 and C4
Clearance of apoptotic and necrotic cells C1q, C4b, (i)C3b, MBL; together with IgM, 
collectins, and pentraxins
 
BCR = B cell antigen receptor, FDR = follicular dendritic cells, GC = germinal centers, CR = 
complement receptors, MBL = mannan-binding lectin, IgM = immunoglobulin M. Modifi ed from 
refs.68, 300, 378.
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5.1.1 Complement pathways and factors
Alternative pathway
While CP and LP are activated through their PAMP-sensing initiating factors, 
AP is kept at a low level of steady-state activation (“tick over”) through the 
spontaneous hydrolysis of the thioester group of native C3191. C3 is able to 
interact with over 20 diff erent proteins of complement and non-complement 
origin150. Various bacteria, fungi, viruses, and tumor cells activate AP378. 
Likewise, IgA and IgG2 can activate AP at high antigen concentrations85. Th e 
activation of C3 through AP requires three additional plasma proteins: factor 
B (fB), factor D (fD), and properdin (P). During activation, the metastable 
C3b fragment forms a properdin-stabilized C3bBb convertase with fB cleaved 
by fD. Th is leads to the cleavage and activation of additional C3 molecules363. 
Once C3 is activated through any of the pathways, the C3b fragment can 
bind covalently to the hydroxyl and amino groups of the activating structure. 
Th is leads to opsonization of foreign structures. Activation of the terminal 
pathway (TP) by the AP is achieved through C5 convertase C3bBbC3b. Th e 
smaller cleaved fragments C3a and C5a further act as anaphylatoxins. To 
avoid self-damage, the positive, continuously-activated feedback loop of AP 
needs to be tightly controlled (Table 1.2). Naturally occurring antibodies (at 
least of the IgG2 subclass) forming a complex with C3bC3b (C3b2-IgG) may 
also amplify AP212.
To be pathogenic, microbes need to produce various immune evasion 
molecules against AP161, 206, 299. Th ose bearing large amounts of surface sialic 
acid are usually poor activators of complement. Th ese include successful 
pathogens such as group A and B streptococci, Streptococcus pneumoniae, 
Neisseria meningitidis, Haemophilus infl uenzae type B, Escherichia coli K1, 
and some Salmonellae. Pathogens further escape the AP by exploiting, for 
example, host complement regulators and complement receptor analogues 
on their surfaces161, 206.
Lectin pathway
Th e main human PAMP recognition molecule of the LP is a collectin named 
mannan-binding lectin (MBL). Similar to its counterpart in the CP, C1q, 
MBL comprises three polypeptide chains forming a trimeric structure368. 
Th eir globular CRD heads recognize specifi c carbohydrate groups present 
on microbial surfaces, for example D-mannose, N-acetylglucosamine 
(GlcNAc), and N-acetylmannoseamine (Table 1.1)338. MBL recognizes 
various pathogenic organisms: Gram-positive, Gram-negative, and anaerobic 
bacteria, Mycobacterium avium, viruses like infl uenza A, herpes simplex 
virus 2, and human immunodefi ciency virus 1 and 2, as well as yeasts, 
fi lamentous fungi, and protozoa125, 159. 
In addition, plasma L- and H-fi colin, and locally secreted plasma soluble 
H- and M-fi colins in the airways are capable of initiating the LP. Th e basic 
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structure of fi colins is similar to MBL151. H-fi colin binds to GlcNAc and 
N-acetylgalactosamine, whereas L- and M-fi colins bind to N-acetylated 
carbohydrates and noncarbohydrate compounds on microbes and other 
surfaces (Table 1.1). L-fi colin binds to the capsules of serotype III group B 
streptococci, Streptococcus pneumoniae serotype 11F, and multiple serotypes 
of Staphylococcus aureus. H-fi colin agglutinates human erythrocytes coated 
with lipopolysaccharide (LPS) derived from Salmonella typhimurium, 
Salmonella minnesota, and Escherichia coli201. 
MBL and fi colin oligomers form complexes with MBL-associated serine 
proteases (MASP) (Table 1.1). Aft er binding to an activating structure, MBL/
MASP-2 and fi colin/MASP-2 complexes opsonize the target structure and 
activate the LP. MASP-2 then effi  ciently cleaves C4 and C2, which leads to the 
formation of the CP convertase C4b2a304, 361. Th e biologic roles of the other 
MASPs are unknown324. Th e LP also takes part in the clearance of dying and 
apoptotic cells. MBL defi ciencies are frequent in certain populations70.
Classical pathway
Classical pathway is activated by the binding of C1q to its target (Table 1.4). 
C1q has six subunits radiating like a bouquet of tulips, its overall structure 
thus resembles MBL and fi colins. Each of the subunits comprises three 
structurally related polypeptide units (A, B, C) with an N-terminal domain, 
a collagen-like sequence, and C-terminal globular domain (gC1q) (Table 
1.1)124. Th e globular domains of each polypeptide appear to be structurally 
and functionally independent178. In addition to immune complexes, various 
pathogens, infected cells, molecules, and cellular structures can bind C1q 
directly and initiate CP (Table 1.4). Since many diverse structures are 
recognized by C1q, it is likely to function as a charge-pattern recognition 
molecule124.
Antibody-dependent complement activation is initiated by C1q that 
recognizes IgM- or IgG-molecules bound with suffi  cient density to an 
antigen178. C1q binds to the Fc regions of IgM and IgG, i.e. to the Cμ3 
domain (Asp417-Glu418-His420) on IgM and the Cγ2 domain on IgG178, 
291. Th e binding sites of IgG1 and IgG3 diff er from each other178. In addition, 
the relative effi  ciency of IgG subclasses and Caucasian allotypes to bind C1q 
diff ers in the order: G3mg > G3mb > G1mf > G1ma >> IgG285, 291. Although 
IgG1 binds fewer C1 molecules, the deposition of C4b on the cell surface is 
much more effi  ciently mediated by IgG1 than by IgG3. Th us the effi  ciency to 
initiate complement-dependent cell lysis varies in the order: G1mf = G1ma 
> G3mb > G3mg >> IgG285, 291. Th e effi  ciency of classical pathway-mediated 
complement lysis also varies with antigen concentration. At higher antigen 
concentrations, IgG1 is more active than IgG3, whereas IgG3 is relatively 
more effi  cient at lower concentrations228. IgG2 initiates effi  cient lysis only at 
very high antigen concentrations. IgG4 does not fi x complement at all228.
C1q circulates in a complex with two C1r and two C1s molecules 
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(C1qr2s2), forming C1 (Table 1.1)124, 178. C1r and C1s have homologous 
modular architectures that resemble the structures of MASPs: an N-terminal, 
non-catalytic interaction domain that mediates C1r2s2-tetramer assembly, 
and a C-terminal catalytic serine protease domain17. Both domains take 
part in the interactions between the C1q collagen-like stems and the C1r2s2-
subcomplex124. Th e binding of C1q to a target via the C-terminal globular 
domain induces a conformational change in the collagen region of C1q124, 
178. Th is elicits the self-activation of C1r, a serine protease which, in turn, 
converts proenzyme C1s into a protease17, 124. C1s cleaves C4 and C2 in a 
highly specifi c manner126.
Figure 1.2 Schematic structure of C4. 
S-S represent the interchain disulphide bonds, a dashed line marks the C4d region.
When C4 is activated, a single arginyl bond at its C-terminus is cleaved, 
leading to the release of C4a (Fig. 1.2, Table 1.3). In the remaining C4b 
molecule, an internal thioester bond is exposed. Within a brief time period, 
and in the immediate vicinity of C1 at the surface of the activator, its acyl 
group becomes highly reactive with amino or hydroxyl groups. Although 
the binding of C4b is indiscriminate, complement regulators on normal 
cells prevent complement deposition and amplifi cation on their surfaces, 
providing self-nonself discrimination16. Attached C4b is then capable of 
binding C2 (Table 1.1). Binding by C4b renders C2 available for limited 
proteolysis by C1. Aft er C1s cleaves a single Arg-Lys bond, C2 splits into an 
N-terminal C2b fragment and a C-terminal catalytic fragment C2a126. C2a 
remains bound to C4b, and the classical pathway C3 convertase C4bC2a is 
formed. C4bC2a then cleaves C3, releasing the C3a fragment. C3a and C4a 
have similar functions (Table 1.3). A thioester on the remaining C3b fragment 
is exposed, and like C4b, C3b becomes capable of covalently binding to the 
nearby target surface. When C3b binds to C4bC2a, the classical pathway 
C5 convertase is formed, and the C2a subunit acquires specifi city for the 
cleavage of C516.
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Table 1.4 Examples of activators of the classical pathway
Class Activator
Immune complexes IgM-, IgG1-, IgG3-, (IgG2-)1 antigen complexes, CD209a-antigen complex2
Bacteria Escherichia coli, Salmonellae, Klebsiellae, Mycoplasma pneumoniae
Viruses Sindbis, Epstein-Barr, cytomegalovirus, human immunodefi ciency virus 1 and 2, 
human T lymphotropic virus, Paramyxoviridae
Parasites Schistosoma mansoni, Trypanosoma brucei
Cellular structures Cellular and subcellular membranes, apoptotic cells
Proteins C-reactive protein, myelin, β-amyloid peptide, serum amyloid protein A, prion 
proteins
Other molecules Oligosaccharides, polysaccharides, lipid A, cardiolipin, polyanions (DNA, 
heparin)
Ig = immunoglobulin. 1IgG2 fi xes complement weakly, see text. 2Described in mice. Modifi ed 
from refs.16, 362.
Terminal pathway
Th e TP is activated by C5 binding to C3b either as part of the AP (C3bBbC3b) 
or CP (C4bC2aC3b) C5 convertases336. C5 is cleaved into C5a and C5b. C5a 
acts as a chemotactic factor and an anaphylatoxin (Table 1.1). C5b then 
interacts with the terminal complement proteins in a nonenzymatic sequential 
association, resulting in the formation of the membrane attack complex 
(MAC). As each protein incorporates into the complex, a conformational 
rearrangement exposes a binding site for the next component. C5b-7 
becomes cell membrane-bound and binds C8. Th is allows C8α to become 
more deeply buried in the target cell membrane. C9 binds C8α, goes through 
a conformational change, and traverses the membrane336. Additional binding 
sites for C9 are exposed, and 12-18 C9 molecules may become incorporated 
into the C5b-C9 complex in a circular confi guration. A pore, able to function 
as a protein-walled channel and causing the loss of membrane integrity, 
is formed336. MAC then causes cell activation, or cell death through cell 
necrosis or apoptosis94, 336. Sublytic levels of C5b-9 promote cell survival 
and protect from apoptosis94.
Regulators of complement activity
Since complement is capable of attacking host cells as well as nonself 
structures, its activation must be confi ned to designated targets. Th is 
is accomplished by plasma soluble and membrane-bound regulators of 
complement activation (RCA) (see Tables 1.1 and 1.2 for details). AP is 
constantly activated at a low level and has a powerful positive feedback 
loop. Th us it needs to be tightly regulated. CP, being a linear cascade that is 
activated mostly by adaptive immunity or tissue destruction, is less tightly 
controlled. 
Regulation takes place at diff erent levels of complement pathways16. 
Properdin is the only known positive regulator of C, and stabilizes the AP 
C3 convertase. Most of the other RCA: membrane-bound regulators on 
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autologous cells including complement receptor 1 (CR1, CD35), decay 
accelerating factor (DAF, CD55), and membrane cofactor protein (MCP, 
CD46), as well as soluble regulators factor H, factor I, and factor H-like protein 
1 (FHL-1) inhibit mainly the C3 convertases by binding C4b and C3b16, 175, 
227. In addition, carboxypeptidases N and R (TAFI) inactivate anaphylatoxins 
and opsonins (Table 1.1). Vitronectin, clusterin, and protectin (CD59) inhibit 
MAC formation175. Various RCA proteins also regulate bradykinin and 
coagulation cascades175, 227. RCA are exploited by various pathogens; bacteria 
use RCA for cell entry and viruses have RCA homologues on their surfaces 
that prevent complement activation52, 188, 206, 239.
Only those RCA that regulate CP are discussed in more detail below. In 
addition, any RCA that inactivates C4 activation products may be viewed 
as a regulator of CP. Th ese include DAF, fI, its cofactor fH, MCP, and CR1 
that regulate the CP C3 convertase (Fig. 1.1)16, 175.
C1 inhibitor (C1inh), a serine protease inhibitor (serpin), is the only 
known serum inhibitor of C1 protease, MBL-MASP-2, as well as fi colin-
MASP-2 activities (Table 1.1)16. It also inactivates factors of the contact 
(factor XII, kallikrein), coagulation (factor XI, thrombin), and fi brinolytic 
(tPA, plasmin) systems. When C1inh is cleaved by activated C1s and C1r, 
its major fragment forms a covalent complex with the active site of the two 
proteases and renders the complex inactive83. C1inh, through non-covalent 
binding, prevents spontaneous C1 activation16, 227. 
C4b-binding protein (C4bp) is a potent inhibitor of CP and LP at the 
level of C3 convertase assembly. Its major plasma isoform, which constitutes 
approximately 80% of plasma C4bp, has seven identical α-chains and one β-
chain (Table 1.1). In circulation, all isoforms that contain the β-chain of C4bp 
circulate in a complex with an anticoagulatory protein, protein S52. C4bp 
prevents the assembly of the CP C3 convertase C4bC2a and accelerates its 
decay by promoting the dissociation and replacement of C2a from C4bC2a 
(Table 1.1). It is also a cofactor for factor I in the cleavage of C4b to C4c and 
C4d (Fig. 1.2). Via its interaction with the membrane-binding protein S, 
C4bp is able to localize its RCA activity to the surface of apoptotic cells. By 
interacting with CD40, it may also act as a survival factor for B cells52.
5.1.2 Complement factor C4
C4 structure and function
C4 is synthesized as a single-chain precursor (Table 1.1). Th e major polypeptide 
sequences of the C4 precursor show homology with α2-macroglobulin. In 
the central part of the molecule is a short anaphylatoxin motif. During 
proteolytic processing, a basic tetrapeptide is excised at the N-terminal end 
of the anaphylatoxin module, followed by a two-step removal of a 26-residue 
sequence16. Th e mature circulating protein has three chains (α, β, γ) linked 
by disulfi de bridges (Fig. 1.2). C4 has a metastable thioester site in its α-
25
chain. When C4 is activated by C1, a single arginyl bond at the C-terminus 
of the anaphylatoxin module is cleaved, leading to the release of C4a, a weak 
anaphylatoxin. C4b, the activated form of C4, then forms a covalent bond 
with either hydroxyl or amino groups on cell surface macromolecules or 
immune complexes. C4b and the cleaved N-terminal fragment C2a form 
the C3 convertase of CP. Bound C4b is also able to bind non-covalently to 
CR1 of phagocytes and thus acts as an opsonin16. 
C4 genes, isotypes, and allotypes
C4 is the most polymorphic protein of the complement system. Human 
C4 is encoded by a duplicated gene giving rise to the genes C4A and 
C4B, which lie 10 kb apart within the central, class III MHC region in 
chromosome 6 (Table 1.1). BF, C2, C4A, and C4B gene alleles together form 
a complotype9. Complotype SC01, for example, contains the polymorphic 
alleles BFS,C2C,C4AQ0,C4B1. Each C4 consists of 41 exons coding for a 
5.4 kb transcript. In Caucasians, ~ 75% of C4 genes harbor a 6.4 kb human 
endogenous retrovirus HERV-K(C4) that gives rise to long (L) variants. 
Th e long C4 gene is 20.6kb and the short (S) 14.2 kb. Moreover, 55% of 
Caucasian MHC haplotypes have a 2-locus, C4A-C4B confi guration, but 
45% have an unequal number of C4A and C4B genes (Fig. 1.3)51. Duplication 
of a C4 gene always concurs with the adjacent genes RP (a nuclear protein 
kinase), CYP21 (steroid 21-hydroxylase), and TNX (extracellular matrix 
protein tenascin X); together they form a genetic unit called RCCX (Fig. 
1.3). Monomodular, bimodular, and trimodular RCCX structures with one, 
two, and three C4 genes have population frequencies of 17%, 69%, and 14%, 
respectively51. Further, quadrimodular RCCX units with SLSL or LLLL 
structures and, for example, a trimodular RCCX with the homoexpression 
of C4A3 protein have been described. In duplicated RCCX units, RP, CYP21, 
and TNX genes between C4 genes are mostly nonfunctional. Over 24 diff erent 
RCCX haplotypes have been described in Caucasians. Consequently, there 
is great variation in the C4A and C4B gene dosages between individuals51. 
In a diploid genome, Caucasians have 2-6 C4 genes and about 52% of them 
four C4 genes. Having fewer than two functional C4A or C4B causes a low 
level of the corresponding C4 protein (C4Q0, “C4 null”) and is considered 
a defi ciency. C4 defi ciencies are caused by gene deletions, point mutations, 
insertions, or conversions51, 158. In Caucasians, a complete defi ciency of 
C4A is present in 3% and C4B in 8% of the population. Up to 35-40% of 
individuals have at least one null allele51. In the human genome, somewhat 
comparable variations in the number of immunologically active genes are 
only seen in two other complement genes MBL2 and C2, which also take 
part in LP and CP activation, respectively170, 361.
In the MHC region, genetic polymorphisms are oft en inherited as 
conserved, fi xed combinations resulting in linkage disequilibrium. Th is 
happens in ~ 50% of Caucasian MHC haplotypes9. C4 genes are also 
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inherited with these extended conserved (“ancestral”) MHC haplotypes 
together with other immunologically active genes such as candidate genes 
associated with CVID in human leukocyte antigen (HLA) region carrying 
HLA-DR (important in antigen presentation), and with complement and 
cytokine genes BF, C2, tumor necrosis factor (TNF), lymphotoxin α (LTA), 
and lymphotoxin β (LTB)9, 65. At least a third of common (frequency > 
0.01) European Caucasian haplotypes are fi xed from HLA-B through the 
complotype to HLA-DR/DQ. Th is extensive linkage equilibrium makes 
diffi  cult the determination of single, functionally relevant polymorphisms 
associated with diseases9, 67.
Th e two C4 isotypes C4A and C4B are more than 99% identical in primary 
amino acid sequence64. All mammals have C4B. C4A and C4B express 
diff erent, serotypically identifi able antigenic determinants. In general, C4A 
expresses the Rodgers, and C4B the Chido blood group determinants. Only 
four amino acids between 1101 and 1106 are specifi c to either C4A or C4B64. 
C4A binds predominantly to free amino groups, and C4B preferentially to 
hydroxyl groups. Consequently, C4B is hemolytically more active294. Th e 
diff erent binding specifi cities of the isotypes can be correlated with a single 
His (C4B)/ Asp (C4A) substitution at position 1106. Th is substitution also 
gives rise to a prolonged half-life of activated C4A (~ 10 s) when compared 
with the very short half-life (~ 0.5 seconds) of C4B198. Th e biological 
signifi cance of having the two isotypes remains enigmatic. C4A may be 
more effi  cient in binding immune complexes and in maintaining immune 
complex solubility than C4B294. Th e HLA-independent association between 
C4A null phenotypes and systemic lupus erythematosus (SLE) might be 
explained by impaired clearance and processing of necrotic and apoptotic 
cells, and immune complexes. Even though C4A may bind CR1 (involved 
in immune complex clearance) more effi  ciently than C4B, in certain 
populations only C4B null alleles are associated with SLE294. Experimentally, 
C4A-reconstituted guinea pigs are also able to class switch from IgM to IgG, 
whereas C4B-reconstituted animals are not395. 
C4A and C4B further exhibit extensive structural polymorphism giving 
rise to > 41 allotypic forms51. Th ese allotypes are designated according to their 
electrophoretic mobility by increasing Arabic numbers from the cathode 
to the anode1. Th e most common allotypes are C4A3, C4A2, C4A4, C4A6, 
C4B1, C4B2, and C4B3, all of which are found in > 1% of Caucasians. C4A6 is 
hemolytically inactive due to its inability to form a functional C5 convertase. 
In addition to these, rare structural variants have been recognized64. Only 
minor diff erences in the three-dimensional structures of the two most 
common allotypes, C4A3 (in ~ 85% of Caucasians) and C4B1 (in ~ 87%) have 
been found. However, activated C4A3b and C4B1b diff er in secondary and 
tertiary structure, electrostatic surface charge, and surface hydrophobicity. 
Hypothetically, this may confer selective advantage for binding to diff erent 
microbes and diff erent types of immune complexes294.
27
Figure 1.3 Schematic representations of a trimodular and a bimodular 
RCCX gene element 
Mono-, bi-, tri-, and quadrimodular structures of RCCX can be found in the population. Modifi ed 
from ref.51.
C4 synthesis
Like other complement components, C4 is mainly produced by the liver. 
Many extrahepatic tissues are also capable of producing C4 (Table 1.1). 
Plasma or serum protein levels of total C4 vary between 0.05 and 0.8 g/L 
among individuals, as do the relative quantities of C4A and C4B296, 395. 
Likewise, the CH50 diff ers greatly between individuals. Part of this variation 
is caused by acquired factors: obesity and age between 40 and 65 years 
increase C4 concentrations297, 395. Most of the variation is caused by genetic 
diff erences between individuals. C4 concentration and its hemolytic activity 
are increased by higher C4 gene dosages, the presence of C4B, and by C4(S) 
genes. C4(S) genes are more common in blacks, who also have ~ 40% higher 
plasma C4 concentrations395.
5.1.3 Genetic complement defi ciencies
Complement genes have a high degree of polymorphism (Table 1.5). Several 
complement genes belong to related gene families: the C5 family (C3, C4, 
C5, and α2-macroglobulin), the C9 family (C6, C7, C8α, C8β, and C9), the 
complement serine protease family (C1r, C1s, MASP-1, MASP-2, MASP-3, 
C2, fD, fB, and fI), and the RCA family (C4bp, fH, MCP, DAF, CR1, and 
CR2). CR3 and CR4 are integrins, whereas C3aR, C5aR, and C5L2 are G-
protein coupled receptors300. Various complement genes are clustered in 
the same gene regions and may present as conserved haplotypes: the RCA 
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region (1q32; MCP, CR1, CR2, DAF, C4bp, fH), the major histocompatibility 
complex (MHC) class III complement cluster (6p21; C2, fB, C4A, C4B), the 
MAC I cluster (1p32;C8α and C8β), the MAC II cluster (5p12-14; C6, C7, 
C9), and C1r and C1s in 12p13 (Tables 1.1 and 1.2)300, 394. Some complement 
proteins are the result of alternatively spliced products (e.g. FHL-1) or consist 
of multiple separately encoded gene products (e.g. C1q and C8, Tables 1.1 
and 1.2)300.
Genetic complement defi ciencies comprise about 1-6% of primary 
immunodefi ciencies248. Genetic defi ciencies for nearly all of the complement 
components have been described. With the exception of C1inh, MBL, C2, 
and C9, complete or near complete complement defi ciencies are rare (Table 
1.5). Th ere is great regional variation in the frequencies of TP defi ciencies. 
It is estimated that approximately 1 in 10 000 individuals is defi cient in 
one of the components of the TP, but, for example, 1 in 1000 Japanese are 
C9-defi cient394.
Th e importance of MBL defi ciencies has been questioned, because in 
a large population study the incidence of hospitalization or death from 
infections or other common serious disorders did not diff er between MBL-
defi cient homozygotes and non-carriers100. In adults, MBL defi ciency has 
been associated with, for example, infectious morbidity or mortality in 
patients with cancer, burns, mycoplasma infections, and sepsis103. Th e high 
frequency of MBL defi ciencies in certain populations may imply that limited 
LP activation is even benefi cial to humans in epidemic situations70. Some 
of the suggested consequences of MBL defi ciencies are discussed below 
together with C4 and C2 defi ciencies.
Patients with CP component defi ciencies commonly suff er from 
autoimmune phenomena: systemic (SLE) or discoid (DLE) lupus, vasculitides, 
renal, immune complex -mediated, and other immune diseases36, 300. SLE 
is also found in some MBL defi ciencies361. Th e frequency of SLE in partial 
or complete C1q, C4A and C4B, C2, and MBL defi ciencies has marked 
regional diff erences301. Th e more proximal the defect, the more probable is 
the development of SLE (Table 1.5). In population, the most frequently found 
CP defi ciency in SLE is C4A defi ciency, found in up to 15% of Caucasian 
SLE patients36. A defect in the clearance of apoptotic cells may be more 
important than the ability to clear immune complexes or to negatively select 
self-reactive B cells36, 300. Cutaneous and renal manifestations are especially 
common in early CP defi ciencies, which usually manifest in patients aged 
less than 20 years. Antibodies against nuclear (75%) and extractable nuclear 
(70%) antigens, and against double-stranded DNA (usually absent) are found 
less commonly than in the general SLE population. Only 1% of Caucasian 
SLE patients have C2 defi ciency36. 
Alternative pathway (C3, fH, fI), and membrane-bound RCA defi ciencies 
that are caused by GPI anchor defi ciency are associated with renal and 
hematological manifestations (Table 1.5). No fi rm associations between 
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autoimmune diseases and TP, properdin, fB, or fD defi ciencies have been 
found36.
Almost all complement defi ciencies, with the exception of those of 
membrane-bound and TP regulators of complement activity, are associated 
with an increased risk of infections. Th e infections are commonly invasive and 
caused by encapsulated bacteria119. Th ose with AP and early CP component 
defi ciencies oft en manifest at an early age. Late CP and TP defi ciencies may 
manifest only aft er the patient has reached adulthood119. Mostly neisserial 
infections are seen in properdin, TP, and fB defi ciencies. Isolated strains of 
meningococci oft en belong to the less common serotypes Y, W135, B, and 
C, or cannot be typed. A defi ciency of any of the TP components increases 
the risk of meningococcal disease 1000-fold. Defects leading to CR3 or CR4 
defi ciency cause leukocyte adhesion defi ciency (LAD) type I300.
C4 defi ciencies
C4A null alleles are most oft en inherited as part of the conserved haplotype 
8.1 (HLA-A*1,B*8,SC01,DRB1*0301), associated with a wide variety of 
autoimmune diseases65. In Finland, C4B nulls are most oft en found together 
with HLA-B35* or -B27*203. C4 defi ciencies have mainly been associated with 
various autoimmune and infectious diseases36, 202. In many of the diseases 
studied, other MHC-genes may also be involved and the relative risks or 
odds ratios may be stronger for other MHC antigens (Table 1.6)332. 
C4A, C4B, C2, and MBL are functionally related, being active in CP and 
LP activation. Interestingly, overlapping associations with human polygenic 
diseases have been suggested for their genetic defi ciencies (Table 1.6). Disease 
associations with C4 defi ciencies have frequently been disputed, based on 
studies with varying selection criteria from diff erent general or patient 
populations48, 74, 112, 117, 305. Yet there are marked similarities in the described 
associations with defi ciencies in these four complement genes, examples 
of which are listed in Table 1.6170, 361. Th is may point towards functional 
signifi cance of complement defi ciencies in the etiopathogenesis of these 
diseases. Th e most consistent association of CP defi ciencies (e.g. C4, C2) is 
with immune complex diseases, especially with SLE (which is also associated 
with MBL defi ciency)36. Repeatedly, C4 defi ciencies have been associated 
with diseases where an association with C2 or MBL defi ciency or both has 
also been described (Table 1.6). Of infectious diseases, invasive or respiratory 
bacterial infections caused by encapsulated bacteria (S. pneumoniae, H. 
infl uenzae, N. meningitidis) and chronic viral infections (hepatitis B, hepatitis 
C, human immunodefi ciency virus) seem to be associated with CP and LP 
factor defi ciencies48, 74, 112, 117, 145, 170, 230, 269, 305, 361. Notably, in the available 
studies partial C4 defi ciencies and MBL and C2 defi ciencies mainly modulate 
disease progression, and may thus require other minor defi ciencies in 
immunity to manifest clinically169.
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Table 1.6 Suggested disease associations of C4 defi ciencies
Disease Type of C4 
defi ciency
Association 
with C2 or MBL 
polymorphism?
Examples of other MHC 
genes associated with the 
disease
Infl ammatory diseases
Atherosclerosis1 C4A, C4B C2, MBL2 LTA
Autism1 C4B - DRB1*0401
Autoimmune hepatitis1 C4A - DRB1*0301;DRB1*0401
Behcet’s disease1 C4A MBL2 B*5101;MICA
Capillary leak syndrome 
during cardiac surgery
C4A - -
Diabetic nephropathy1 C4A MBL2 (high 
production)
MICA
Glomerulonephritis1,2 C4 C2 A2,B5,DR5;B65,DR1
Henoch-Schönlein purpura1 C4B C2 B*35
Inclusion body myositis1 C4A, C4B - B*8,DRB1*0301;B*35,
DRB*0101
IgA nephropathy C4B MBL2 (high 
production)
DQB1*0602 (protection)
Liver cirrhosis of varying etiology1 C4B MBL2
Multiple sclerosis, relapsing-remitting1 C4A C2 DRB1*15;TNF
Photosensitivity1 C4A - B*8,DRB1*0301;DRB1*15
Primary biliary cirrhosis1 C4A MBL2 DRB1*08, HLA-DPB1
Sarcoidosis1 C4B - HLA-G*
Severe rheumatoid arthritis1 C4B MBL2 DRB1*;TNF
Sjögrens’s syndrome1 C4A - DRB1*15;DRB1*03;TAP2*
Spontaneous abortion1 C4B - HLA-E*;G*
Systemic lupus erythematosus1 C4A, C4B, C4 C2, MBL2 B*8,DRB1*0301
Systemic sclerosis1 C4A,C4B - B*8,DRB1*0301;DR5;TAP1
;TAP2
Infections
Hepatitis B, serologic response1 C4A MBL23 (severity) DRB1*03;DRB1*07;
DRB1*14;TNF
Hepatitis C, severity1 C4B MBL2 DRB1*0701;HLA-DRB4*0101
Human immunodefi ciency virus, 
progression1
C4A, C4B MBL2 B*35-Px group;
(B* 27 protective)
Invasive infections by encapsulated 
bacteria
C4B C2, MBL2 A3 (recovery)
Leprosy, erythema nodosum1 C4B MBL24 DRB1*15;TNF
Paracoccidioidomycosis1 C4B - -
Subacute sclerosing panencephalitis 
(measles)1
C4A - -
1Refers to ≤1 isotype genes, otherwise refers to total isotype / total C4 defi ciency. 2Includes various histological 
diagnoses, e.g. membranoproliferative and membranous glomerulopathy). 3Associated with persistence of the 
disease. 4Associated with protection from the lepromatous form. MICA = major histocompatibility complex 
class I chain-related A gene.
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5.1.4 Laboratory assessment of complement
If MAC is assembled on the cell membrane of red blood cells (RBC), lysis 
will occur. Th is phenomenon is used in the classical methods to assess the 
functional activity of CP (CH50), AP (AH50), and LP (CH50MBL). CH50, 
AH50, and CH50MBL refer to the reciprocal serum dilutions required to 
produce 50% hemolysis of a standard preparation of antibody-sensitized 
sheep, rabbit, or mannan-coated sheep RBC, respectively. During the 
measurement of AH50, CP activation is inhibited by chelating calcium ions 
from the serum. Controls and standard conditions are vitally important, 
because the CH50 unit obtained depends on the amount and type of the 
antibody used247.
Alternatively, serum diluted together with blockers of the other two 
pathways is added to ELISA plates coated with a CP (e.g. IgM), AP (LPS), or 
LP activator (mannan). Th e appearance of C5b-C9 is detected with a labeled 
antibody to the neoantigen expressed during MAC formation247. Measuring 
all three pathways side by side allows a presumptive diagnosis of the probable 
complement factor(s) defi cient from the patient’s serum sample323.
Th e extent of complement activation can be measured by assaying 
complement activation products (e.g. C4d) or stable macromolecular 
complexes (e.g.C1s-C1inh, C3bBbP, C5b-C9) produced during complement 
activation247. Novel assays measuring cell-bound complement activation 
products are under development.
Individual plasma components of complement (e.g. C3, C4, C1inh) can 
be quantifi ed by with immunochemical assays. C1inh-defi cient patients 
may have measurable C1inh without function, and so it is necessary to 
also perform a functional assay. When complement defi ciencies of selected 
complement factors (e.g. C1q, C1inh) are suspected, it may be necessary 
to assay complement autoantibodies (e.g. C3 nephritic factor) in order 
to exclude secondary complement defi ciencies. Flow cytometry with 
monoclonal antibodies against complement receptors can be used to detect 
their presence in cell suspensions247.
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5. 2 Antibody-mediated immunity
More than 90% of all primary immunodefi ciencies are caused by defects 
in B cell-dependent humoral immunity248. Th ese lead to low or absent 
serum Ig concentrations, or to qualitatively impaired antibody responses 
(Table 2.1, Fig. 2.1)54. Severe primary antibody defi ciencies are caused by 
genetic or acquired defects in B cell maturation and activation248. Low IgG 
subclass levels are mainly caused either by a heterozygous carriership of 
gene deletions in the corresponding heavy chain gene, or more commonly 
by a dysfunctional, cytokine-regulated switch recombination that is partly 
allotype-linked (Fig. 2.2)140. To understand these better, it is of paramount 
importance to acquire insight into B cell development and regulation. 
Not all immunodefi ciencies associated with decreased Ig levels are classifi ed 
as antibody defi ciencies. Defects aff ecting early lymphocyte diff erentiation 
before commitment to B and T cells, such as adenosine deaminase defi ciency, 
lead to severe combined immunodefi ciencies (SCIDs). Of SCID patients, 
mostly those with a decreased number of CD4+ T helper (Th ) cells have 
hypogammaglobulinemia248. In addition, hyper-IgM syndromes (HIGM) 
types 1 and 2 with early defects in class switching (Fig. 2.2) that disturb the 
CD40L-CD40 costimulatory activity may also be classifi ed as combined 
immunodefi ciencies249. Circulating B cells may be absent or immature, and 
an impaired B cell function is found in most SCID, HIGM1 and HIGM2 
patients248, 249.
5.2.1 B cells
Th e human body contains ~ 2 x 1012 T and B lymphocytes. Both cell types are 
morphologically similar with a dominant nucleus and very little cytoplasm, 
but express diff erent cell surface molecules. In adults, B cells originate from 
the hematopoietic bone marrow stem cells, migrate to secondary lymphoid 
organs (spleen, lymph nodes, Peyer’s patches, mucosal surfaces, tonsils, 
appendix) and produce antibodies53. Each B lymphocyte carries ~ 105 
membrane-bound antibody molecules that determine the unique specifi city 
(idiotype) of its B cell receptors (BCRs)174. B cells expressing the same 
BCR idiotype together form a B cell clone that is committed to synthesize 
antibodies of the same specifi city. An individual’s serum contains, as an 
estimate, between 105 and 107 idiotypes53. 
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Figure 2.1 Abnormalities of B cell maturation leading to severe immunoglobulin 
defi ciencies
AR = autosomal recessive, XL = X-linked, Cµ = IgM heavy chain, Igα/β = B cell receptor-
associated Igα/β heterodimer (CD79a/CD79b) responsible for intracellular signaling, λ5 = V 
pre-B pseudo-light chain, BLNK = B cell linker, BTK = Bruton’s tyrosine kinase, ICOS = inducible 
T-cell costimulator, CD19 = BCR-associated co-receptor, BAFF-R = B-cell activating factor 
belonging to the TNF receptor family, TACI = transmembrane activator and calcium-modulator 
and cyclophilin ligand interactor, CD40 = signaling molecule of the TNF receptor family on B 
cells, CD40L = CD154, CD 40 ligand on activated T cells, AID = activation-induced cytidine 
deaminase, UNG = uracil-N-glycosylase. Modifi ed from ref.107.
B cell development and immunoglobulin gene recombination
Th e earliest B cell precursors (pre-pro-B cells) express the B cell-specifi c form 
(B220) of the leukocyte common antigen CD45, and leucosialin (CD43)63, 
141. Pre-pro-B-cells have little or no Ig gene rearrangement141, 214. During 
maturation, through targeted and regulated alterations of genomic structure 
and sequence, variable (V) regions of antigen receptors are constructed by 
gene element recombination (Fig. 2.2)343. Th is takes place between V, diversity 
(D), and joining (J) elements of Ig heavy chain gene (VDJ rearrangement 
at IGH@ in chromosome 14q32.33) and between V and J elements of the 
Ig light chain genes (VJ rearrangement at IGL@ in 22q11.1-q11.2 and at 
IGK@ in 2p12). Th is creates the necessary repertoire of idiotypes needed 
for eff ective defense against pathogens108, 214, 343. Superimposed on this, 
BCRs are further diversifi ed by a factor of 10-100 by insertion of extra N 
(non-templated) or P (palindromic) nucleotides at the V(D)J junctions53. 
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Th e Ig receptor also has a limited set of conserved eff ector regions coded by 
constant region (C) gene segments. Altogether IGH@ encodes more than 
100 V, 27 D, six J, and nine C genes253. V(D)JC gene segment combinations 
are the basis for the generation of heavy chains and light chains, as well as 
class switching during B cell activation (Fig. 2.2)53, 214.
IgG1, IgA1, IgG2, IgG4, IgA2, and IgE (sub)class defi ciencies may be 
caused by homo- and heterozygous C gene deletions in IGH@ (Table 2.1). 
Th ese may cover one or more genes neighboring each other. Multiple types 
of deletions, created either by non-equal homologous recombination or by 
looping-out excision, have been described in the Caucasian population262. 
Th e total frequency of these is ~ 0.015. Heterozygous deletions of Cγ1, Cγ2, 
and Cγ4 are associated with a ~ 50% reduction in the serum level of the 
aff ected subclass, causing partial IgG subclass defi ciency (SCD). Homozygous 
deletions that result in complete absence of the corresponding subclass are 
rare (one per 5000-10000 subjects in the general population)262. Subjects 
with a complete defi ciency of any of these IgG subclasses are – paradoxically 
– usually asymptomatic192.
Gene rearrangements fi rst take place at IGH@ during pro-B cell-stage 
and, starting from the pre-B cell-stage, further at the Ig light chain loci141, 
214. Pre-B cells express the pre-BCR formed by Igα/β, heavy chain of IgM 
(Cµ) and by a pseudo-light chain (V pre-B/λ5)53, 174. Th is maturation step 
is antigen- and T cell-independent and takes place in the bone marrow. 
Pre-B cells further mature into immature B cells expressing a BCR of IgM 
isotype. Immature B cells then emigrate to the secondary lymphoid organs, 
where maturation of the antibody repertoire takes place. In severe antibody 
defi ciencies, the genetic blocks in normal B cell maturation take place from 
the pro-B stage on (Table 2.1, Fig. 2.1)73, 86, 107, 249. 
To eliminate precursors that fail to produce a complete heavy or light 
chain, and to avoid self-reactivity, the production of B cells is tightly 
controlled63, 141. Only 10% of the produced immature B cells are exported 
to the periphery53, 63. B cell tolerance, leading to the inability to respond to 
antigenic stimuli, is achieved both by central tolerance in the bone marrow 
and by peripheral tolerance in the secondary lymphoid organs. When 
immature B cells encounter self-antigens in the bone marrow, they undergo 
negative selection. If a self-reactive V gene is encountered, B cells fi rst try 
to replace it with a new V gene (receptor editing). Th ose with high affi  nity 
interactions between BCR and self-antigen are clonally deleted, those with 
low avidity to self-antigen can become unresponsive (anergy)53. Autoimmune 
phenomena are commonly found in humoral immunodefi ciencies (Table 
2.1)96, 337.
Immature B cells that leave the bone marrow and enter the spleen can be 
divided (based on diff erential surface expression of B220, AA4, IgM, and 
CD23) into type 1 (T1), T2, and T3 transitional cells that further mature 
into follicular (B-2), marginal zone (MZ, a subset of B-2), and B-1 B cells53. 
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Mature, unswitched B cells co-express IgM and IgD (Fig. 2.1)53, 141, 214. In 
the spleen, T1 B cells with high-affi  nity BCR for blood-borne self-antigens 
are negatively selected. Th ereaft er, T2 B cells moving into follicles proliferate 
(positive selection). Negative selection is an antigen-dependent event, 
whereas positive selection requires antigenic and non-antigenic signals 
such as B-cell factor belonging to TNF family (BAFF) signaling53. 
Both MZ and B-1 B cell maintenance requires BCR signaling53, 141. MZ 
B cells are located exclusively in the splenic MZ. Th ey are fully formed only 
aft er two years of age and are selectively maintained during decreased B 
cell output from the bone marrow (e.g. aging, bone marrow failure). It is 
unknown whether MZ B cells arise from transitional or follicular B cells. MZ 
B cells provide a fi rst line of defense against blood-borne pathogens and may 
not typically contribute signifi cantly to the germinal center (GC) reaction8. 
Th e slow development of MZ B cells may contribute to the susceptibility of 
newborns to encapsulated pathogens141.
B-1 cells (CD23-B220+IgMhiIgDlo) dominate in the newborn spleen. 
Found in large numbers in the tonsils and peritoneal cavity, they comprise 
a minor subset (3-7%) of adult splenic B cells53. In aged subjects, B-1 cell 
numbers increase again. All peritoneal B-1 cells express macrophage-specifi c 
surface molecule Mac-1. Almost all B-1 cells in the spleen and the majority 
of those in the peritoneum express the T cell diff erentiation antigen CD5137, 
141. B-1 cells are further divided into B-1a (CD5+Mac-1+IgM+) and B-1b 
(CD5-Mac+1-IgM+) cells53, 137. B-1 (especially B-1a) cell repertoire is more 
restricted than that of B2 cells due to limited usage of variable heavy chain 
(VH) genes and of N-region addition during VDJ rearrangement141. B-1 
cells are involved in responses against T cell-independent antigens, in the 
production of so-called natural antibodies, and in autoimmune responses149, 
215.
5.2.2 B cell activation and antibody production
Th e B cell receptor and the respective antibodies produced aft er B cell activation 
recognize antigenic determinants (epitopes) formed by any structure of the 
antigen that is accessible to solvent389. When the BCR of a resting B cell 
recognizes an antigen, clonal expansion by cell division and diff erentiation into 
Ig-producing plasma cells or maturation to memory B cells may ensue. Th e 
early events of primary B cell activation are initiated by the BCR. It consists 
of membrane-bound Ig (mIg, IgM and/or IgD) together with a noncovalently 
associated disulfi de-linked heterodimer of Igα (CD79a) and Igβ (CD79b) that 
mediates the intracellular signaling pathways174. Th e developmental stage and 
the context, in which BCR is crosslinked by an antigen, determine whether 
proliferation, diff erentiation, anergy, or apoptosis follows. Signals from other 
receptors on B cell surface (e.g. complement receptors, Toll-like receptors, 
cytokine receptors) profoundly infl uence B cell activation and antibody 
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production149, 190, 262. Aft er antigen binding, BCR is internalized and targets 
antigen for processing. Th e multiprotein signaling machine (signalosome) 
mediating early signaling events is relatively well characterized and includes, 
among others, Bruton´s tyrosine kinase (BTK) and B cell linker protein 
(BLNK). Further downstream, CD19 forms a complex with CD21, CD81, 
and CD225 in the membrane of mature B cells. Th is complex, signaling 
together with BCR, signals the B cell to decrease its threshold for activation 
by the antigen. Genetic defi ciencies of CD79A, Bruton´s tyrosine kinase, and 
B cell linker protein cause agammaglobulinemia, whereas CD19 defi ciency 
causes a common variable immunodefi ciency (CVID) phenotype (Table 2.1, 
Fig. 2.1)73, 86, 174.
BCRs and the respective antibodies recognize antigenic epitopes through 
their antigen-binding sites (paratopes). Paratopes are highly solvent-exposed 
structures located at the tip of each Fab arm (formed by the variable regions 
of light and heavy chains, see below). Th ey are formed by six hypervariable 
polypeptide loops called complementarity-determining regions (CDR). 
Th ree CDRs from the variable light chain region (CDR-L1-3) and three 
from VH (CDR-H1-3) exist, of which at least four are used to bind an antigen 
(Fig. 2.3). Th ese generate a spatial surface (e.g. concave or groove-like) that 
determines the antigen specifi city of the antibody108, 389, 390. Mainly H3, H2, 
and L3 participate in the binding. H3 displays the greatest variability and 
seems to be the most crucial CDR for antigen recognition108, 389. Antibody 
affi  nity describes the strength of antigen-antibody bond. It is the sum of the 
diff erent non-covalent attractive and repulsive forces between the paratope 
and the epitope389.
Before the production of an antibody, a resting B cell becomes activated. 
It then expands clonally and diff erentiates into an antibody-secreting plasma 
cell. It may also mature into an (initially quiescent) memory B cell that during 
a subsequent encounter with the antigen becomes involved in antibody 
production. Th e secreted Ig is either its IgM receptor, or it shares the same 
V region but has a diff erent C region (isotype) (Figs. 2.2, 2.3)53.
Natural antibodies
Human serum contains polyreactive, low-affi  nity, mainly IgM isotype 
antibodies with germ line V gene confi guration. Th ese are thought to be 
produced by B-1a cells without previous exposure to an antigen or in response 
to B cell PAMP receptor signals leading to the production of so-called 
“natural” or “innate” antibodies (Table 2.2)137, 215. For example, mucosal 
B-1 cell stimulation by bacteria is thought to enhance the production of 
natural IgA antibodies at mucosal sites, whereas CR2-dependent natural 
IgM antibodies may be necessary for the self-recognition of ischemic self-
tissues149, 215, 293. Natural antibodies contribute to innate immunity and 
off er fi rst-line defense against invading organisms before specifi c immune 
responses149.
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Antibody responses to thymus-independent antigens
B-cells respond to three types of antigens: thymus-independent (TI) antigens 
types 1 and 2, and to those that are thymus-dependent (TD) (Table 2.2.)11. 
Bacterial lipopolysaccharide (LPS) is the prototypic TI-1 antigen. Some TI-1 
and most TI-2 antigens are multivalent polysaccharides or other antigens 
with repetitive structures. Th ese are found on clinically important bacteria 
causing respiratory, mucosal, and invasive infections such as Streptococcus 
pneumoniae, Haemophilus infl uenzae, and Neisseria meningitidis11. 
Polysaccharides are not degraded in vivo and are not recognized by the T 
cell receptor (TCR). Th ey have the ability to bind directly to BCRs, crosslink 
them, and to activate B-1 and MZ B cells into an antibody response without 
Th  cells53. Yet, for example S. pneumoniae-specifi c plasmablast reaction 
requires antigen capture and antigen-presenting cell (APC)-derived signals 
for MZ B and B-1a responses11. TI antigens generally fail to elicit a secondary 
response (which requires specifi c T cell help), but eff ective long-lasting TI 
IgM memory by B-1b has been described for S. pneumoniae (Table 2.2.)137. 
Natural antibodies and IgM+ memory B cells are required for protection 
against pneumococci in humans69. Young children, elderly subjects, and 
splenectomized individuals are susceptible to recurrent infections against 
encapsulated bacteria. Lack of CD21+ MZ B cells (CD21 is required for 
MZ B TI-2 responses) in the spleens of children under 2 years of age, or a 
lack of B-1b cells may be the basis for this susceptibility11, 54, 137, 238. Th ese 
patients also have a limited usage of VH genes, likewise a feature of (only) 
B-1a responses3, 141. Partly supporting this, children with clinically signifi cant 
immunodefi ciency and an impaired production of pathogen-specifi c 
antibodies (selective antibody defi ciency, SAD) oft en become asymptomatic 
and start producing anticapsular antibodies when they become older254. On 
the other hand, asymptomatic impaired production of antibodies against 
pneumococci, associated with a limited usage of VH genes and with specifi c 
IgG2 and κ light chain allotypes (see below), is common in the population237, 
238.
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Table 2.2 Main characteristics of B cell responses to diff erent types of antigens
Feature T cell-
independent 
antigen type 1
T cell-
independent 
antigen type 2
T cell-dependent antigen
primary 
response
secondary response
B cell type B-1a, B-1b B-1, MZ B-2 B-2
Clonality of 
response
Poly- or 
monoclonal1
Polyclonal2 Oligoclonal Oligo-monoclonal
Signals required BCR and PAMP 
receptor1
BCR 
crosslinking
Mainly APC B cell importance ↑
Antigen 
concentration 
required
Relatively low1 High Relatively high Relatively low
Examples of 
microbial 
antigens
LPS
PnP SIII
Salmonella 
polymerized 
fl agellin
Vesicular 
stomatitis virus
Rotavirus
As TI type 11
LP
Mycoplasma
PPD 
Staphylococcus 
aureus 
protein A
Polysaccharide
Protein
Protein
Response Rapid, short-
lived2
Rapid, short-
lived2
5-10 days, 
short-lived
2-5 days
Somatic 
hypermutation
No No Low High
Predominant 
antibody isotype
IgM (natural 
antibodies)
IgM IgM Site-dependently IgG 
or IgA
Affi  nity Low2 Low2 Low High
Location of 
response
Bone marrow, 
GALT
Also spleen Secondary lymphoid organs
1At low antigen concentrations only specifi c B cells are activated, at high concentrations the 
response is mediated by direct engagement of multiple BCRs and becomes polyclonal. 2Certain 
antigens (e.g. Streptococcus pneumoniae, Borrelia hermsii) can elicit a long-lasting, protective T 
cell-independent IgM memory by specifi c B-1b cells. Natural antibodies are polyreactive and 
of low affi  nity. PAMP = pathogen-associated molecular pattern, BCR = B cell receptor, LPS = 
lipopolysaccharide from Gram-negative bacteria, PnP = pneumococcal polysaccharide, LP = 
lipoprotein from Gram-negative bacteria, PPD = purifi ed protein derivative of tuberculin, GALT 
= gut-associated lymphoid tissue. 
Highly organized and repetitive structures on the surfaces of at least some 
viruses such as vesicular stomatitis, polyoma, and rotaviruses are also able to 
trigger specifi c type 1 TI responses producing high affi  nity IgG antibodies, 
but without affi  nity maturation. Th ese responses are biologically important, 
because these viruses are exclusively controlled by antibodies, which also 
serve to maintain cytotoxic T lymphocyte activation30, 31. In addition, early TI 
responses facilitate and enhance the ensuing long-lived TD IgG responses31, 
32.
Antibody responses to thymus-dependent antigens
T cell-dependent (usually protein) antigens have a very limited number of 
epitopes and are thus less able to crosslink the BCRs to initiate direct B-cell 
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activation. B-cell responses also tend to remain transient and short-lived 
without the cognate help by CD4+ Th  cells specifi c for the same antigen. 
On the other hand, most antigens recognized on viruses, bacteria, and 
parasites are proteins that are able to trigger Th  responses30. Benefi cially, to 
avoid autoimmunity, TD activation is also more tightly regulated30, 162. In 
antigen presentation, the antigen is engulfed following binding, degraded 
intracellularly, and the peptide produced is eventually re-expressed on the 
surface of the cell in association with MHC class I or II molecules. MHC 
II molecules are found mainly on cells of the immune system that include 
B cells, activated T cells, dendritic cells (DCs), macrophages and thymic 
epithelium. Cognate B cell activation and regulation begins with the MHC 
II glycoprotein on APCs presenting an antigenic peptide to a specifi c TCR 
on CD4+ Th  cell223. Th ree types of APCs exist: DCs, macrophages, and B 
lymphocytes. Another signal relayed by the interaction of costimulatory 
molecules on APCs and their ligand on T cells (most notably B7-1 and B7-2 
interaction with CD28) is required for T cell activation, absence of proper 
costimulation results in T cell inactivation223. 
DCs, as APCs located at the border zones of the body, are uniquely 
effi  cient at protein antigen uptake, processing, and presentation. Th ey 
travel from the blood to the peripheral tissue to capture foreign antigens250. 
Conserved motifs on pathogens are recognized by various PAMP receptors 
on DCs68, 223. Th ereaft er, DCs travel to the draining lymphoid organs and 
prime naive CD4+ Th  cells into type 1 (Th 1), Th 2, and other, less well 
characterized subgroups of Th  cells342. Diff erential activation of CD11c+ DC 
subgroups further regulates the ensuing immune response223. Activated DCs 
upregulate costimulatory molecules (e.g. CD40, CD80, CD86, TRANCE) 
and chemokine receptors such as CCR7 to relocate from the infl amed sites 
to T cell areas of draining lymph nodes. Th ere the interaction between the 
antigen-primed DCs presenting the antigen to specifi c TCRs on naive Th  
cells represents the fi rst immunologic synapse in TD B cell regulation. When 
Th  cells become antigen-primed, antigen-specifi c clonal Th  cells expand 
extensively and diff erentiate into eff ector Th  cells223.
Th e specifi c BCRs and TCRs usually recognize diff erent epitopes on an 
antigen. In TD B responses, both T and B cells need to become activated 
and to cooperate. Th is, the second immunologic synapse of B cell regulation 
that leads to the development of eff ector B cell responses, takes place as 
the activated B cells pass through the T cell areas of lymphoid tissue where 
the activated T cells are trapped223, 389. Th ere a large number of cell surface 
molecules regulate the ensuing responses174, 223. For example, CD 40 is 
constitutively expressed on B cells and CD40L only on activated T cells. It 
is at this stage, and during the ensuing downstream events that defi ciencies 
of costimulatory, regulatory, and signaling molecules that govern the 
BCR responses lead to severe congenital antibody defi ciencies or HIGM 
syndromes (Fig. 2.1, Table 2.1)249, 382.
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Th e strength of the antibody response is further positively (e.g. by Toll-like 
receptors[TLR]) or negatively (e.g. by CD22, FcγRIIB) regulated by contact-
mediated and soluble factor-mediated signals174, 190. Activated B cells then 
migrate to splenic medullary cords and diff erentiate fi rst to plasmablasts, and 
then into short-lived, terminally-diff erentiated plasma cells that secrete IgM 
or IgG during the primary response (Table 2.2). Alternatively, the activated 
B and Th  cells migrate together into the B cell areas of lymphoid tissue and 
enter the primary follicles389.
5.2.3 Somatic hypermutation, affi nity maturation, and class 
switching
In primary follicles, B cells begin to form GCs. GC reaction regulates 
antigen-specifi c clonal evolution during the development of B cell memory 
(the third immune synapse of B cell development)223. Compared with a 
primary response, typical features of a secondary TD response are class 
switching, somatic hypermutation, and affi  nity maturation (Table 2.2, Fig. 
2.2). During GC reaction, activated B cells displace resting follicular B 
cells while rapidly and clonally expanding to become centroblasts (sIgD-
sIgMlo)160. Somatic hypermutation occurs during this rapid proliferative 
phase, when a large number of mutations in the VH genes occur (Fig. 2.2)214. 
Somatic hypermutation is induced by targeted DNA deamination by the 
B-cell-specifi c activation-induced cytidine deaminase (AID). Its eff ects are 
counterbalanced by a B-cell-specifi c reparatory enzyme uracil nucleoside 
glycosylase (UNG). Genetic mutations in their genes result in HIGM 
syndromes (Fig. 2.2)214, 249.
During affi  nity maturation, VH mutations may result in centroblasts 
expressing specifi c antibody of either lower or of higher affi  nity (Fig. 2.2)160, 
214. Centroblasts then further diff erentiate into centrocytes that begin to 
upregulate their surface Igs (sIg). Th ereaft er, centrocytes with high affi  nity sIgs 
interact with antigen bound by FDCs (via their complement or Fc receptors), 
and subsequently with Th  cells. Th ose with lower affi  nity sIgs undergo 
apoptosis160, 223, 389. Repeated exposure to the same antigen thus results in the 
production of antibodies that bind, and protect from, pathogenic microbes 
more effi  ciently223, 389. Impaired affi  nity maturation is found in humoral 
immunodefi ciencies with impaired class switch recombination or somatic 
hypermutation (HIGM syndromes) and in some subsets of CVID106.
During class switching, the antibody-secreting plasma cells switch the 
C region of the secreted antibody whereas the V portion (and specifi city) 
remains unchanged. Th is is achieved by class switch recombination events, 
when the Vµ is joined to a Cγ, Cα, or Cε present in the respective isotype IgG, 
IgA, or IgE (Fig. 2.2). Which isotype is generated is infl uenced by a number 
of factors, including the antigen composition, infection site, and the route 
of immunization. Class switching is strongly infl uenced by the dose of the 
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antigen, by Th -derived cytokines provoked by the infecting agent, and requires 
CD40L signaling53, 342. Defects at the stage of CD40L-CD40 signaling cause 
combined immunodefi ciencies. Defi ciency of CD40L results in the classical 
form of X-linked HIGM syndrome (X-HIGM). CD40 defi ciency causes an 
autosomal recessive disease; this has a phenotype that is indistinguishable 
from X-HIGM (Fig. 2.1)214, 249. CVID phenotype is also shared in the 
defi ciencies of two B and T cell surface-signaling molecules: B-cell-activating 
factor belonging to the TNF receptor family (BAFF-R) and transmembrane 
activator and calcium-modulator and cyclophilin ligand interactor (TACI). 
Th ese participate in isotype switching; defi ciency of the latter is the most 
common known genetic cause of primary hypogammaglobulinemia, found 
in as many as 10-20% of “idiopathic” Caucasian CVID patients73.
Cytokines are able to regulate germ line transcription at the IGH@. In 
humans, Th 1 cytokines interleukin (IL)-2, interferon (IFN) γ, LTα, and 
IL-12 are generally thought to promote cell-mediated immunity and the 
switching to opsonizing antibody subclasses IgG1 and IgG3, whereas Th 2 
cytokines IL-4, IL-13, and IL-10 would suppress cell-mediated immunity 
and promote the class switch to IgG2, IgG4, and IgE53, 148, 160, 342. However, 
in experimental conditions in vitro, the Th 2 cytokines IL-4 and IL-10 may 
in the presence of CD40L stimulation induce IgG1 and IgG3 switching. 
Likewise, IL-12 and IFNγ (Th 1 cytokines) may promote switching to IgG2. 
Interestingly, the “anti-infl ammatory” cytokines transforming growth factor 
(TGF)-β and IL-10 promote switching to IgA, which in its circulating form 
may also have anti-infl ammatory actions53, 97, 262. IgA defi ciency is associated 
not only with susceptibility to infections, but also with autoimmune and 
infl ammatory complications such as celiac disease97, 109. A costimulatory T 
cell molecule, inducible T-cell costimulator (ICOS), strongly induces IL-10 
production and also increases the secretion of IL-4, IL-6, and IL-6. Mutations 
in inducible T-cell costimulator have been found in ~ 1% of CVID patients 
(Table 2.1)73. 
5.2.4 Immunoglobulin allotypes
Variations in subclass levels are associated with Ig allotypes326. Allotypes 
are genetic variants of Ig subclasses and light chains (Table 2.3). Th ough 
the exact mechanism is insuffi  ciently characterized, diff erent allotypes 
are associated with diff ering numbers of B cells producing the particular 
allotype. Th is has commonly been attributed to variant effi  ciencies of the 
class switch regions of allotypic genes (Fig. 2.2)221, 257. Altogether at least 28 
Mendelian Ig allotypes defi ned at the protein level occur (Table 2.3)257. Two 
diff erent, alphameric and numeric, nomenclatures for results obtained by 
serologic testing are commonly being followed in the literature. Th e precise 
designation given to an Ig allotype can be highly variable and complex. An 
allotype of an Ig molecule is recognized by the expression (e.g. G2mn) or 
45
nonexpression (e.g. G2mn-) of a unique epitope (allotope)134. Th e heavy 
chain class or the light chain type (κ) is designated by a capital letter, with 
either a small “m” (Km) or a capital “M” (KM) standing for “marker”. Th e 
appropriate subclass is oft en, but not always, shown by the inclusion of the 
appropriate numeral (e.g. G1m, G3m). Yet italics, superscripts, numeric 
or alphameric nomenclatures or both, and capital letters are used variably. 
Th us, the common Caucasian allotype G1ma can have multiple designations, 
for example “G1m(1)”, “GM a”, or “G1ma(1)”. Depending on the antibodies 
used for typing, these may be unable to diff erentiate two known allotypes 
from each other, e.g. G1ma/a(x) includes allelic markers “a(1)” and “x(2)” 
of IgG1 that both give a positive reaction with an antibody against G1ma. 
When additional serotyping with anti-x has not been performed, G1ma/a(x) 
is used (Table 2.3)134, 257, 390. At the gene level, even further polymorphism 
can be recognized within an allotype154.
Table 2.3 Human antibody allotypes
Gene locus IGHG3 IGHG1 IGHG2 IGHA2 IGK@
Designation G3m G1m G2m A2m Km
Allotypes g1(21), g5(28), 
b0(11), b1(5), 
b3(13), b4(14), 
b5(10), s(15), t(16), 
c3(6), c5(24), u(26), 
v(27)
a(1), x(2), f(3), 
z(17)
n(23), n-(23-), 
ny
1, 2, 3 1, 2, 3
Alphameric designation is shown fi rst, followed by numeric designation in brackets. Modifi ed 
from refs.134, 154, 390.
In Caucasians, allelic variants of IGHG3, IGHG1, and IGHG2 of heavy chain 
genes form four predominant, tightly-linked genetic haplotypes (frequencies 
in Finns in parenthesis) : G3mb,G1mf,G2mn (0.380); G3mb,G1mf,G2mn- 
(0.224); G3mg,G1ma/x,G2mn (0.017); G3mg,G1ma/x,G2mn- (0.379) (Fig. 2.2)257, 
326. G3mg and low IgG3, as well as G1mf and low IgG1 are associated262, 326. 
G3mg is also marginally less effi  cient to activate complement than G3mb85. 
If testing includes other IGHG allotypic loci (Am, Em), a more extended 
haplotype may be reported221, 257. Patients suff ering from symptomatic 
SCDs commonly manifest together with an increased level of some other 
(sub)class192. Accordingly, the carriership of a haplotype may be associated 
with multiple Ig concentrations and functions that deviate from the mean. For 
example, in Caucasians homozygosity for the haplotype G3mg,G1ma/x,G2mn-, 
A2m1 is, at the population level, associated with lower mean concentrations 
of IgG3 and IgG2, less effi  cient complement activation by IgG3, poor anti-
polysaccharide responses, and higher concentrations of IgG1 and IgA2. In 
addition, the increase in IgG2 concentrations is enhanced but those of IgG1 
retarded aft er birth in the homozygotes27, 221, 238, 259, 326. 
In subjects with low subclass levels, it is common to fi nd a simultaneous 
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low level of another (sub)class coded by the neighboring gene(s) (e.g. 
IgG1 and IgG3 or IgA1, IgG2, and IgG4)27, 192. Yet the eff ects of the 
above-mentioned common Caucasian IGH@ allohaplotypes on IgG1 and 
IgG3 serum concentrations are invariably reciprocal (Fig. 2.2)326. Th e 
allohaplotype of an individual thus explains low subclass levels only in a 
subset of individuals. Subclass switching is clearly further regulated by 
other activating signals and genetic diff erences between individuals than 
those tested thus far. Th e local cytokine milieu in lymphatic tissue strongly 
aff ects the produced antibody (sub)class128, 262. Defi ciencies in one arm of 
immunity may also be asymptomatic, because another arm of immunity is 
able to compensate169. To manifest clinically, low subclass levels probably 
require additional genetic, regulatory, or structural defects262. 
Figure 2.2 Schematic representation of immunoglobulin heavy chain locus in 
chromosome 14q32.33 during class switching and somatic hypermutation
Promoter regions (P) shown only on the fi rst line. During switch recombination a rearranged 
and expressed heavy chain variable region (VDJ) is joined to a new downstream constant region 
(C). Junctions form within switch regions (S). Arrows denote V and S region activation by 
transcription. Somatic hypermutation alters V sequence (stars). MAR = matrix attachment region, 
Eµ = intronic enhancer, 3’α1 and 3’α2E = downstream enhancers. ψ = pseudogene. Modifi ed 
from refs.214, 262, 389.
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5.2.5. B cell memory
During affi  nity maturation, centrocytes with high affi  nity sIg move to the 
edge of the GC and interact with specifi c Th  cells expressing CD40L. Provided 
that B cells receive the necessary costimulatory signals, they are positively 
selected and may move back to the dark zone of GC. If again positively 
selected, they proliferate further. High affi  nity centrocytes may undergo 
several rounds before they terminally diff erentiate into either antibody 
secreting plasma cells or enter the long-lived memory B cell compartment223. 
Maintenance of serum antibody levels and long-lived B cell memory is tightly 
controlled, mainly by regulating the number of antibody-secreting cells215. 
Th e half-time of circulating IgG is exceptionally long. Like other plasma 
proteins, Igs constantly enter the endocytic compartment of endothelial cells 
via pinocytosis. Unlike other plasma proteins, IgG is bound in the acidic 
environment to an atypical Fc receptor (FcR), FcRn, and salvaged from 
proteolysis back to plasma2. Multiple subtypes of affi  nity-matured B memory 
cells are defi ned, for example, by their antibody isotype and by whether they 
secrete antibody or produce a rapid cellular response to antigen recall223. 
A low percentage of switched memory B cells (CD19+CD27+IgD-) in the 
blood seems to predict, more accurately than Ig levels, whether patients with 
missing specifi c antibody responses to polysaccharide antigens or to CVID 
develop bronchiectasis, splenomegaly, and autoimmunity (Table 2.1)6, 69.
5.2.6 Antibody structure, antibody classes, and Fc receptors
Each milliliter of normal human serum contains ~ 1016 Ig molecules. 
Antibodies are glycoproteins that belong to the Ig superfamily. Th ey serve 
as BCRs, circulate in the plasma and lymph, and can be found in mucosal 
and lymphoid tissues207. Th eir main function is to protect from extracellular 
pathogens85, 207. Th e main eff ector functions of antibodies are achieved 
by direct eff ects mediated by their Fab portions and by eff ector cells that 
become activated upon FcR binding (Fig. 2.3, Table 2.4)85, 207. Cross-linking 
of multiple FcRs on eff ector cells is a prerequisite to their activation207.
Th e basic structure of an Ig molecule is a four-chain unit that consists 
of two identical, heavy polypeptide chains (HC) having four tight globular 
domains and two identical, light polypeptide chains that have two globular 
domains. IgG, the model of the basic structure, adapts a distorted, somewhat 
asymmetrical Y shape where chains are linked by disulfi de bonds (Fig. 2.3)310. 
Two types of light chains exist, kappa (κ) and lambda (λ), shared by all Ig 
isotypes. In a given Ig molecule both light chains are of the same type390. In 
humans, 60% of Igs use κ and 40% use λ chains., No functional diff erences 
are known between them390. 
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Th e amino(N)-terminal globular domains are encoded by V genes and are 
responsible for antigen recognition. Th eir structure is identical with the 
respective BCR (see above)208, 390. Th e functional bivalency created by the 
two identical recognition sites enables cross-linking of antigens. Th is, for 
example, is necessary to inhibit virus replication inside infected neurons, 
possibly through transmembrane signaling.131.
VL
VH
CH1 CH1
CH2 CH2
CH3 CH3
CLCL
Hinge
Fab
Antigen recognition
Antigen binding
Neutralization
Agglutination
H2O2 generation
Fc
N-terminus
C-terminus
Main effector functions
Complement activation
Binding to Fc receptors
Opsonization
Transport: placenta and epithelium
Membrane-bound or secreted
Light chain Heavy chain
Variable 
region
Constant 
region
Carbohydrate 
units
VH
VL
CDR
Figure 2.3 Schematic structure of the basic four-chain unit of a human antibody 
molecule
CDR= complementarity-determining (hypervariable) regions, shown only in one Fab region. 
Modifi ed from refs.207, 390.
In humans, fi ve classes (isotypes) of Igs (IgM, IgG, IgA, IgD, and IgE) exist. 
Th ey diff er in their physicochemical, antigenic, and functional properties, 
and in the amino acid sequence of their constant regions (Table 2.5). IgG, 
IgD, and IgE are monomers, whereas IgM and IgA predominantly form 
pentamers and dimers, respectively. Formation of these polymers requires 
the additional polypeptide-joining (J) chain. In heavy chain structures, the 
hinge region (Fig. 2.3) shows the greatest variation between (sub)classes. It 
varies in sequence, length, number of disulfi de bonds, and in the presence 
of carbohydrates390. Th e degree of sialylation of these polysaccharides may 
regulate the switch from anti- to pro-infl ammatory action172. In IgE and 
IgM, the hinge is replaced by an extra constant domain (CH4)390. Th e hinge 
allows segmental fl exibility of the Fab arm relative to the Fc region. Th is 
fl exibility is important for antigen binding and eff ector functions, because 
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it allows the Igs to cope effi  ciently with diff erent spacings and orientations 
of antigenic epitopes310, 390. Th ough the Fc parts of Ig classes share the same 
general structure, their sequence homology is only about 30%, and their 
carbohydrate moieties may confer additional heterogeneity85, 390.
Within the IgG and IgA classes, there are four IgG subclasses and two 
IgA subclasses having further genetic (Fig. 2.2), antigenic, metabolic, 
and structural variation (Table 2.5)85, 97. Further genetic polymorphisms 
(allotypes) in the heavy chain (C) genes of IgG1, IgG2, IgG4, IgA2, IgE, and 
in κ light chain genes are discussed above (Table 2.3)134, 154, 208, 390.
Diff erent antigens evoke specifi c antibody responses that have variable 
(sub)class profi les and, accordingly, variable eff ector functions conferred by 
the Fc portion of the antibody (sub)class (Fig. 2.3, Table 2.4). Th e ability to 
Fc-FcR interaction is an important determinant of eff ector functions that a 
given antibody (sub)class is able to mediate (Tables 2.4 and 2.5)47, 244. Th e 
only FcR that can commonly be found on B cells, FcRγIIb, is an inhibitory 
FcR. FcRγIIb downregulates immune activation and serves as a distant 
checkpoint in B cell maturation against autoimmunity244. Other common 
FcγRs are activating receptors. If several activating receptors of the same 
isotype specifi city are present on the same cell, only those FcγRs that have 
the optimal affi  nity are engaged244. FcRγII and FcRγIII only bind IgG that 
is aggregated in an immune complex207, 244. Th e relative binding effi  ciencies 
to diff erent FcRs are thus determined by the isotype produced during an 
antigenic challenge286. Since diff erent FcRs are expressed on diff erent eff ector 
cells, the isotype produced further modulates the immune response (Table 
2.4). Th is may, for example, regulate the release of Th 1 and Th 2 type cytokines 
by activated cells286. As an example, activated myeloid DCs induce Th 1 
responses mediated by IL-12 secretion, whereas plasmacytoid DCs mediate 
Th 2 responses and the release of IL-4, but little or no IFNγ by CD4+ T cells34. 
Genetic polymorphisms of FcRs may modulate infectious and autoimmune 
diseases (Table 2.4)244. For example, the H131 allele (with histidine in amino 
acid position 131) of FcRγIIA is the only FcγR that binds IgG2. Th e R131 
allele (with arginine) fails to bind IgG2, its frequency is ~ 0.23. Homozygous 
carriage of this R131 allele leads to an impaired removal and phagocytosis 
of encapsulated bacteria and Plasmodium spp. from the bloodstream. It is 
associated with an increased severity of invasive disease caused by these 
pathogens, whereas homozygosity for H131 protects from these207. In persons 
carrying FcγRIIA-H131, IgG2 may mediate opsonophagocytosis47.
IgM
IgM is mostly found in the intravascular pool. Compared with the basic 
Ig structure, it has a high content of carbohydrates. Th ese are N-linked to 
the CHµ1, CHµ2, and CHµ3 domains. IgM exists mainly as a star-shaped 
pentamer (Table 2.5). Two of its monomers are linked by an extra J chain. 
Th e µ chain has an extra CHµ4 domain with a “tail” polypeptide attached 
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to it, and IgM has no hinge. Still, IgM can adopt a crab-like structure when 
bound to its antigen, making it a potent binder of antigens even when its 
affi  nity is low207. Adopting the crab-like orientation leads to the exposure 
of C1q binding site in each subunit of the pentamer. Accordingly, IgM is a 
strong complement activator207. Natural antibodies belong to IgM class, as 
well as those produced in responses against TI antigens (Table 2.2). It is the 
fi rst antibody produced in the primary response (Table 2.2). IgM also acts 
as an opsonin, as well as aids in the clearance of apoptotic cells251. It reacts 
with ABO blood group antigens and fails to cross the placenta. Th is protects 
the fetus against the consequences of blood group incompatibility with the 
mother207. A poorly-characterized IgM/IgA Fc receptor named Fcα/µR may 
mediate B-cell endocytosis of IgM-opsonized bacterial targets393.
IgG and its subclasses
IgG is the major antibody class of the secondary response, and most 
anti-protein antibodies belong to IgG class (Table 2.2)389, 390. It is evenly 
distributed between the intra- and extravascular pools, and accounts for 
70-75% of the total serum Ig population (Table 2.5). Structurally, the overall 
shape of IgG follows the basic Ig structure depicted in Fig. 2.385, 207, 390. IgG 
subclasses display a 95% sequence homology, but diff er in their structural 
and functional properties (Table 2.5)85, 208. IgG1 is the least glycosylated 
subclass310. IgG3, like IgD, has an extended, heavier hinge with additional 
disulfi de bonds compared with the other IgG subclasses. Th is off ers it greater 
fl exibility and thus more adaptable antigen binding. Th e relative fl exibility 
of IgG subclasses is in the order: IgG3 > IgG1 > IgG4 > IgG2390. Half-lives 
of antibody classes vary greatly between individuals, IgG3 and IgG4 having 
the shortest390. 
IgG1 and IgG3 production is thought to be enhanced by Th 1 responses148, 
342. Somewhat paradoxically, in in vitro models IgG1 and IgG3 production 
is enhanced by IL-10 and CD40L128, 262. IgG1 and IgG3 engage all common 
human Fcγ receptors present on cells of the immune system (Table 2.4). 
Th us they are capable of all antibody-mediated eff ector functions47, 85. In 
general, the IgG1- and IgG3-mediated neutralization, complement activation, 
complement-dependent lysis, opsonization, and antibody-dependent cell-
mediated cytotoxicity (ADCC) defend us from intracellular pathogens such 
as viruses90, 184, 219. In particular, ADCC is primarily mediated by IgG1 and 
IgG385. Th e main eff ector cell of ADCC is the NK lymphocyte. Expression 
of foreign antigens on the surface of infected cells leads to their recognition 
by specifi c antibodies. Antibody-coated target cells are then recognized by 
the NK cell FcγRIII receptor (or FcRs on monocytes and macrophages). Th is 
leads to FcRγRIII crosslinking and NK cell activation, granule exocytosis, 
and the release of cytotoxic substances such as perforin and granzymes 
causing cell lysis207. Th e diff ering hinge-region lengths of IgG1 and IgG3 
aff ect their capacity to mediate ADCC and the affi  nity to diff erent FcγRs292. 
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IgG1 is more active than IgG3 in ADCC and complement activation. Its 
plasma concentrations are 10-20 times higher than those of IgG385. IgG1 also 
defends us against pathogens having polysaccharide antigens. In humans, 
IgM, IgG1 and IgG3 are the main complement-fi xing (sub)classes85. 
IgG2 and IgG4 appear during the secondary response. Since IgG2 
and IgG4 generally bind FcγRs only weakly, their main function is in 
the neutralization of extracellular pathogens (Tables 2.4 and 2.5)85. Th e 
production of IgG2 is enhanced by Th 2-dominant responses128, 148, 342. IgG2 
is the most abundant subclass in response to carbohydrate antigens390. IgG2 
activates complement CP only at very high concentrations, but has the ability 
to activate AP (Table 2.5)85. Genetic inter-individual variation in the effi  ciency 
and development of IgG2- and IgG4-mediated protection from pathogens 
exists. G2mn- is, clinically signifi cantly, associated with diminished or missing 
specifi c antibody responses to polysaccharide antigens54, 254, 259. In addition 
to the eff ect of the above-mentioned FcγRIIa-R/H 131 polymorphism in 
IgG2-mediated immunity, FcγRIIIa has F/V158 polymorphism; FcγRIIIa-
V158 is able to engage IgG447. FcγRIIIA -V158 is a putative risk factor of 
chronic periodontitis in Northern European Caucasians204. IgG4 does not 
fi x complement85, 390. It is produced in response to a prolonged exposure 
to mucosal antigens causing Th 2-biased responses, such as those during 
helminth infections and during simultaneous exposure to multiple allergens2, 
128. Unlike other antibody classes, IgG4 is oft en functionally monovalent 
and bispecifi c. Th is is achieved, probably during endocytic salvage, by the 
exchange of half-molecules of IgG4 between two IgG4 molecules having 
diff erent specifi cities2. IgG4 may defend us against parasites, and bispecifi c 
IgG4 may have anti-infl ammatory activities2, 128. 
Secretory IgA and serum IgA
IgA has a more T- than Y-like structure, and it exists in monomeric and 
polymeric (mostly dimeric) forms; monomeric IgA dominates in the serum 
(Table 2.5)393. Approximately 60% of all Igs produced daily belong to the IgA 
isotype, but more than half of this is selectively transported into external 
secretions as secretory IgA (S-IgA)97, 393. In S-IgA, the tailpieces of monomers 
are linked by the J chain. S-IgA also contains the secretory component, 
which is the extracellular proteolytic fragment of the polymeric Ig receptor 
(pIgR) responsible for the transport of IgA and IgM into secretions (Table 
2.5)97, 393. S-IgA is produced locally at mucosal surfaces, mainly by the gut-
associated lymphoid tissue (GALT). Approximately 25% of S-IgA in mice 
is produced thymus-independently by B-1 cells, and 75% comes from B-2 
lymphocytes in response to TD antigens393. S-IgA serves as the fi rst line 
of humoral defense – also in a breast-fed infant – by neutralizing toxins 
and viruses, blocking the entry of bacteria across mucosal surfaces, and by 
opsonizing pathogens393. Th ere is one well-characterized FcαR, FcαRI. It is 
constitutively expressed on many APCs (Table 2.4)234, 393. 
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Serum IgA has a much shorter half-life than IgG (Table 2.5). IgA has 
two subclasses IgA1 and IgA2. Over 90% of B cells with sIgA in the bone 
marrow are IgA1 positive. Accordingly, serum IgA1:IgA2 subclass ratio is 
about 9:1. Th e subclasses are more evenly distributed in secretions. IgA2 
allotypes diff er in their susceptibility to bacterial proteases, but no allotype-
dependent disease associations are known. Binding of antigens to S-IgA fails 
to initiate infl ammatory processes. Even though polymeric IgA is able to 
activate complement LP upon binding to MBL, IgA is a poor opsonizer and 
complement activator. As such it may inhibit and protect mucosal surfaces 
from excessive complement activation by complement-fi xing Igs97, 234, 393. 
Th e function of serum IgA is poorly known, but may have systemic anti-
infl ammatory functions. Yet in experimental conditions binding of antigen-
complexed IgA to FcαRI can initiate infl ammation: ADCC, phagocytosis by 
resident macrophages such as Kupff er cells, release of cytokines, superoxide 
generation, and antigen presentation (Table 2.4)393. IgA defi ciency, the 
most common primary immunodefi ciency, is associated with atopy, 
frequent mucosal infections, and autoimmunity97, 393. SCDs and impaired 
vaccination responses are frequently found in IgA-defi cient patients, but fail 
to diff erentiate those with more severe symptoms5, 109, 123.
IgE and IgD
IgE-committed B cells can be found in the circulation, skin, lungs and 
gut. IgE makes up about 0.002% of the total Ig pool, 50% of it is found 
intravascularly with a short half-life (1-5 days, Table 2.5.)286. Like IgM, IgE 
has an extra CH4 domain and no hinge390. IgE mainly exists bound to its 
receptors on various cells, only very low quantities are present in serum 
(Tables 2.4 and 2.5)286, 390. IgE is produced by Th 2-dominant responses in 
response to IL-4 or IL-13 or both together with CD40L128, 286. Th ere is a 
high affi  nity IgE Fc receptor FcεRI, and two low-affi  nity receptors FcεRIIa 
and b286. FcεRII engagement controls IgE responses60. Th e density of human 
basophil FcεRI α-chain expression correlates with serum IgE286. IgE does not 
activate complement. Instead, activation of complement receptors C3aR and 
C5aR by anaphylatoxins acts synergistically with IgE-mediated responses286. 
Th e main actions of IgE are mediated by mast cells and basophils carrying 
FcεRIs. Th eir activation through FcεRI cross-linking leads to the release 
of secretory granules that contain infl ammatory mediators, proteases, and 
cytokines. Besides immediate IgE-mediated hypersensitivity reactions, mast 
cell activation contributes to the delayed hypersensitivity reaction286. IgE is 
involved in parasite- and allergen-specifi c responses128, 286, 390. Evidence of 
IgE-mediated response, either by skin prick testing or by the measurement 
of allergen-specifi c IgE levels in serum, is required for the diagnosis of 
allergy286. In addition to severe allergies, high levels of IgE are seen in parasitic 
infections, hematological malignancies, autoimmune disorders, hyper-IgE 
syndromes, and several other forms of combined immunodefi ciencies132, 
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286. Absence of measurable serum IgE may point to disturbances of class 
switching (Table 2.1)286.
IgD is mainly found as a membrane-bound BCR, which kinetically is 
expressed aft er IgM. IgD makes up only 0.25% of the Ig population, its serum 
levels are low (Table 2.5). Both sIgM and sIgD of the same specifi city are 
found on unprimed B cells. Upon antigen stimulation, IgD is turned off  and 
IgM secreted. IgD´s precise function is unknown, but it may regulate B cell 
activation, development of immune tolerance, immunologic memory, and 
enhance specifi c IgM, IgA, and IgG responses390. 
5.2.7 Clinical aspects of low IgG subclass levels 
Low levels of IgG subclasses are defi ned as those below two standard 
deviations from the mean. Still, there is a lack of universally accepted 
reference values and analysis methods26, 61, 315. Th e clinical signifi cance of 
any given subclass(es) in patients without any known immunodefi ciency but 
with recurrent infections is unclear and controversial54, 61. Individuals with 
low IgG subclass levels are common and frequently asymptomatic61. Th us, 
the fi nding of low levels of one or more subclasses is generally considered 
insuffi  cient for the diagnosis of immunodefi ciency54. 
At population level, the frequency of having low levels of more than one 
subclass is only known among blood donors, but oft en considered to better 
diff erentiate those with more serious infections61. Th e distribution of low 
(sub)class levels according to age and sex is uneven. In children, there is a 
3:1 male: female preponderance235. Boys more frequently have low IgG1192. 
Refl ecting the allotype-associated delayed maturation of IgG2- and IgG4-
mediated humoral immune responses against polysaccharide antigens, low 
IgG2 (associated with G2mn) and abnormal vaccine responses (associated 
with IgA defi ciency and G2mn-) are relatively more frequent in children61, 
235, 257, 259, 263. Aft er puberty, low IgG1 and IgG3 levels together with female 
preponderance become more common26, 235. Nearly half of symptomatic 
SCD patients aged more than 40 have low IgG126.
IgG1 subclass is the quantitatively predominant IgG subclass and may 
lead to low total IgG levels. Genetically, serum IgG1 levels below two 
standard deviations from the mean (“[partial] IgG1 subclass defi ciency”) 
are uncommonly associated with heterozygous Cγ1 deletions, and more 
commonly with the G1mf allotype, regardless of the full haplotype (see 
above)262, 326. Clinically, selective IgG1 defi ciency (without low levels of other 
[sub]classes) is associated with mostly moderate upper respiratory tract 
infections and sinusitis caused by pathogens found in patients with humoral 
immunodefi ciencies, e.g. S. pneumoniae, H. infuenzae. According to the largest 
available study on 119 symptomatic IgG1-defi cient patients, approximately 
9% suff er from invasive infections (e.g. severe bronchopulmonary infections 
with bronchiectasia, gastrointestinal infections, septicemia, or meningitis). 
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Vaccination responses were not tested in the study192. Severely symptomatic 
patients with low IgG1 levels, especially if an impaired response to 
carbohydrate antigens is found, are more properly diagnosed as having 
CVID. Th ese patients fulfi ll the internationally accepted diagnostic criteria 
for possible CVID54, 87. If prophylactic antibiotics are not suffi  cient for the 
treatment, these patients are candidates for intravenous or subcutaneous 
immunoglobulin treatment54, 254.
Low IgG3 levels, regardless of the full Gm haplotype, are codominantly 
associated with the G3mg allotype326. Th ey are also autosomally dominantly 
associated with the HLA-B*8,SC01,DR*3 haplotype10. The clinical 
signifi cance of low IgG3 levels is controversial61. In relatively small patient 
populations, frequent but mild upper respiratory tract infections, bronchitis, 
bronchopneumonias, bronchial asthma, erysipelas episodes, and herpes 
simplex recurrences have been noted26, 235, 260. Of haplotypes carrying the low 
producing allotype G3mg in Caucasians, the G3mg,G1ma,G2mn- haplotype 
with G2mn- is more frequent (~ 0.30) than G3mg,G1ma,G2mn (~ 0.01). 
Despite this, diminished vaccination responses are rarely seen in patients 
with IgG3 defi ciency37.
In adults, low IgG2 levels are associated with the G2mn- allotype. During 
childhood, low serum IgG2 may be caused by the retarded maturation of 
IgG2 production in connection with the G2mn allele259. IgG2 defi ciency 
alone is commonly asymptomatic. In children, low IgG2 is relatively weakly 
and diminished vaccination responses relatively strongly associated with 
recurrent sinopulmonary infections caused by the typical pathogens S. 
pneumoniae, H. infl uenzae, and M. catarrhalis61. Th ough low polysaccharide 
antigen responses are most commonly seen in subjects with IgG2 defi ciency, 
severely symptomatic specifi c antibody defi ciency without low subclass levels 
is not infrequently encountered in specialized centers54. Symptomatic IgG2 
or IgA defi ciencies in childhood may progress to full-blown CVID54, 140. 
Patients may also become asymptomatic or (sub)class levels and vaccination 
responses may become normal or both54, 254. No consensus on the clinical 
phenotype of subjects with selective low IgG4 exists, but in studies on sinus 
infections it is most oft en seen in control groups18, 153, 222, 262, 313, 355.
Combined low IgG subclass levels
Th e genetic causes of a combined partial IgG1 and IgG3 SCD are mostly 
unknown. It is thought to be associated with Th 2-dominant immune responses 
aff ecting class switching of neighboring genes (Fig. 2.2)148, 342. Associations 
between low IgG3, IgG1, IgA1, and IgA2 levels and clinical diseases are 
complex and allotype-dependent. IgA defi ciency by itself predisposes to 
atopic and autoimmune diseases54, 97. Persons with IgA defi ciency may have 
more severely decreased lung function if it occurs together with decreased 
IgG2 or IgG3 levels5, 49. Patients with nonatopic or atopic bronchial asthma 
with sinopulmonary symptoms frequently have low IgG1 or IgG3192, 257. 
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Atopic diseases causing sinopulmonary symptoms in patients with associated 
IgG1, IgG3, and IgA defi ciencies frequently cause misguided therapy and 
diagnostic confusion with recurrent sinopulmonary infections61, 97, 192. A 
higher prevalence of familial bronchial asthma and IgE-mediated atopy is 
seen in persons with the G3mb,G1mf,G2mn haplotype associated with high 
serum IgG3, low IgG1, and high IgG2192, 257. Nonatopic, but asthmatic, 
children tend to have the opposite haplotype G3mg,G1ma,G2mn- associated 
with low IgG3, high IgG1, and low IgG2257. Likewise, low levels of IgA2 are 
found together with the G3mg allotype221. Accordingly, both low IgG1 and 
low IgG3 levels are associated with chronic obstructive lung disease and 
lower respiratory tract infections260. Combined IgG1 and IgG3 defi ciency 
may be seen in CVID patients, though G2mn- homozygotes and combined 
IgG2, IgG4, and IgA defi ciencies are more common258, 261, 285. 
Vaccination responses and low subclass levels in clinical practice
Diminished vaccination responses to polysaccharide antigens are associated 
with the G2mn- allotype and low levels of IgG2, IgA1, IgG4, and IgA2 
(encoded by neighboring genes). In the clinic, all these are more commonly 
found in children than in adults54, 235, 259, 263. In pediatric practice, vaccination 
responses are preferentially used in patient assessment, and subclass levels 
are rarely measured since poor vaccination responses have been found to 
better predict recurrent infections61. Yet subjects with impaired responses to 
polysaccharide antigens are commonly asymptomatic. Impaired responses 
are seen in the studied populations, as a mixed co-dominant trait, in more 
than 10% of subjects238, 263. Th ere is no universally accepted method for 
the assessment of vaccination responses. Antigens and the valency of the 
vaccines diff er, and diff erent age-specifi c criteria may be used54, 238. Th e use 
of subclass-specifi c responses may be advocated372. Clinical centers assess 
antipneumococcal responses either by using the sum of all responses, or 
defi ne an impaired response as an inadequate response to ≥ 70% serotypes 
measured54, 339. Th reshold values, numbers of pneumococcal serotypes, 
and pre-adsorption methods used are highly variable54, 339, 372. Severely 
symptomatic patients with impaired vaccination responses are said to 
suff er from specifi c antibody defi ciency (SAD). Many of these patients 
are diagnosed only aft er the age of 40, and ~80% suff er from recurrent 
sinus infections78. Yet impaired responses to carbohydrate antigens in 
middle-aged patients with highly-symptomatic sinopulmonary infections 
are surprisingly infrequent, and poorly diff erentiate between symptomatic 
and asymptomatic patients109, 222, 238, 339. When 245 successive, mostly adult, 
patients with recalcitrant rhinosinusitis and SCDs were tested, no adults 
with diminished vaccination responses were found222. Th e highly variable 
clinical phenotype of subjects with low subclass levels or an inability to 
mount antipolysaccharide responses or both suggests that additional genetic, 
regulatory, or structural defects infl uence, or are the true cause of, infection-
proneness169, 262.
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Despite being the two most commonly used methods, the relative clinical 
values of IgG subclass levels and vaccination responses in the assessment of 
adult patients with recurrent infections are unknown. Subclass concentrations 
(other than IgG2) and vaccination responses have been simultaneously 
measured in three pediatric studies. A study on 27 allergic children suff ering 
from recurrent sinusitis reported frequent low subclass levels and no 
diminished responses93. In 61 young children with recalcitrant sinusitis, 
21 patients had low response to one serotype and two to two serotypes 
(4 tested), four hyporesponsive patients also had low subclass values but 
normal IgG. Seven additional patients had only low IgG2 or IgG3331. In a 
study on 165 symptomatic subjects with unreported symptoms and age, 
both IgG subclasses and vaccination responses were measured in 59% of 
the subjects. Total responses to 1-4 vaccines (against tetanus, diphtheria, 
H. infl uenzae, or pneumococci, in varying combinations) were assessed. 
With an in-house nephelometric assay, there was a very low frequency 
of low subclass values (5.2%). According to authors’ assessment, but with 
unreported criteria, only specifi c antibody measurements infl uenced the 
management of the patient290. Hypothetically, simultaneous assessment of 
multiple parameters (e.g. subclass levels, Ig allotypes, vaccination responses, 
FcR polymorphisms, complement defi ciencies, CD27-IgM+IgD+ memory 
B cells) may more reliably predict diff ering clinical phenotypes of patients5, 
168, 169, 262. In the future, enumeration of B cell subsets may even substitute 
some of the earlier assessment methods6, 69.
5.2.8 Laboratory assessment of immunoglobulin levels and 
allotypes
Normal immunoglobulin levels depend on the age and sex of the individual 
as well as on the ethnic background. Total Ig and Ig subclass levels from 
plasma, serum, or bodily secretions are usually measured with radial 
immunodiff usion or nephelometry. In radial immunodiff usion, the antigen 
(Ig class measured) is allowed to diff use radially into a gel that contains 
antibody (anti-Ig antibody). Th e size of the precipitin ring is directly 
proportional to the concentration of the antigen, which is determined relative 
to standards containing known amounts of antigen. Radial immunodiff usion 
is particularly useful when trace concentrations of Ig are present in the tested 
sample50. Compared with older methods, automated nephelometry is faster, 
more precise, and less variable. In solution, specifi c reaction between the 
measured Ig (sub)class and monospecifi c high-avidity antiserum creates 
immune complexes. Th ese are quantifi ed either by end-point or rate 
nephelometry. Scattered light, which increases with antigen concentration, is 
measured. In end-point nephelometry, maximum scattered light is measured 
aft er antigen-antibody reaction has reached equilibrium or aft er a fi xed 
reaction time. Ig concentration is calculated relative to calibration curves, 
59
which are obtained with standard serum containing known amounts of 
antigen (Ig class) tested under similar conditions (including antiserum 
and equipment). At the same time, a control serum is assayed to check the 
validity of the calibration curves and the accuracy of the assay. Non-specifi c 
light-scatter may be observed in turbid (e.g. lipemic) samples or at low 
dilutions of serum samples (when trace concentrations are measured). Th is 
can be detected by running a parallel assay, in which the anti-Ig antibody 
is omitted (“blank reagent”). Rate nephelometry, which measures the peak 
rate of immune complex formation relative to a reference curve, is employed 
especially in the USA50. Mostly polyclonal antisera are used in all methods. 
No universally accepted antisera or reference values exist, and normally 
in-house or manufacturers’ reference values are used26, 315.
Serologically, allotypic markers are detected, for example, with double 
diff usion precipitation in gel or obtained as a byproduct of their quantitation 
with an inhibition ELISA, usually by employing in-house methods312, 326. 
Allotype-specifi c monoclonal antibodies are used134. Specifi c serologic 
reagents against the products of some allelic genes (e.g. G2mn-) are not 
available. Numerous polymorphic sites in the switch regions, Ig genes, and 
pseudogene regions occur at IGH@ (Fig. 2.2). Many of them are in positions 
which do not carry codons for Gm, Am, or Em. Th ese polymorphisms are 
mostly in linkage disequilibrium with Gm and Am. Polymorphisms in the Sµ 
and Cδ gene regions are an exception (Fig. 2.2)134. Consequently, allotyping at 
the gene level is experimentally performed in highly specialized laboratories, 
usually in epidemiologic genetic studies134.
5.3 Human major histocompatibility region and human 
leukocyte antigens
Human immune system must recognize a high diversity of micro- and 
macroorganisms. Diff erent eff ector mechanisms must be applied against 
these organisms. For example, the elimination of intra- or extracellular 
microorganisms and intestinal worms requires diff erent eff ector functions. 
Unlike B cells and antibodies, MHC molecules recognize both the presence 
and the location of a pathogen. Th is is achieved by two classes of MHC 
molecules. MHC molecules present antigenic peptide structures (derived from 
self-antigens or pathogens) to TCRs. Class I molecules recognize invading 
intracellular and class II molecules extracellular organisms179, 180.
MHC gene region
Major histocompatibility region includes a physical region on the short 
arm of chromosome six (6p21.3) that spans ~ 4700 kb. MHC was fi rst fully 
sequenced, as a mosaic of diff erent haplotypes, in 1999179. With high density, 
it encodes ~ 240 genes, of which ~ 130 are considered to be functional. At 
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least 40% of the functional genes are involved in immune response67. MHC 
is divided into three distinct non-overlapping regions: class I, class II, and 
class III. Th e regions localize, from the telomeric to centromeric end of the 
region, in the order MHC I (1.8 Mb), MHC III (0.7 Mb), and MHC II (0.7 
Mb). Relatively strong associations with MHC genes have been found in 
> 100 diseases332. Characteristically, MHC contains large numbers of gene 
duplications and pseudogenes. It has the largest number of polymorphic 
proteins within the human genome. Some HLA genes are known to have > 
200 alleles. Of MHC genes, ~ 44 are HLA-related and ~ 180 are non-HLA 
genes179, 332. Th e extremely high level of polymorphism and heterozygosity 
is thought to increase the host’s fi tness against infections by providing 
the immune system with a selective advantage against the variability of 
pathogens67. Less advantageously, the high level of mutation in HLA genes 
may result in susceptibility to infections, autoimmune and infl ammatory 
diseases180. MHC genes are inherited as haplotypes. Accordingly, genetic 
linkage analyses are marred by the large number of functionally related and 
active loci, and the strong linkage disequilibrium between these loci within 
the MHC9, 67. Except for the “classical” class I and II molecules, there is little 
data to support any functional signifi cance for most of the polymorphisms 
identifi ed; they may only serve as markers for the neighboring disease loci 
(e.g. transporters of antigen presentation TAP1 and TAP2)67. 
HLA nomenclature
Replacing older HLA nomenclatures, in the contemporary (gene level) 
nomenclature the lettered class (and in class II, family and chain) designation 
is followed by an individual Arabic numeral for the gene, aft er which the 
numerous allelic variants are diff erentiated by a numeric notation preceded 
by an asterisk217. For example, HLA-DRB1*0401 stands for allelic variant 
0401 of gene 1, encoding the β-chain of a class II molecule that belongs to 
family R179.
MHC class I genes and function of class I molecules in host defense 
Class I genes code for the α-polypeptide chain of the class I molecule; the gene 
encoding the β-chain (β2-microglobulin, B2M) is located on chromosome 
15. Additionally, class I encodes e.g. two coding MHC class I chain-related 
genes (MIC) A and B. Of the 6 non-pseudogenes in MHC I, HLA-A, -B, and -
C are called “classical” (class Ia) genes and HLA-E, -F, and -G are called “non-
classical” class Ib genes. Ib genes also encode respective α-chains. MICA and 
MICB are involved in interactions with γδ T cells, HLA-E in interactions 
with NK cells and together with HLA-G, in immune tolerance179, 332.
Class Ia antigens are highly polymorphic, ubiquitously expressed cellular 
membrane-bound glycoproteins, which together with B2M form the class 
Ia molecule. Each assembled class Ia molecule is able to bind a diff erent 
range of peptides (of 8-11 amino acid residues) that are generated when 
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an intracellular pathogen infects the cell. Aft er tight intracellular control, 
class Ia molecules present the intracellularly processed, short, pathogen-
derived peptide antigens with the help of their peptide-binding grooves. Th is 
presentation to TCRs of CD8+ T cells takes place on the surface of the cell 
and initiates a cytotoxic response. Class Ia molecules are thus specialized 
for recognition of intracellular pathogens (such as viruses) that infect any 
somatic cells of the host179.
MHC class II genes and function of class II molecules in host defense
Listing from the telomere to the centromere, the classical MHC II genes 
HLA-DR (which oft en contain an additional β-chain gene), -DQ, and -DP are 
organized in pairs: one locus encodes the α- and the other the β-polypeptide 
chain of the class II molecule. Between HLA-Q and -P, “non-classical” class 
II genes encode α- and β- chains of molecules that inhibit (HLA-DO; on B 
cells) or catalyze (HLA-DM; on all professional APCs) peptide-binding to 
class I molecules. MHC II also contains genes that encode other molecules 
involved in antigen processing and presentation, for example tapasin, TAP1, 
and TAP2179, 332.
Analogous to HLA Ia molecules, the α- and β-chains associate with 
each other and form a heterodimeric class IIa molecule. It associates with 
the invariant chain (Ii) in the endoplasmic reticulum. Invariant chain is 
involved in the maturation of the molecule, and in antigen binding and 
presentation. Eventually, each class II molecule will present, in its peptide-
binding groove, a diff erent range of peptides (of 15-25 amino acid residues 
in length) at the cell surface. Th e use of class II molecules is usually restricted 
to the professional APCs (DCs, B cells and macrophages). Class II molecules 
primarily present, to CD4+ helper T cells, pathogenic antigens that enter 
by phagocytosis into the APCs. Th ey thus play an important role in defense 
against extracellular pathogens such as bacteria and parasites179.
Th e extensive allelic polymorphism in HLA molecules is concentrated 
mainly among amino acid positions that determine their specifi city for 
foreign peptides67. Due to protein processing, there are roughly 100 000-
300 000 peptide-laden class I or II products of each of the highly expressed 
HLA loci on the cell surface. Uninfected cells display hundreds of thousands 
of self peptides on their cells. Simultaneous expression of all three classical 
HLA I and three to four classical HLA II molecules at the surface of cells 
enables the immune system to simultaneously recognize a wide array of 
pathogen-produced peptide antigens179.
MHC, infectious diseases, and HLA homozygosity
For successful protection against a pathogen, an individual’s HLA molecules 
must be able to bind pathogen-derived molecules, and the T and B cell 
repertoires must include clones that can be activated by the HLA molecule-
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peptide complex. If either of these requirements is not fulfi lled, this may 
render a person carrying such ineffi  cient combination of HLA molecules 
susceptible to the given pathogen. Malaria, HIV, hepatitis B, hepatitis C, 
and mycobacterial diseases display the strongest recognized associations 
between pathogens and specifi c HLA alleles67, 179. For example, B*5301 and 
the haplotype DRB1*1302,DQB1*0501 protect against severe malaria. In 
endemic areas, this confers a selection advantage. B*5301 is present in ~ 25% 
of Gambians, but only in ~ 1% of Europeans67, 179. Other consistently reported 
associations have been those between slow progression of HIV and B*27 and 
B*57, rapid progression of HIV and B*35-Px alleles, clearance of hepatitis B 
and DRB1*1302, and clearance of hepatitis C and DQB1*030167. In herpes 
simplex type 2 infections, an uneven distribution of HLA alleles between 
patients and control subjects has been reported200. In bacterial infections, 
HLA associations have rarely been studied. Recurrent sinopulmonary 
infections without any apparent primary immunodefi ciency and with normal 
Ig levels have been associated with HLA-B*44168. Given the large number 
of HLA alleles, conclusive association study on the infl uence of HLA on an 
infectious disease requires large samples, accurate clinical information, and 
proper statistical design and statistical models67, 179.
Hypothetically, individuals heterozygous at the HLA loci present a greater 
variety of antigenic peptides to eff ector cells than homozygotes. Th is may 
result in more effi  cient handling of pathogenic challenges. Th is phenomenon 
is called heterozygote advantage. Homozygosity of MHC genes may allow 
viral escape from cytotoxic T cell responses. Heterozygote advantage against 
rapid progression has been reported between HIV and HLA-A and –B loci, 
as well as against chronicity between hepatitis B and C and HLA-DR and 
-DQ loci67. In addition, a heterozygote disadvantage has been reported in 
succumbing to malaria and in progression of hepatic fi brosis in patients 
with chronic hepatitis. Th us, a broad immune response may also result in 
overt injury270.
5.4 Studied mucosal infections, immune defense, and 
immune evasion
5.4.1 Herpes simplex viruses type 1 and 2
Herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2) belong to α-
herpesviruses. Th ey have diverged approximately 8 million years ago. 
Th e virion has an electron-dense core containing the viral DNA, an 
icosapentahedral capsid, an amorphous layer of proteins surrounding 
the capsid called tegument, and an envelope. Th ey have a large double-
63
stranded DNA molecule386. Th e genomic structures of HSV-1 and HSV-2 
are identical; their genomic sequences are closely related with over 50% 
homology92, 245. Th e type-specifi c genomic regions appear to be important 
in host immunity. 
Both species have a total of 74 genes encoding distinct proteins, with 10 
additional genes proposed245. Each protein serves multiple, in total several 
hundred diff erent functions386. Most of the produced polypeptides are 
antigenically related. Th eir diff erences can be used in serologic diagnosis 
and seroepidemiology273, 375. Th e viral envelopes contain at least 12 viral 
glycoproteins, fi ve of these (gB, gC, gD, gH, and gL) mediate entry and 
cell-binding to host receptors (e.g. heparan sulphate, nectin-1 and -2, and 
herpesvirus entry mediator)340. gD and the gE/gI heterodimer further 
mediate cell-to-cell spread279. Both viruses have multiple strains57. 
Aft er the fusion of the virion envelope with the host cell membrane, 
the synthesis of viral gene products (RNA and proteins) commences in 
three sequential waves. Immediate early (α) gene products shut off  host 
protein synthesis by increasing cellular RNA degradation and block the 
presentation of antigenic peptides on infected cell surfaces, as well as turn 
on the transcription of early (β) genes. Th e β-polypeptides – the main targets 
for antiherpetic medication – are mainly regulatory proteins and enzymes 
required for DNA replication or they post-translationally modify viral 
proteins and their function. Th e third (γ) class of HSV proteins requires viral 
DNA replication for expression. Th ey assemble to form the capsid, tegument, 
and eventually the envelope, before virion transport to extracellular space 
aft er approximately 18 hours92, 387.
HSVs are able to establish latent life-long infections and to reactivate 
– with or without symptoms – despite pre-existing adaptive immunity. 
Aft er acquisition, the virus replicates in epidermal and dermal cells and 
further infects either sensory or autonomic nerve cells121. Th e virus or its 
nucleocapsid is transported by retrograde intra-axonal fl ow to the nerve 
bodies in ganglia, most commonly trigeminal or spinal sensory ganglia in the 
posterior horn. Experimentally, the virus replicates inside the ganglia and in 
surrounding neural tissue during the initial phase of infection. Th e neurons 
become productively infected, and the virus is transmitted along synapses to 
more distant sites181. Th e virus then centrifugally migrates to other mucosal 
sites, causing the more severe clinical manifestations of a primary disease92. 
Th ough HSV-1 favors trigeminal and HSV-2 sacral ganglia, virtually any site 
in the central nervous system can be infected, even without readily apparent 
clinical symptoms322. Th e so-called latency-associated transcript region 
specifi c for a given subtype is thought to determine the site specifi city of 
recurrences. Aft er the resolution of primary disease no infectious virus, only 
viral DNA, can be found in 10-50% of the ganglion cells of the corresponding 
anatomical region. Th e viral genome then resides within neuronal cells in 
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a latent state, without gene expression of the productive cycle110. A limited 
transcription of viral genome to RNA does occur, producing latency-
associated transcripts387. Th ese may allow more frequent reactivations110.
Transmission and epidemiology
Humans constitute the sole reservoir for transmission of HSVs386. HSV is 
most commonly transmitted through close contact with a carrier who is 
asymptomatically shedding the virus at a peripheral site. Th e host is infected 
aft er direct inoculation of the virus onto susceptible (e.g. oropharyngeal, 
genital, conjuctival) mucosal or fi ssured skin surfaces exposed to a mucosal 
site, oral or genital secretions92. Th e fi rst acquired HSV (type 1 or 2) infection 
is called the primary fi rst episode59. When a carrier of either HSV-1 or HSV-2 
acquires the remaining HSV type, the infection is called the initial infection, 
or non-primary fi rst episode59. Primary and initial infections are oft en 
asymptomatic. Only 37-52% of primary infections are symptomatic91, 195. 
Asymptomatic seroconversion is 2.6 times more likely in patients with initial, 
non-primary HSV-2 infection195. In 15-25% of patients, symptomatic infection 
occurs aft er a latent period and is called the fi rst clinical episode59, 195. If the 
two subtypes reside in the same anatomical regions, they both can reactivate 
and cause clinical symptoms (called recurrence or recrudescence)353. Strains 
with increased virulence have been described366. Exogenous reinfections 
with diff erent strains, called superinfections, are rare. Th ey have occasionally 
been associated with more aggressive clinical course295.
Herpes simplex viruses occur worldwide. Seroprevalences vary according 
to e.g. age, region, socio-economic status, and the number of sex partners273. 
In Finland, the age-standardized seroprevalences are 52.4% for HSV-1 and 
13.4% for HSV-2. Females are more commonly seropositive273. Th e mean 
age of HSV-1 acquisition has shift ed to older age groups (over 25 years 
of age in Finland), and has been associated with a higher rate of HSV-
1 genital infections and an altered clinical course of HSV-1 and HSV-2 
infections114, 273, 274. Th e rate of transmission of HSV-2 is in women about 
9 and in men 1.5 per 10 000 sex contacts195, 377. Pregnant women are more 
susceptible to acquire HSV infections127. In serodiscordant couples, the 
yearly risk is 6-11% for women and 1-3% for men. Th erapy with valaciclovir 
reduces transmission, and condoms off er partial protection for women91, 377. 
Symptomatic genital herpes leads to impaired self-esteem, sexual functioning, 
personal relationships, and ability to work. It causes a signifi cant decrease 
in the quality of life, most notably when the yearly recurrence rate is six or 
more271.
Reactivations are induced e.g. by mechanical stress, instrumentation, high 
levels of ultraviolet light, menses, lactation, malnutrition, extensive fatigue, 
anxiety, and infections with other viruses387. Asymptomatic shedding is 
common and can further be provoked e.g. by hormonal contraception and 
bacterial vaginosis80. Th e reported rates of shedding vary according to the 
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immunocompetence of the host and the survey methods. If PCR is used for 
assessment, approximately 76-100% of immunocompetent HSV-1 carriers 
shed the virus at least once during 2-11.5 months of follow-up99. Similar 
frequencies have been noted for HSV-2 infection, in which most, if not all, 
seropositives are likewise considered infectious307. HSV is shed from multiple 
anatomical sites. In genital HSV-1 and orolabial HSV-2, the frequencies of 
shedding are lower than for the other subtype307, 376.
Clinical syndromes
Herpes simplex viruses cause multiple clinical syndromes, but infections 
caused by the two types are clinically indistinguishable (Table 3.1)92. Th e 
probability to cause a given manifestation and the severity of symptoms 
vary according to the subtype, strain, anatomical region, age, and 
immunocompetence of the host. In immunodefi cient patients and neonates, 
atypical and severe manifestations are reported more frequently92, 387. In 
otherwise immunocompetent patients, HSV may rarely cause e.g. cranial 
neuritis, brainstem encephalitis, transverse myelitis, meningoencephalitis, 
radiculomyelitis, sacral radiculomyelitis with parasympathetic ganglionitis 
and urinary retention (Elsberg’s syndrome), brachial neuritis, urethritis, 
and visceral infections (e.g. lungs, liver)156, 241, 359. Th e pathogenesis of some 
clinical syndromes such as herpetic keratitis and herpes-associated erythema 
multiforme is considered to have an autoimmune component28. Whether 
the found serious sequelae in immunocompetent individuals are caused by 
diff erences in viral virulence or by unidentifi ed narrow immunodefi ciencies 
is unknown.
Oral-facial infections and recurrent gingivostomatitis
A primary oral-facial HSV-1 infection in children is usually asymptomatic75, 
318. Primary herpetic gingivostomatitis, with fever and oral lesions lasting 
10-14 days, is the most common specifi c syndrome. It is symptomatic in 25-
30% of children acquiring the disease, and occurs most commonly before the 
age of three13. HSV-1 viremia has been observed in 34% of cases142. In young 
adults, HSV-1 accounts for 10% of cases of pharyngitis and tonsillitis345. 
Approximately 15-30% of HSV-1 seropositive individuals develop recurrent 
labial herpes33, 347. One quarter of symptomatic adult volunteers experience 
recurrences more than once per month. Th e frequency and severity of 
recurrences decreases with time33, 347.
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Table 3.1 Most frequently reported clinical manifestations of HSV infections in 
immunocompetent individuals
Common syndromes Common agent
Orofacial infections Primary gingivostomatitis HSV-1
Primary pharyngitis HSV-1
Recurrent labial herpes HSV-1
Recurrent facial infections HSV-1
Genital infections Primary genital herpes HSV-2 and HSV-1
Recurrent genital herpes HSV-2 and HSV-1
Proctitis and perianal infections HSV-2 and HSV-1
Common complications
Extraoral and -genital lesions Buttock, groin, and thigh HSV-2
Perioral, facial and intranasal lesions HSV-1
Herpetic whitlow HSV-1 and HSV-2
Central nervous system Aseptic meningitis HSV-2
Uncommon complications
Extraoral and -genital lesions Herpes gladiatorum and venatorum HSV-1 and HSV-2
Generalized eczema herpeticum HSV-1
Ocular complications Blepharitis, conjuctivitis, keratitis HSV-1
Chorioretinitis HSV-1 and HSV-2
Acute necrotizing retinitis HSV-1 and HSV-2
Central nervous system Recurrent aseptic meningitis HSV-2
Encephalitis HSV-1
Neonatal herpes HSV-1
Immunologic sequelae Herpes-associated erythema multiforme HSV-1
Rare complications
Intraoral Recurrent gingivostomatitis HSV-1
Visceral infections Esophagitis, pneumonitis, hepatitis HSV-1 and HSV-2
Autonomic and sensory nervous system Autonomic dysfunction and neuralgia HSV-2
Central nervous system Transverse myelitis HSV-2
Disseminated infection Cutaneous and multiple organs HSV-1 and HSV-2
In immunocompetent children, primary intraoral infection occurs mainly 
on non-keratinized tissues, most oft en on inner lip and buccal mucosa. 
Most recurrent lesions develop within keratinized epithelial tissues at the 
mucocutaneous junction of the lip. Of symptomatic patients with labial or 
genital HSV-1, 16-29% have manifestations at a distant site. Intranasal, facial, 
and hand lesions, erythema multiforme, and keratitis are the most common 
complications33, 42, 347. Recurrent intraoral lesions usually develop within 
keratinized tissues on the hard palate, gingiva, or tongue111, 121. In adults, 
nonprimary intraoral lesions are mainly seen in immunosuppressed patients 
with lymphopenia or monocytopenia320, 392. Unlike in immunocompetent 
patients, non-keratinized mucosa represents approximately 50% of all 
sites111, 392. Th e diff erential diagnosis of intraoral ulcers is complex. Atypical 
manifestations such as glossitis have been reported in patients with secondary 
immunodefi ciency243. 
Primary herpetic gingivostomatitis is only occasionally seen in 
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immunocompetent adults76, 82, 111, 147. Recurrent disease is rarely seen. During 
the last 16 years, approximately 52 adult patients with ≥ 1 clinical recurrence 
have been described in the Anglo-Saxon literature82, 111, 147, 308. Only 28 of 
these have suff ered from multiple recurrences111, 308. All the reports come 
from tertiary referral centers. Th e clinical course of adult patients follows a 
more severe course than that seen in young children147. 
Genital HSV-2 infections, reactivations, and neuralgias 
Symptomatic primary genital herpes frequently manifests as multiple lesions 
within non-keratinized epithelial cells (urethra, medial aspects of the labia 
minora, vagina, and exocervix) and keratinized epithelial cells (penis, lateral 
aspects of the labia minora, and external genitalia). In immunocompetent 
individuals, recurrent lesions mainly develop within keratinized tissues89, 
121. During the fi rst clinical episode of genital herpes, extragenital lesions 
are observed in 25%, 9%, and 2% of patients with primary HSV-1, primary 
HSV-2, and initial HSV-2 infection, respectively. Of these patients, 50% 
will subsequently have extragenital recurrences42. Aft er primary HSV-2 
with genital lesions only, 6.5% of patients will develop non-genital lesions 
over time42. Extragenital HSV-2 recurrences are mainly seen below the 
waist, on the buttocks and legs42, 89. Dermatomal neuralgias have been 
reported mainly in those 0.04-0.7% of individuals with concurrent aseptic 
meningitis, dysfunction of sacral autonomic nervous system, and urinary 
retention during primary infection (Elsberg’s syndrome)89, 91. In those with 
recurrent dermatomal neuralgias, neuralgia is usually the most bothersome 
symptom89.
Severe and widespread primary infections are associated with higher 
recurrence rates40, 42. Suppressive antiviral therapy, previous HSV-1 infection, 
and condom use at the time of the primary infection reduce the frequency 
of the subsequent clinical disease. Female gender, high number of sexual 
partners, and previous sexually transmitted diseases increase the likelihood 
of clinical episodes89, 91, 195. Frequent recurrences are less likely in those with 
HSV-1 genital infection, in a disease manifesting as buttock lesions, and 
those with remotely acquired infection during the fi rst clinical episode42, 
102, 114.
Data on recurrence rates among seropositive persons are limited. Data 
mostly come from studies by Benedetti et al., whose patients come from 
a specialized referral center established for the study of genital herpes. In 
15 years, they were able to recruit 457 referred patients with fi rst-episode 
genital HSV and unknown HIV-status, likely suff ering from more severe 
disease40-42. Of HSV-2 patients, 89% experienced a fi rst-year recurrence, 
the median rate of recurrences was fi ve per year among men, and four per 
year among women40. Of these patients, 38% had ≥ 6 recurrences, and 26% 
of men, 14% of women had ≥ 10 recurrences during the fi rst year40. Th ose 
with a longer follow-up (1–8 years) represent the subgroup of patients 
68
with a severe primary and a recurrent disease. In these, with a mean fi rst-
year rate of 8.5 recurrences, the annual decrease of recurrence rate was 0.7 
recurrences per year41. Based on this selected material, approximately 10% 
of genital herpes patients will have ≥ 10 annual recurrences.
Diagnosis
Diagnostic methods to establish the diagnosis of HSV infection include 
viral culture, antigen detection, nucleic acid amplifi cation techniques, and 
serologic tests306. Serologic tests accurately distinguish between HSV-1 and 
HSV-2375. When modern enzyme-linked immunoassay methods testing type-
specifi c antibodies against gG are used, seroconversion in primary or initial 
infection takes place aft er approximately 3 weeks23. Intrathecal antibody 
detection may be used in central nervous system infections. It has an overall 
specifi city and sensitivity of ~ 80% in herpes encephalitis. Yet intrathecal 
antibodies take 10-12 days to develop, the response may be delayed or absent, 
and cross-reactivity with varicella zoster is seen176. Th erefore, nucleic acid 
amplifi cation tests are the primary diagnostic methods in central nervous 
system infections. 
Since serum seropositivity is common, the demonstration of anti-HSV-IgG 
in serum unreliably distinguishes HSV infection from other diseases causing 
compatible disease forms. Th us in acute disease manifesting with vesicular 
or ulcerative lesions, viral culture and typing of HSV remains the preferred 
diagnostic method306. Its sensitivity, when used to test early vesicular lesions, 
is ~ 90% and falls to ~ 70% in ulcerative lesions, and further to ~ 27% in 
crusted lesions306. Cytospin-enhanced direct immunofl uorescence assays 
to detect HSV antigen may be preferred, because they are rapid and do not 
require living viruses in the sample193. Nucleic acid amplifi cation tests to 
detect HSVs use type-specifi c primers. Th ese tests are highly specifi c and 
sensitive, and they also do not require living virus. Since asymptomatic 
shedding is common, and also takes place during diseases that mimic HSV 
infection, care should be exercised in atypical disease forms when laboratory 
results of samples taken from mucosal sites are interpreted306. When isolation 
of HSV is attempted from otherwise sterile samples (such as cerebrospinal 
fl uid), nucleic acid amplifi cation tests have become the diagnostic gold 
standard176. 
Immune response to infection
Th e clinical recurrence rate of HSV-2 is thought to depend on the immune 
profi ciency of an immunocompetent host, but the predisposing genetic 
factors are largely unknown181, 385. During primary infection, the free virion 
encounters and evades from ever-present, secreted host proteins such as 
complement and natural IgM antibodies105, 152. Th e free HSV virion is also 
recognized by TLR2 and TLR9 on stromal cells, NKs, macrophages, and 
DCs present on infected area236. At an early stage, infected epithelial cells 
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and resident DCs produce type I IFNs (IFNαβ)105. During the next 1-2 
days, recognition by humoral innate immunity triggers the recruitment of 
neutrophils, monocytes, and activated NK cells to the area. IFNγ production 
by recruited NK and T cells commences aft er 2-4 days105. Adaptive responses 
and resolution of the primary infection is delayed in humans, with CD4+ 
T cell responses developing approximately 7-10 days, and ADCC 8-10 
days aft er disease onset183, 387. A robust DC-driven Th 1-dominant cytokine 
response is considered important105, 250, 281. Within infected ganglionic cells 
and peripheral sites, resolution is dependent on and temporally associated 
with the infi ltration of CD8+ T cells66, 182. In ganglia, this is not achieved 
by CTL-mediated killing of neurons, but rather by cytokine-mediated halt 
of replication275.
Cellular immunity is considered more important in recurrent HSV 
infections, as demonstrated by frequent reactivations in HIV positive and 
immunosuppressed subjects282. Th e exact role of antibodies is unknown. In 
recurrent infections, specifi c antibodies and complement off er immediate 
protection. Mounting eff ective cellular immunity against HSV is delayed281. 
Latency in infected sensory ganglia is retained by activated, virus-specifi c 
CD8+ memory T cells284. HSV recurs in the face of persistent functional 
HSV-specifi c CD8+ CTLs280. When HSV reactivates and moves from 
neurons to epithelial cells, complement components, antibodies, CD4+ T 
cells, macrophages, and DCs are present105, 281. During the next 1-2 days 
neutrophils, CD4+ T cells, and NK cells infi ltrate the area105, 281. Low IFNγ 
and Th 1 responses in humans are associated with cutaneous recurrences95, 
184, 224, 346. Yet, IFNγ is mainly secreted by CD4+ T cells and NK cells 
appearing aft er 2-4 days105, 181. Finally, arriving CD8+ cytotoxic T cells 
clear the virus281. 
Antibody and complement responses during reactivations
In mouse models, HSV-specifi c vaginal antibody is mainly IgG266, 267. 
Immunized IgA knock-out mice are not particularly susceptible to HSV-
2 in murine vaginal challenge model181. Antibody responses reduce 
neurovirulence of HSV-1 in mice and in vitro138, 229, 380. ADCC activity 
is associated with protection from HSV in multiple animal models184. 
Accordingly, in mice intact HSV-specifi c antibodies confer passive protection 
against viral challenges, whereas neutralizing F(ab)2 fragments lacking the 
Fc domain do not184. HSV viral Ig Fcγ receptor (vFcR) knock-out viruses 
are less virulent in mice, and B-cell knock-out mice are more susceptible 
to HSV infections239, 267. Th e Ig heavy chain locus on murine chromosome 
12 (igh@)has been identifi ed as a susceptibility factor to corneal HSV-1 
infections, suggesting that Ig allotypes diff er in their protective capacity246. 
In dermal models with HSV-1 as antigen, the CP of complement is required 
for effi  cient formation of specifi c antibodies68. 
Specifi c antibodies produced in recurrent HSV infections are mainly 
70
IgG1, IgG3, IgG4, and IgA144, 219. Anti-HSV-IgG4 is mainly seen in 
patients with nonprimary infections. IgG1 and IgG3 generally defend us 
against intracellular pathogens, and their production is enhanced by Th 1 
responses85, 148. Th ese, in turn, have been associated with protection from 
HSV recurrences95, 333, 346. Serum and local antibody responses are broad, 
and react with envelope glycoproteins, tegument, and capsid proteins22. 
Symptomatic subjects may have higher levels of antibody than asymptomatic 
carriers346. Vaccine development has largely been unsuccessful181. An 
immunogenic gD-adjuvant vaccine has limited effi  cacy against genital HSV-2 
in women who are seronegative for both HSV-1 and HSV-2348. No consistent 
correlations between levels of antibodies, their subclasses, their functional 
activities, or their fi ne specifi cities and the severity of HSV infection have 
been demonstrated181.
Frequent genital recurrences and intraoral HSV lesions are associated 
with reduced ADCC90, 130. Duration of HSV-2 excretion is shortest in patients 
with pre-existing complement-fi xing antibodies90. Th e poor capacity of 
candidate HSV vaccines to elicit ADCC has been associated with poor 
effi  cacy184. Th e relative effi  ciencies in complement activation and ADCC 
against HSV-1 vary according to the Ig subclass and allotype24, 85. Th e data 
above suggest that ADCC and CP are important in defense against HSV90, 
219. Arguing against the role of antibodies, there is no excess of typical 
HSV infections in patients with severe hypogammaglobulinemias385. Yet 
in these patients multiple concurrent defects of cellular immunity could 
even further predispose to HSV98. Intravenous immunoglobulin therapy 
suppresses genital herpes recurrences in humans218.
Wild-type HSV prevents C5 activation through its immune evasion 
molecule gC (see below), protecting against complement-mediated 
neutralization and complement-mediated lysis. Th is enables HSV to retain 
full infectivity340. Immunologic injury of HSV-infected cells requires both 
complement and anti-HSV antibodies58. Th e complement-activating 
innate pattern-recognition receptors recognizing HSV include natural 
immunoglobulin IgM and MBL. C1q does not recognize and opsonize HSV 
directly; surfactant protein A may neutralize the virus in the respiratory 
tract122, 125, 152, 369. Complement aids in the selection and maintenance 
of B1 cells, the main source of natural (IgM) antibody68. During the 
primary response, neutralization of HSV by IgM requires CP225. Later, 
the neutralization of HSV gC-null viruses by human serum also requires 
CP, but not LP, AP, or MAC , whereas active CP in the absence of natural 
IgM antibodies is insuffi  cient to neutralize the virus152. Th e extent of HSV 
neutralization varies up to 10-fold among individuals152. Complement fails 
to aggregate the virus or block its attachment to cells. Inhibition of infection 
takes place before early viral gene expression122. Th e effi  ciency and expression 
of host complement regulators may vary during an infection and between 
tissues289. Th e inhibition of complement-mediated lysis of infected cells by 
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complement regulators of the virus may even serve to protect the host121, 
289. 
In dermal models with HSV-1 as antigen, CP regulates antibody 
production at multiple stages. Without an intact early complement CP 
(C1q, C4, C3, CD21 and CD35), antibody responses against HSV become 
impaired68. Antigens coated by C3 and C4 activation products promote 
positive selection of specifi c B cells, their activation and expansion, formation 
of GCs, antigen retention inside follicular DCs, and eff ective maintenance of 
long-term memory B cells68. During early lesional stages within keratinized 
tissue, CP components may be rapidly consumed and not readily available 
from circulation121. To ensure eff ective coupling of complement CP to HSV 
locally and in peripheral lymph nodes, local myeloid-derived macrophages 
and immature DCs produce its early components72. Yet, intradermal and 
intraperitoneal models with C4 knock-out guinea pigs fail to support a 
critical role of CP in defense against primary HSV-1 infection352. Both 
normal and decreased serum complement levels have been reported in older 
studies on patients with recurrent genital herpes173, 374. 
Genetic susceptibility
Th e genetic background of susceptibility to severe or recurrent HSV 
infections is mostly unknown181, 385. Recurrent HSV infections are seen 
in immunodefi ciencies aff ecting cellular immunity (e.g. SCID, autosomal 
recessive hyper-IgE syndrome)132. Generalized, atypical, or severe infections 
such as HSV encephalitis may be seen in rare patients having SCID (e.g. 
signal transducer and transcription activator [STAT1], and UNC93B1 
defi ciencies), a combined immunodefi ciency (e.g. nuclear factor kappa B 
essential modulator [IKBKG] defi ciency), or CVID39, 71, 391. Encephalitis 
occurs mostly together with defi cient IFNα/β or γ production71. In a murine 
intraperitoneal model, MBL-A and MBL-C double knock-out mice clear 
HSV-2 ineff ectively from the liver. Viral burden of other assessed organs 
remain unchanged. MBL directly recognizes HSV and may have a role in 
the hepatic clearance of HSV-2 in humans56, 125. MBL may thus protect 
from HSV infections and their complications, but the mechanisms of action 
are largely unknown125. Studies on genetic defi ciencies in humans also 
point to the importance of MBL in defense against HSV. MBL2 defi ciency 
and the MBL2 codon 52 mutation have occasionally been associated with 
active genital herpes, herpes-associated erythema multiforme, and recurrent 
aseptic meningitis by HSV-2 in humans125, 360, 367. 
Evasion from host immunity
Delaying and avoiding immune recognition enables HSV to establish a 
chronic infection. To achieve this, HSV subverts the immune system by 
using its immune evasion molecules. Most commonly these defl ect immune 
recognition of infected cells by the cellular immunity: they directly inhibit 
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MHC class I and II expression, attenuate the eff ects of cytokines, or disarm 
diff erent eff ector cells (Table 3.2). HSV mutants lacking immune evasion 
molecules become largely avirulent. During the fi rst one to two days of a 
reactivation, the escape from cellular immunity is highly eff ective281. Defense 
against HSV is then mainly achieved by specifi c antibodies and rapidly 
responding arms of innate immunity (see above).
Table 3.2. Immune evasion of herpes simplex viruses from various arms of 
immunity
Reduced MHC Class I surface expression
ICP 47 prevents peptide transport
Reduced MHC Class II antigen presentation 
Virion-host shutoff  protein vhs causes degradation of host mRNA
Reduced MHC Class II antigen presentation 
γ134.5 protein reverses type I interferon-induced translation block
Disturbed MHC Class II processing pathway
Reduction of the expression of invariant chain in infected cells
Inhibition of peptide loading to HLA-DM and -DR
Binding of gB to MHC Class II heterodimers
Interference with interferon-dependent antiviral response
ICP0 prevents RNase L-independent rRNA cleavage
Interference with interferon-dependent antiviral response
Synthesis of 2’,5’-oligoadenylate synthetase antagonists
Interference with interferon-dependent antiviral response
Reduction of Jak2 and STAT1 levels by SOCS induction
Anti-apoptotic activity of infected cells
Actions of US3PK protein kinase, ICP27, gJ, gD and LAT
Apoptosis of activated HSV-infected cytotoxic T cells
Expression of US3 protein kinase, upregulated production of fratricide and galectin-1
Functional impairment of cytotoxic T cells
Inhibition of T-cell receptor signaling
Apoptosis of activated HSV-infected CD4+ lymphocytes
Disarming of natural killer cells
Disarming of lymphokine-activated killer cells
Inhibition of macrophage diff erentiation
Apoptosis of immature HSV-infected dendritic cells
Killing and functional impairment of dendritic cells
Downregulation of CD1 antigen presentation
Impaired production of interleukin-12 by HSV-infected dendritic cells aft er LPS stimulation
Loss of CD83 surface expression impairing dendritic cell-mediated T cell stimulation
Evasion from immunoglobulin G and C1q binding
Viral Fcγ receptor formed by gE and gI acts through bipolar bridging of specifi c antibody 
Evasion of free virion from complement
Viral complement receptor homologs gC-1 and gC-2 bind C3, C3b, iC3b, and C3c
Evasion of HSV-1 infected cell and free HSV-1 virion from complement
gC-1 accelerates the decay of the alternative pathway C3 convertase and binds C3b on infected 
cells 
Th e HSV vFcR, which mediates evasion from antibodies in vitro and in vivo, 
is formed by a heterodimer of surface glycoproteins gE/gI104, 239. Its affi  nity 
to IgG subclasses is in the order IgG4 > IgG1 ≥ IgG224. In Caucasians, vFcR 
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fails to bind IgG3164. Th e effi  ciency of IgG1 binding to vFcR also depends 
on the genetically determined allotype of IgG124. HSV-1 eff ectively evades 
IgG1 coded by G1ma 21, 24. At physiologic concentrations, G1mf -coded IgG1 
is less eff ectively bound by the HSV vFcγR. Over 80% of vFcγR’s are then 
occupied by non-complement-fi xing IgG421, 24. vFcR is able to participate 
in bipolar bridging, where a single IgG molecule binds by its Fab end to 
its specifi c target and by its Fc end to vFcR. Th rough bipolar bridging the 
virus eff ectively resists complement-enhanced antibody neutralization and 
ADCC206, 239. vFcR inhibits the binding of C1q, although vFcR binding site 
on Fc (on CH3) does not directly overlap with the C1q binding site near CH2 
domain344. gE or gI or both are also indispensable for effi  cient cell-to-cell 
spread and axonal localization279, 380.
HSV has also surface glycoproteins to avoid the AP of complement (gC-1 
and gC-2)105, 206, 340. gC-1 diminishes the effi  ciency of complement-mediated 
neutralization of the free virion and inhibits complement-mediated lysis of 
infected cells152. To achieve this, gC-1 binds C3 and its activation products, 
C3b, iC3b, and C3c205. Furthermore, gC-1 inhibits the binding of C5 and 
properdin to C3b, blocking activation of both the CP and the AP187. It also 
accelerates the decay of the alternative, but not classical, pathway convertase. 
gC-1, unlike gC-2, acts as an attachment protein for the virus340. HSV-2 
glycoprotein gC-2 binds only to C3 and its activation products. Accordingly, 
gC-2 acts only to reduce complement-mediated neutralization, also that 
induced by natural IgM, and to facilitate cell-free spread of the virion by 
binding C3b, iC3b, and C3c152. It does not contain a C5- and properdin-
interacting domain, and does not accelerate the decay of AP convertase364. 
Mutant viruses unable to express gC are neutralized by the CP, even in the 
absence of antibodies340. In systemic models, gC-2 does not appear to be an 
important virulence factor166. Intradermal models, in which gC-1 of HSV-1 
does seem important in vivo, have not been studied using gC-2340.
5.4.2 Acute and chronic rhinosinusitis
Rhinosinusitis is a group of disorders characterized by infl ammation of the 
mucosa of the nose and the paranasal sinuses226. Paranasal sinuses, 4-17 
in number, constitute a collection of air-fi lled spaces within the anterior 
skull. Th ey communicate with the nasal cavity through small meatuses. 
Goblet cells and nasal glands of the ciliated epithelium that line the nasal 
cavity and paranasal sinuses produce mucus115, 341. Th is serves to keep the 
nose moist and to trap particles and pathogens before they enter the lower 
airways. Th e mucus contains enzymes that render foreign particles harmless 
and, with the help of cilia (“mucociliary transport”), transports them 
down to esophagus43, 226. Together, patent maxillary sinus ostia, anterior 
ethmoidal cells and their ostia, ethmoid infundibulum, hiatus semilunaris, 
and middle meatus (i.e. “ostiomeatal complex”) ensure the maintenance of 
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optimal sinus ventilation and mucociliary transport. During infl ammatory 
conditions or impaired ciliary function, mucus production may overwhelm 
the transport capacity of the ostiomeatal complex. Th is further impairs the 
ciliary function and export of infl ammatory substances and pathogens, 
causing and exacerbating sinus infl ammation. If this condition persists, it 
can result in chronic rhinosinusitis115, 341. Th e decrease in the quality of life 
of CRS patients may equal that caused by malignancy226.
Epidemiology
In US surveys, self-reported chronic “sinus trouble” for more than three 
months in the previous year aff ects up to 16% of the adult population, 
ranking it as the second-most common chronic condition in that country43, 
115. Th e prevalence of doctor-diagnosed CRS is much lower, 1-2.4%. CRS 
is approximately twice more common in women than in men and in the 
elderly than in young adults115. Th e prevalence of objectively observed 
nasal polyps is 0.5-2.7%, 30-50% of the subjects are asymptomatic. Polyps 
are more common in non-atopic (13%) than in atopic asthma (5%). Th ey 
are approximately twice as common in men and the elderly. Nasal polyps 
are commonly observed together with bronchial asthma115. Women more 
oft en have associated comorbidities: the occurrence of polyps and asthma 
together is twice more prevalent in women than in men. Polyps can be 
found in 36-96% of subjects sensitive to non-steroidal anti-infl ammatory 
drugs (“aspirin sensitivity”), radiographic fi ndings compatible with mucosal 
infl ammation are found in up to 96% of them. Patients that have aspirin 
hypersensitivity, asthma, and nasal polyps (“aspirin triad”) are frequently 
non-atopic and over the age of 40115, 226.
Clinical syndromes
Th e mildest form of sinus infection is acute viral rhinosinusitis (common 
cold), with abnormal paranasal sinus CT imaging in ~ 90% of patients136, 
226. Viral infection and exposure to pathogenic bacteria result in the loss of 
cilia and ciliated cells. Adults suff er approximately two to fi ve common colds 
per year43, 115. Of common colds, ~ 0.5-2% is complicated by some form 
of bacterial infection115. Factors such as allergic rhinitis, nose blowing, or 
dental infections may predispose to acute or recurrent (presumed bacterial) 
rhinosinusitis (ARS)115, 226. 
Numerous subclasses of non-allergic CRS with or without demonstrable 
infl ammatory changes in nasal histology have been proposed, with causative 
pathogens (e.g. fungal, bacterial) or associated diseases (e.g. polyposis, 
allergy, diabetes mellitus) as the reason for subclassifi cation226, 330, 334. For 
example, dysregulated activity of autonomic nerve pathways and nociceptive 
dysfunction may predispose to CRS226. In a subgroup of CRS patients, a 
“ballooning” of the nasal mucosa leads to the development of nasal polyps 
(Table 3.3). A partly overlapping subgroup of patients have nasal polyposis, 
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fungal growth from sinuses, and suff er from allergic fungal rhinosinusitis, 
a disease that immunologically and histopathologically resembles allergic 
bronchopulmonary aspergillosis (Table 3.3.)226, 321. “Non-allergic” or 
“perennial allergic” rhinitis may be caused by year-round exposure to molds 
and danders that leads to persistent nasal mucosal edema and eosinophil, 
mast cell, macrophage, and Th 2 lymphocyte infi ltration. It has no established 
defi nition, but is usually defi ned as a disease that persists > 9 months each 
year with symptoms mimicking allergic rhinitis226, 330, 334. Its role in the 
etiopathogenesis of CRS is unclear. Th e coexistence of CRS and asthma, with 
upper and lower airway infl ammation and lower airway hyperresponsiveness, 
has been named “chronic infl ammatory respiratory syndrome” or “integrated 
airway syndrome”226, 255.
Diagnosis 
Th e used diagnostic criteria of rhinosinusitis vary (Table 3.3). According to 
present defi nitions, the nasal and sinus symptoms of acute viral rhinosinusitis 
last < 10 days; allergic symptoms should be included in diff erential 
diagnostics115, 226. 
Th e most important cause of ARS is bacterial superinfection of damaged 
nasal mucosa. In ARS, there is a sudden onset of two or more of the 
symptoms: blockage or congestion, anterior discharge or post nasal drip, 
facial pain or pressure that last > 10 days, or symptoms worsen aft er initial 
regress226. Objective criteria for ARS include purulent drainage found 
beyond vestibule or radiographic evidence226. Th e most common bacteria 
cultured from maxillary sinus aspirates during adult community-acquired 
ARS are S. pneumoniae (~ 40%) and non-typable H. infl uenzae (~ 35%). 
Other streptococci, anaerobes and M. catarrhalis are cultured from 4 to 
7 percent of samples. S. aureus and S. pyogenes are uncommon in ARS226. 
Normal nasal fl ora in adults includes coagulase-negative staphylococci, 
Corynebacterium species, S. aureus, and S. pneumoniae115, 226. 
Repeated infections may lead to long-standing impairment of ciliary 
function and predispose to CRS. Th e exact defi nitions for clinical practice and 
research, of CRS in particular, diff er between the three most commonly used 
criteria (Table 3.3)115, 196, 226. Various infl ammatory and non-infl ammatory 
conditions can cause symptoms mimicking CRS226, 330. Th e most common 
cause of diagnostic confusion is allergic rhinosinusitis334. Due to the 
commonness of symptoms mimicking ARS and CRS, radiologic imaging 
is frequently used. Anterior-posterior and Waters views best visualize the 
frontal and maxillary, and lateral views the sphenoid sinuses. Ethmoid 
sinuses are poorly displayed. Radiography cannot diff erentiate between 
viral and bacterial sinusitis. In the diagnosis of adult ARS, it has a sensitivity 
of ~ 0.76 and specifi city of ~ 0.79 compared with sinus puncture (the gold 
standard), but the criteria for its interpretation are controversial276, 341. 
Standard radiographs are inadequate for determination of the need for 
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and guidance of endoscopic sinus surgery. For evaluation of infl ammatory 
disease secondary to obstruction of the ostiomeatal complex, the coronal 
plane of computed tomography is the gold standard341. 
In CRS, the most common organisms cultured by various methods 
(e.g. aspiration, lavage, swab, during endoscopy, cytology) are coagulase-
negative staphylococci, S. aureus, S. viridans, anaerobes (e.g. pigmented 
Prevotella, Fusobacterium, Peptostreptococci), and gram-negative enteric 
rods (e.g. P. aeruginosa, K. pneumoniae, P. mirabilis, Enterobacteriacae, E. 
coli). Pathogenicity of many of these organisms has been disputed, claimed 
as colonization, or that isolates are recoverable secondary to a repeatedly 
damaged mucosal lining having lost its normal sterility115, 226. S. aureus 
frequently accompanies nasal polyposis, with a more pronounced multiclonal 
IgE response to S. aureus enterotoxin (~ 80%) in nasal mucosa compared 
with other CRS patients (~ 60%)226. When bacterial culture and PCR are 
used, bacteria deemed to be pathogenic are frequently lacking in prominent 
polypoid tissue226. Anaerobe recovery rate varies greatly, but specifi c IgG 
antibodies against F. nucleatum and P. intermedia have been demonstrated 
in CRS patients and noted to decrease in titer with successful therapy115, 226. 
If there is no invasive growth in histology and the patient has no recognized 
form of non-invasive fungal rhinosinusitis (i.e. fungal ball, allergic fungal 
rhinosinusitis), the signifi cance of fungal growth in sinus samples of CRS 
patients is unclear (Table 3.3)115, 226. Since on CT an irregular bony thickening 
of sinus walls is frequent, a smoldering osteitis has been suggested as a 
contributing factor to CRS development. 
Grading of rhinosinusitis
Th e most commonly used computed tomography staging system is the 
Lund-Mackey score. In it, each sinus group is graded between 0 and 2 (0: no 
abnormality; 1: partial opacifi cation; 2: total opacifi cation) and ostiomeatal 
complex adds 2 points if obstructed. A total score between zero and 24 is 
possible210. It has been validated in several studies, but the correlation between 
computed tomography fi ndings and symptoms has consistently been poor, 
and it is not a good indicator of prognosis115, 226. In 2004, a newer classifi cation 
has been proposed226. Th e role of structural variations of paranasal sinuses 
(e.g. concha bullosa, nasal septal deviation, displaced uncinate process) in 
predisposition to CRS is disputable115, 171, 226. No consistent diff erence in 
the prevalence of anatomical variations between symptomatic and control 
subjects has been found115, 226. Th e prevalence of both ostiomeatal complex 
blockade (60%) and low IgG subclass concentrations (81%) has been assessed 
in one pediatric study on allergic children93. 
Th e extent of performed operations may be used to grade disease severity. 
Th e most accepted surgery score is the Lund-Kennedy score, where seven 
listed procedures each give one point on each side, up to a total of 14209. 
Accepted absolute and relative indications to surgery have been proposed14, 
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196. Th e presence of infl ammatory changes should be noted in studies on 
rhinosinusitis226. Sinus fl uid of CRS patients undergoing sinus surgery 
is predominantly neutrophilic. Eosinophil counts per visual fi eld in the 
mucosal lining of CRS patients without nasal polyposis rarely exceeds 10%, 
but can be found in ~ 80-90% of patients with polyposis. Tissue eosinophilia 
may be one of the hallmarks of CRS with nasal polyposis115. 
Immune response to infection
Relatively little is known of local responses during acute rhinosinusitis. 
Rhinoviruses infect ciliated and non-ciliated epithelial cell135. Th ere they 
activate host immune cells such as monocyte-macrophages through PAMPs 
such as TLR-3, inducing cytokine and IFN production165. Infecting viruses 
are further transported from the nasal mucosa in the mucus stream to 
the adenoid region. For example, rhinoviruses reach the lymphoepithelial 
cells that overlie lymphoid follicles and are rich in rhinovirus receptor 
intracellular adhesion molecule 1 (ICAM-1)226. Plasmacytoid DCs present 
in perifollicular T cell areas and monocytoid DCs recognize the virus and 
act as APCs to the cellular immunity143. Genetic variations may aff ect the 
immune responses to respiratory viruses and lead to the development 
of asthma and its exacerbations in susceptible individuals314. In ARS, a 
pronounced infl ammatory reaction characterized by edema and massive 
polymorphonuclear and mononuclear cell infi ltration, microabscesses, 
and necrosis ensues locally. Increased numbers of T lymphocytes are 
diff usely scattered throughout the submucosa, and B cells are organized in 
aggregates around small veins, adjacent to seromucous glands, and under 
the epithelium45. 
Histologically, CRS without nasal polyps is characterized with 
predominantly neutrophilic infl ammation with a lesser contribution of 
eosinophils. In CRS patients with polyps, a more than 10-fold increase in 
IgE-producing plasma cells and pronounced eosinophilic infi ltrate, IL-4, 
IL-5, and eotaxin expression may be observed locally within the polyps. Th is 
happens regardless of whether the patient is atopic or not226. Allergic patients 
with or without nasal polyposis display a more characteristic Th 2 prominent 
response, whereas non-allergic patients have a mixed Th 1/Th 2 cytokine 
profi le. Th 2 profi le suggests that delayed hypersensitivity contributes to CRS 
development in polyposis226. Recent – still unproven – hypotheses trying to 
relate the frequent microbiologic fi ndings and the development of CRS with 
each other include: 1. biofi lm formation that needs debridement, 2. microbial 
superantigens (S. aureus, Alternaria, Aspergillus) that cross-link MHC II 
on APC with TCR variable β region and cause extensive T lymphocyte 
activation (up to 30% of T cells) and generate multiclonal IgE synthesis 
and anti-superantigen IgE antibodies, and 3. fungal antigen-induced 
sustained eosinophilic infl ammation in most CRS patients226. Toxins such 
as S. aureus protein A enhance IL-4 release, expression of CD40L on T cells 
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and costimulatory molecules on B cells, and cause a VH bias by interacting 
with IGH@ VH -family gene products115. Eosinophilic disease-forms have 
also been suggested to associate with specifi c antifungal antibodies of IgG3 
subclass, and diff erentiate these from simple CRS265.
Bacteria obtained from maxillary eff usion aspirates of CRS patients are 
oft en, in the order of decreasing frequency, coated with IgG, S-IgA, and 
C3b288. In IgA-defi cient patients, low S-IgA levels may be compensated 
with raised IgM and IgG levels in nasal secretions. In CVID patients on 
Ig substitution, despite IgG levels in nasal secretions equal to those in 
healthy control subjects, infl ammatory cytokine levels are raised and Ig 
substitution frequently fails or requires large doses62, 118, 298, 303. Th us even 
in patients with hypogammaglobulinemias, factors other than the lack of 
suffi  cient Ig levels may play a role in CRS pathogenesis. An impaired T 
cell response to recall antigens tetanus and mumps in ~ 55% of patients 
has been found in a study on 79 CRS patients77. Relatively little is known 
about the signifi cance of complement in protection from CRS. Complement 
tissue regulators DAF and CD59 are needed to protect nasal epithelium, 
and both CP and AP are active locally120, 371. In ARS, C3b-CR1-mediated 
phagocytosis takes place, but in CRS C3b binding-capacity of CR1 may be 
overwhelmed44, 231. Genes of complement factors C3, fB, and properdin are 
similarly expressed in sinonasal tissues of CRS patients with or without nasal 
polyposis, and in healthy control subjects194. Of complement-interacting 
factors, the gene expression of surfactant protein A is upregulated in CRS, 
and of serum amyloid A decreased in patients with CRS who suff er from 
early recurrence of nasal polyps aft er surgery194, 199. Surfactant protein A 
prevents CP activation and together with C1q enhances the clearance of 
foreign particles by macrophages381. In CRS, low serum C4 and fB levels 
have been reported252.
Genetic susceptibility
Th e prevalence of allergies is higher in CRS patients, but data on it as a 
predisposing factor to CRS is confl icting115, 226. Almost all forms of genetic 
immunodefi ciencies predispose to CRS. In particular, primary antibody 
defi ciencies, primary ciliary dyskinesia, cystic fi brosis (CFTR), and hyper-
IgE syndromes are frequently complicated by CRS54. In a series of 68 CVID 
patients, recurrent ARS or CRS was present in 76% and preceded the 
diagnosis of CVID by 15 years319. CRS is found in ~ 86% of patients with 
agammaglobulinemia. Th e associations between IgG, IgA, and IgG SCDs 
and bacterial infections discussed in Chapter 2 include CRS. However, there 
are relatively few studies with even moderate numbers of adult CRS patients 
recruited, where SCDs would have been assessed. Methodologies of these 
studies are variable and oft en poor. Low subclass concentrations, mainly low 
IgG1222, 329, 370, IgG2222, IgG318, 153, 211, 313, and IgG4163 concentrations together 
with or without low IgA have been described. Frequencies of low subclass 
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levels may vary depending on the ethnic origin of CRS patients163. Despite 
the reported high frequency of low IgG3 in adult CRS, Gm3 allotypes are 
not associated with adult CRS355. Yet in adult CRS patients, G3mg correlates 
with low levels of specifi c anti-M. catarrhalis IgG3 antibodies: these, in 
turn, correlate with adult CRS129. Th e clinical effi  cacy of pneumococcal 
polysaccharide and polysaccharide-conjugate vaccines for prevention of 
mucosal S. pneumoniae infections may be poor in homozygous carriers of 
FcγRIIaR131, which binds IgG2 poorly388. Low levels of IgG2 or G2mn- of 
adult blood donors have not been associated with increased susceptibility to 
recurrent infections240. Impaired vaccination responses in adult CRS patients 
seem extremely rare, with none found in a consecutive series of 245 mainly 
adult patients with low subclass levels222.
C2 defi ciency predisposes to CRRS170. Little is known of genetic factors 
predisposing to CRS with or without nasal polyposis in patients without 
overt immunodefi ciency. Interestingly, B8, B44, B54, DR3(17), and DR7 are 
more frequent in patients suff ering from CRRS but having normal antibody 
levels (not tested in B54 carriers)168, 358. Th e two most common antibody 
defi ciencies, IgA defi ciency and CVID, with susceptibility loci in DQ/DR, 
oft en occur in association with two extended haplotypes: A1,B8,SC01,DR3(17) 
(with C4A defi ciency) and/or all or a portion of A29,B44,SB31,DR7189, 
319. A1,SC01, B8 (and presumably C4A defi ciency) is overrepresented in 
patients with IgG4, IgD, or IgG3 defi ciency, as well as in patients suff ering 
from nasal polyposis10, 232. Further, DR3 is associated with nasal carriage of 
S. aureus177. AFRS and other chronic hypertrophic rhinosinusitis disorders 
have recently been associated with HLA-DQB1*03321. Polymorphism of 
another MHC gene, LTA, is associated with higher TNF production and 
CRS357. Recently, IL-1 receptor antagonist gene (IL1RN) polymorphism has 
also been associated with adult CRS79.
Th e signifi cance of low IgG subclass values in predicting adult CRS, in 
patient evaluation, and in the choice of treatment is highly controversial61. 
No studies on the frequency of low subclass values in ARS patients exist, and 
data on normal population are insuffi  cient (discussed in Chapter 2). Despite 
the low amount of IgG3 in preparations, intravenous immunoglobulin 
eff ectively reduces sinopulmonary infections in severely symptomatic 
children with low serum IgG3 levels and normal vaccination responses or 
levels of anti-pneumococcal antibodies37, 46.
Evasion from host immunity by causative pathogens
IgA proteases that enzymatically destroy IgA1 (distributed predominantly 
in serum) are produced by S. pneumoniae and H. infl uenzae. Such activity 
results in monomeric Fab bound to microbial antigens and blocks the access 
of intact antibody molecules and antibody-mediated eff ector functions268. S. 
pneumoniae utilizes attached Fab as a signal to adhere to pharyngeal epithelial 
cells213. S. pneumoniae can also interact with secretory component, with the 
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secretory component portion of polymeric immunoglobulin receptor, and 
with S-IgA; this may further aid it in immune evasion101. S. pyogenes is able 
to degrade both IgG and FcRs4. With high affi  nity, S. aureus protein A binds 
IgG, and M. catarrhalis binds human IgD, the proposed benefi t is their 
ability to act as B cell superantigens. Th is results in an unspecifi c polyclonal 
antibody response309.
Streptococci and M. catarrhalis evade from complement by expressing 
surface molecules that bind fH, FHL-1, or C4bp. Group A and B streptococci 
also secrete proteins and enzymes that inhibit complement activation and 
complement-mediated chemotaxis161, 188. H. infl uenzae inhibits complement 
by interacting with vitronectin (Table 1.2)139. S. aureus staphylokinase 
degrades cell-bound IgG and C3b, and secretes a chemotaxis inhibitory 
protein that binds to C5a157.
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5.4.3 Adult periodontitis
Periodontitis is characterized by the gradual loss of deep tooth-supporting 
connective tissue (periodontium) and alveolar bone as a result of an 
infl ammatory response to subgingival bacteria. Th is results in the formation 
of soft  tissue pockets or deepened crevices between the gingiva and tooth 
root. In adult periodontitis, the infl ammatory process may progress 
asymptomatically, cause occasional pain and discomfort and impaired 
mastication, but eventually results in loosening teeth and tooth loss277.
Epidemiology
Periodontal diseases are common inherited or acquired disorders. Of 
US adult population, ~ 22% have mild and ~ 13% moderate to severe 
periodontitis277. Its prevalence varies geographically and according to the used 
diagnostic criteria7. For example, all forms of tobacco use, excessive alcohol 
consumption, scurvy, osteoporosis, diabetes, and atherosclerosis have been 
associated with, and may aff ect the prevalence of adult periodontitis277.
Diagnosis
Th e clinical diagnosis of chronic periodontitis is based on visual, spatial, 
and radiographic assessment of the periodontal tissues and on the space 
between the tooth and gum. Th is space deepens from the normal depth 
of 1-3 mm as the supporting structures are lost. Pocket depths and tissue 
support are measured at 4-6 locations around each tooth, the amount of 
supragingival biofi lm (plaque), dental calculus, gingival bleeding, and exudate 
are recorded19. In the order of increasing sensitivity, orthopantomography, 
dental radiographs, or digital subtraction radiography are routinely used 
to assess the degree of bone support for the teeth277. Various diagnostic 
and classifi cation criteria for infl ammatory periodontal diseases have been 
advocated, but there are no generally accepted, uniform criteria20.
Bacteria grow as biofi lms on tooth surfaces. More than 500 bacterial 
species can be cultured from dental plaque; supragingival surfaces of 
one tooth may contain up to 109 bacteria. Subgingival load of bacteria 
is 105 times higher in periodontitis patients than in healthy subjects277. 
Th e number of gram-negative bacteria, anaerobes, and spirochetes that 
produce leukotoxins, collagenases, fi brinolysins, and other proteinases 
increases113. Most common putative pathogens include Porphyromonas 
gingivalis, Actinobacillus actinomycetemcomitans (in young adults), as well 
as Prevotella, Treponema, and Capnocytophaga species116. Epstein-Barr and 
cytomegalovirus have also been associated with periodontitis335. Th ere is 
insuffi  cient evidence that microbiologic assessment can improve treatment 
outcomes of chronic periodontitis277.
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Complement in the immune response against associated pathogens
In histologic examination of gingivitis or periodontitis lesions, 
polymorphonuclear leukocytes line the junctional epithelium in large 
numbers and appear to attempt to wall off  the underlying tissues from 
the bacterial biofi lm316. Subgingival dental plaque bacteria are coated with 
C1q and C481. Gingival fl uid C3 is activated and consumed locally during 
periodontal infl ammation. At the same time, the ratio between local and 
serum C4 decreases25, 242, 272. Yet cleavage to C4c has been indemonstrable in 
gingival fl uid272. CP activation may thus be halted locally, before or aft er the 
cleavage of C4 to C4c. A decreased level of CH50 in periodontitis patients 
has been suggested by several studies15, 25, 167, 233. 
Genetic susceptibility
It is not fully understood why some adults are prone to overgrowth of oral 
bacteria, or what triggers the destructive immune response that leads to 
periodontitis. Data from twin studies indicate that ~ 50% of population 
variance in periodontitis can be attributed to genetic factors317. A number 
of rare inherited systemic diseases such as Papillon-Lefévre syndrome cause 
juvenile periodontitis277. Of a total of 140 studies on genetic polymorphisms 
recently reviewed, an association with periodontitis was found in 28 out of 34 
studies addressing one or multiple genes in or near MHC. Th ese include 17 
out of 20 studies on polymorphisms in class I and II HLA loci, 10 out of 14 
studies on TNF, two out of two on LTA, one out of one on AGER (advanced 
glycosylation end product-specifi c receptor gene), and one out of one study 
on EDN1 (endothelin-1 gene)356. It is not clear whether these associations are 
themselves associated with a gene mutation (present in multiple haplotypes 
in diff erent populations) that causes the susceptibility to periodontitis and is 
in linkage equilibrium with the candidate genes, or if specifi c predisposing 
haplotypes with multiple susceptibility genes exist349.
Primary and secondary immunodefi ciencies predisposing to periodontitis 
are most commonly associated with impaired opsonization, decreased 
neutrophil function, neutrophil numbers, production of neutrophil-derived 
antimicrobial factors such as cathelicidins, or genetic variations in or near 
cytokine genes277, 287, 316, 317, 356. Predisposing primary immunodefi ciencies 
include, for example, cyclic neutropenia, leukocyte adhesion defi ciencies, 
Chédiak-Higashi syndrome, and Morbus Kostmann. Interestingly, 
patients with Morbus Kostmann are unable to produce cathelicidin LL-37 
that is required specifi cally for defense against A. actinomycetemconcomi-
tans396. Th e presence or generation of chemotactic factors is required for 
polymorphonuclear leukocytes to appear, and eff ective opsonization of 
foreign material is required for appropriate function of polymorphonuclear 
leukocytes. Studies addressing polymorphisms of FcγR genes have found 
predisposing gene variants, mostly pointing towards the importance of 
84
IgG1- and IgG3-mediated eff ector functions204, 316, 317. CP defi ciencies have 
not been studied in adult severe chronic periodontitis.
Evasion from complement by associated pathogens
Th e major virulence factors of the best-studied pathogen P. gingivalis, 
proteinases called gingipains, are able to degrade C4, C3, C5, and fB. 
Gingipains are able to generate local C5a chemotactic activity that allows the 
prominent accumulation of neutrophils in infl amed subgingival tissues283. 
Whether the assembly of C5a convertase complex, and consequently, the 
complement-mediated lysis of bacteria is locally impaired, has not been 
studied (Fig. 1.1). 
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6. Aims
Th e aims of the present study were to:
1. assess the frequencies of C4A and C4B defi ciencies, and of low IgG subclass 
levels in the general population (II, III, IV) and in blood donors without a 
history of rhinosinusitis (II),
2. assess the frequencies of C4 defi ciencies and low subclass levels in patients 
with rhinosinusitis (II),
3. examine whether genetic defi ciencies of C4 (I, II, III, IV), low IgG subclass 
levels (II, III), IgG1 and IgG3 allotypes (III), and HLA-A*, -B*, and DRB1* 
gene polymorphisms (I, III) are associated with recurrent or chronic mucosal 
infections such as herpetic gingivostomatitis, genital herpes infection, 
rhinosinusitis and periodontitis,
4. examine, whether immunologic defi ciencies or polymorphisms found in 
the study patients associate with any complications of the diseases studied, 
or with any associated comorbidities (I, II, III),
5. compare the applicability of a new PCR-based quantitative analysis of 
C4A and C4B genes with the traditional C4A and C4B protein allotyping 
(II, III, IV).
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7. Subjects and methods
7.1 Study subjects
Patients were recruited into case-control studies applying strict criteria that 
were designed to select those with a severe, recurrent or chronic, form of 
the respective disease. Th e subjects and their inclusion criteria are listed 
in Table 4.1. For HLA* typing, subjects from the Finn90 cohort served as 
historical control subjects203. Th e local scientifi c ethics committee approved 
the study protocols.
7.2 Defi nitions
Th e group of 150 consecutive voluntary control subjects (II, III, IV) was 
named as the “unselected group” (used below). Due to small diff erences 
between the unselected and healthy group in Study II, they were analyzed 
together and named the “combined group”. In Study III, those seropositive 
for HSV-1 or HSV-2 were named “HSV seropositive”. In all studies, “low” 
levels of plasma C3, C4, IgA, IgM, IgG, IgG1, IgG2, IgG3, and IgG4 and 
serum CH50 were defi ned as values below two standard deviations from 
the mean and applying manufacturer’s reference values. Activity above 200 
IU/ml was coded as 200.
In Study II, nasal polyposis was based on histology, anterior rhinoscopy, 
or perioperative clinical fi ndings. Septal deviation was diagnosed 
clinically. Bronchial asthma was diagnosed by a specialist, with the right to 
reimbursable medication through the Social Insurance Institution of Finland. 
Hypersensitivity to non-steroidal anti-infl ammatory agents (NSAIDs) was 
based on clinical history of provoked, compatible symptoms. Allergy was 
diagnosed by a previous positive skin prick test or allergen-specifi c IgE in 
serum. Nonallergic rhinitis was defi ned as recurring or perennial, typical 
infl ammatory symptoms to inciting allergens (e.g. pollens, animals, foods) 
together with negative allergy test results330. In irritant rhinitis, the patient 
had frequent symptoms to nonspecifi c irritants (e.g. fumes, solvents). 
Immunodefi ciency or rheumatic disease was based on published criteria146, 
248. In cases of multiple FESS operations, we used the highest-scoring. In 
noneosinophilic histology, no surplus of eosinophils was reported by the 
pathologist.
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Table 4.1 Subjects in studies I-IV
Recruited from Inclusion criteria1 and study entry No.
studied (excluded)
Study
Division of Infectious 
Diseases
Helsinki University Central 
Hospital
Finland
Consecutive patients with intraoral HSV-1 infection
> 10 recurrences yearly
Clinically typical recurrent blisters predominantly 
in the hard palate and gingiva 
Study entry between March 1999 and June 2000
3 (0) I
Consecutive patients with chronic or recurrent 
rhinosinusitis
Rhinosinusitis Task Force 1997 criteria2 fulfi lled
No clear response to sinonasal surgery other than 
septoplasty, to short-course antibiotics, and to 
maximal topical medical management
Study entry between March 1996 and March 2001
48 (73) II
≥ 10 HSV-2 recurrences yearly for > 12 months aft er 
the fi rst clinical episode
Clinically typical disease with vesicles
Positive HSV-2 culture result from an active genital 
or extragenital lesion
Study entry between April 2000 and June 2004
52 (54) III
Vihti Municipal Health 
Center
Finland
Consecutive voluntary patients with acute 
rhinosinusitis
< 4 yearly episodes of purulent rhinosinusitis, no 
previous episodes 
No previous rhinosinusitis episodes lasting > 3 
months
Symptoms lasting > 7 days
Fluid level or opacity in a sinus radiograph or 
purulent discharge in sinus puncture with lavage
Study entry in 4 time-periods between February 
2001 and June 2002
50 (0) II
Dental offi  ces of three 
periodontists
Helsinki, Finland
Consecutive patients attending scheduled post-
treatment maintenance care
Native Finns treated by the same periodontist for ≥ 
5 years
Periods of reemerging gingival infl ammation and 
deepening periodontal pockets despite good oral 
hygiene and regular maintenance care 3-12 months 
apart
Favorable response aft er the initial series of 
periodontal treatment 
18-55 years old at the time of referral to the 
specialist clinic
Advanced periodontal disease: > 20 aff ected teeth, 
alveolar bone loss in > 10 teeth
Study entry between March 2002 and November 
2003
37 (15) IV
Vita Laboratory Ltd
Helsinki, Finland
Consecutive voluntary subjects coming for a health 
survey before accepting a new occupational post
Study entry between February and October 2003
150 II, III, 
IV
Finnish Blood Transfusion 
Service
Helsinki, Finland
Age- and sex-matched subjects from 100 
consecutive voluntary blood donors with no 
reported history of rhinosinusitis
Study entry in 2 time-periods between May and July 
2001
48 (52) II
HSV = herpes simplex virus. 1In all studies, the subjects had to be > 18 years old. In I, III, and 
IV, only patients without a known immunodefi ciency were recruited. 2See Table 3.3. 32 patients 
refused, 2 died before inclusion, 1 had small vessel vasculitis, 1 was pregnant, and 1 patient was 
found to have human immunodefi ciency virus infection. 43 patients refused, 2 patients were 
noncompliant. 5Withdrew from the study.
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In Study III, neuralgias were classifi ed as prodromal (ending in ≤ 24 
hours aft er vesicle formation), prolonged (lasting > 24 hours aft er vesicle 
formation), or chronic.
7.3 Collection, processing, and storage of blood samples
Blood samples were drawn into tubes containing heparin, citrate, or EDTA 
(10mM), as appropriate. In Studies I and III, all blood samples were taken 
during an asymptomatic period of > 4 weeks, typically during prophylactic 
antiviral treatment. Genomic DNA from blood leukocytes was isolated with 
commercial kits (QIAamp DNA Blood Kit, Qiagen, Austria or Puregene Kit, 
Gentra Systems, USA). All samples were kept frozen at -70oC.
7.4 Analytical methods
Microbiologic analyses
In Studies II and III, bacteria and viruses were isolated with standard 
cultures. In Study I, the combination of positive anti-HSV-gG1 antibodies 
and negative anti-HSV-gG2 antibodies (HSV-1 ELISA IgG and HSV-2 ELISA 
IgG; MRL Diagnostics, CA, USA) together with positive in-house HSV-1 
PCR, histology with HSV-specifi c immunostaining, or cytospin-enhanced 
direct immunofl uorescence assay was used186, 193, 278, 373. Slides were stained 
with polyclonal rabbit anti-HSV-IgG followed by fl uorescein isothiocyanate-
labeled anti-rabbit IgG (Jackson ImmunoResearch Laboratories, PA, 
USA). 
In Study III, type-specifi c anti-HSV IgG (HerpeSelect 1&2 ELISA IgG, 
Focus Diagnostics, CA, USA) against gG and IgM (EIAgen HSV IgM, Adaltis, 
Italy) antibodies were analyzed. For anti-HSV-2 IgG subclass measurements, 
microtiter plates were coated with HSV gG-2 protein (Aalto Bio Reagents, 
Ireland). Sera were tested at a dilution of 1:100 (anti-HSV-2-IgG1) or 1:10 
(anti-HSV-2-IgG2-4). Aft er incubation with anti-human-IgG, subclass-
specifi c mouse monoclonal antibody, peroxidase-conjugated anti-mouse 
antibodies (DakoCytomation, Denmark) were used to detect the amount 
of bound antibody311, 325. Results were displayed as enzyme immunoassay 
units (EIU) with a standard curve as a reference185.
Immunologic analyses
Th e principal immunologic studies performed are listed in Table 4.2. 
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Table 4.2 Laboratory methods used in Studies I-IV
Method Used in
Allotyping of C4A and C4B proteins by electrophoresis I, II, III, IV
Serum/plasma C3 and C4 concentrations by nephelometry I, II, III, IV
Serum classical pathway hemolytic activity by standardized hemolysis-in-gel 
assay
I, II, III, IV
Serum alternative pathway hemolytic activity by standardized hemolysis-in-gel 
assay
I
Plasma IgM, IgG, IgA, IgG1, IgG2, IgG3, IgG4 by nephelometry I, II, III
Allotyping of G1ma, G1mf, G3mg, and G3mb proteins and quantitation of 
allotypic subsets
III
Anti-HSV-1- and anti-HSV-2-IgG by ELISA I, III
IgG1-, IgG2-, IgG3-, and IgG4-subclass specifi c anti-HSV-2-antibodies by ELISA III
HSV isolation I, III
Non-quantitative isotype-specifi c PCR amplifi cation of C4A and C4B I
Quantitative isotype-specifi c real-time PCR amplifi cation of C4A and C4B II, III, IV
HLA-A*, -B*, -DRB1* genotyping (HLA-C* genotyping in study I) I, III
HLA = human leukocyte antigen, HSV = herpes simplex virus, PCR = polymerase chain reaction, 
EIA = enzyme-linked immunoadsorbent assay.
C3 and C4 concentrations in serum (I) or plasma (II, III, IV) were measured 
by nephelometry (Behringwerke AG, Germany). Serum CH50 was analyzed 
either by a standardized hemolysis-in-gel assay (I, Binding Site, UK) or by 
an enzyme-linked immunosorbent assay (ELISA) technique (II, III, IV, 
CH50, Quidel Corporation, CA, USA). Serum alternative pathway hemolytic 
activity (I, Binding Site, UK) was analyzed by a standardized hemolysis-in-
gel assay. 
Immunoglobulins IgG, IgM, and IgA were measured from the sera by 
nephelometry using the reagents and BN ProSpec Analyzer from Dade 
Behring (Marburg, Germany). IgG subclasses were measured by nephelometry 
with Behring BNA Analyzer using PeliClass reagents (Sanquin, Amsterdam, 
Th e Netherlands). 
Gene analyses
Allotypic markers G1ma and G1mf of IgG1 were detected with a double 
diff usion precipitation in gel (IsoGel Agarose, FMC BioProducts, Rockland, 
Maine, USA) containing 3.8 per cent of Polyethylene glycol 6000 (Fluka, 
Switzerland)312. Allotyping for IgG3 proteins was obtained as a byproduct of 
their quantitation with an inhibition ELISA as referenced326. Th e allotype-
specifi c reagents used were mAb clone 5E7 code 102 for G1ma, mAb clone 
12D9 code 301 for G3mb, mAb clone 8D10 code 303 for G3mg (Central 
Laboratory of the Netherlands Red Cross Blood Transfusion Service, 
Amsterdam, Th e Netherlands) and mAb GG-6 (Bio Makor, Rehovot, Israel) 
for G1mf. Allotyping of C4A and C4B proteins to detect C4 nulls (C4Q0) was 
performed electrophoretically from carboxypeptidase B (Roche Diagnostics 
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Gmbh, Mannheim, Germany) and neuraminidase (Sigma-Aldrich Chemie 
Gmbh, Type IV, Steinheim, Germany) treated serum samples followed by 
immunofi xation with polyclonal anti-C4 antibody (DiaSorin Inc, Stillwater, 
MN, USA) with the standard procedure216. C4A and C4B allotypes were run 
to specifi c positions on the gel in relation to the standards.
In Study I, the absence of a C4 isotype was confi rmed by isotype-specifi c 
PCR amplifi cation of C4A and C4B genes35. For quantitative analysis of 
C4A (II, III, IV) and C4B (III, IV) genes we used probe-based Scorpions 
technology384. Both probes and reverse primers were based on published 
primer sequences35. Th e tests employed 5-carboxyfl uorescein (FAM) -labeled 
Scorpions C4A and 6-carboxyrhodamine (ROX) -labeled C4B probes and 
an unlabeled reverse primer, according to manufacturer’s instructions with 
minor modifi cations. Th e actual probes were designed and manufactured by 
Eurogentec (Seraing, Belgium). Some of the samples were re-checked with 
unlabeled primers with SYBR Green QPCR (Stratagene, Cedar Creek, Texas, 
USA) or Absolute QPCR SYBR GREEN MIX (Abgene, Epsom, UK). 
In Study I, DNA samples were genotyped for HLA-A*, -B*, -C*, and -
DRB1* with commercial kits of Pel-Freez (PF-ABC-SSP, Brown Deer, WI, 
USA), One Lambda (SSP ABDR, Canoga Park, CA, USA) or INNO-Lipa 
(LiPA HLA-DRB1, Zwijndrecht, Belgium). In Study III, HLA-A*, -B*, 
and -DRB1* were typed (Biotest HLA-ABDR SSPtray, Biotest, Dreieich, 
Germany).
7.5 Statistical analyses
In Study I, no formal statistical analysis was performed. In Studies II-IV, 
diff erences in proportions between groups were tested by the χ2 or the 
Fisher’s exact 2-tailed test, as appropriate. Odds ratios (OR) and their 
confi dence intervals (CI) calculated with logistic regression analysis were 
used to measure the diff erences between the groups. Forward stepwise 
logistic regression was used to identify any potential predictors of CRRS, of 
frequent recurrences of genital herpes, and of severe chronic periodontitis 
from candidate variables in comparisons of these groups versus their control 
groups in the respective studies. In continuous variables, comparisons 
between more than two groups were done by non-parametric analysis of 
variance (Kruskal-Wallis test, Jonkcheere-Terpstra test for ordinal groups) 
If the variance analysis showed signifi cant diff erences between groups, 
the 2-sample t test with Bonferroni correction was used to locate them. 
In Study IV, the diff erences in the means of C3, C4, and classical pathway 
hemolytic activity of complement (CH50) between groups were evaluated 
by ANCOVA, and the results were presented with adjustment for age.. 
Correlations between continuous variables were studied with Spearman’s 
rhos. Stepwise linear regression was used to estimate the eff ect of C4 gene 
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numbers, age, and gender on the levels of C4 and CH50.
In Study II, ORs for C4 nulls were calculated with Epi Info version 6. In 
Study III, patients’ MHC haplotypes were constructed, using three markers 
(HLA-A*, -B*, -C*), by PHASE V.2.02 soft ware350, 351. For all other analyses, 
we used SPSS package for Windows, versions 12.0.1 (II, III) and 13.0.1 (IV). 
Missing values were excluded from the analyses.
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8. Results
By concurrently surveying multiple arms of immunity, we found subtle 
disturbances in adaptive or innate immunity or both in all our studied 
patient groups with exceptionally recurrent or chronic mucosal infections. 
To the best of our knowledge, our study was the fi rst to suggest the following 
associations: intraoral herpes and HLA homozygosity or total C4 isotype 
defi ciency or both; CRRS and C4A defi ciency or the combination of low 
plasma levels of IgG4 together with low levels of either IgG1 or IgG2 or 
both; frequently active genital HSV-2 infection and the G3mg,G1ma/a(x) 
haplotype or low plasma IgG1 or IgG3 concentrations or all; protection from 
herpetic neuralgias caused by HSV-2 and C4 defi ciencies; and severe chronic 
periodontitis and C4 defi ciencies. Somewhat surprisingly, this was the fi rst 
published study to assess the frequency of low Ig concentrations in ARS 
patients and of low IgG subclass concentrations in a carefully selected general 
adult population not consisting of blood donors. Th is was also the very fi rst 
study to associate a genetic polymorphism or mutation (G3mg,G1ma/a(x) 
haplotype), in a carefully characterized patient population, with frequently 
symptomatic typical genital herpes125, 181, 360.
Table 4.3 Percentage of subjects with C4A and C4B gene numbers fewer than two in 
study groups
Study group n < 2 C4A No C4A < 2 C4B No C4B < 2 C4A or 
C4B
Frequent intraoral 
HSV-1 recurrences1
3 33 33 67 67 100
Chronic or 
recurrent 
rhinosinusitis2
48 38 2 46 6 83
Acute 
uncomplicated 
rhinosinusitis2
50 8 4 48 4 56
No lifetime history 
of rhinosinusitis2
48 19 0 38 13 56
Frequent genital 
HSV-2 recurrences1
52 25 0 44 15 64
Severe chronic adult 
periodontitis1
37 22 0 54 8 76
Subjects from 
general population3
150 18 / 17 1 / 1 39 / 41 10 / 10 57 / 56
1Results obtained by genotyping. 2Results obtained by allotyping. 3Results obtained by allotyping 
/ genotyping.
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8.1 Frequently recurring intraoral herpes caused by HSV-1
In Study I, the three successive patients suff ering from exceptionally active 
intraoral HSV-1 infection were all found to be homozygous for their HLA-
A*, -B*, -C*, and DR1* alleles. Th ey also had a total C4A (1 patient) or C4B (2 
patients) defi ciency and reduced serum C4 levels. Th e patient with total C4A 
defi ciency had reduced serum CH50, and it was below the detection limit in 
the two patients with total C4B defi ciency. In Finns, the prevalence of HLA 
homozygosity for the 9 most common haplotypes is known to be in total 0.03. 
All three patients had low Ig (sub)class values. Patients 1 and 3 had low levels 
of the IgG1 subclass. Patient 2, a HLA A1*,B8*,DR3* homozygote, had a slightly 
decreased level of IgA.
8.2 Frequently recurring genital herpes simplex type 2 
infection
Th e 52 consecutive adult patients included in the Study III all had highly frequently 
recurring genital herpes caused by herpes simplex virus type 2 cultured from 
typical lesions (Table 4.4). 
Table 4.4 Characteristics of 52 patients suff ering from frequently recurring genital 
herpes
Characteristic Value
Male sex 19 (37)
Mean age at diagnosis (range) -yr 38.2 (23-62)
Mean duration of clinical disease at study entry (range) - yr 9.1 (2-32)
Mean number of recurrences (range) / yr 20 (10-48)
Severe fi rst symptomatic genital infection 22 (42)
Aft er fi rst clinical episode, patient-reported typical recurrences
Frequent recurrences within months 14 (27)
Frequency accelerating slowly over the years 28 (54)
Frequent recurrences delayed for over 2 years 10 (19)
Factors predisposing to recurrences
Stress 40 (77)
Disturbed diurnal rhythm 22 (42)
Sun exposure 16 (31)
Respiratory infections 15 (29)
Mechanical irritation 6 (12)
Premenstrual period (of women) 18 (55)
Mid-period (of women) 9 (27)
Atypical (aborted) lesions 11 (21)
Radicular neuralgias: 31 (60)
Only during prodrome 8 (15)
Duration > 24 hours aft er vesicle formation, not chronic 17 (33)
Chronic 6 (12)
Immunoglobulin G antibodies against herpes simplex virus type 1 23 (44)
NOTE. Values are n (%), if not otherwise specifi ed. From Study III, ref.327, with permission from 
University of Chicago Press.
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Recurrent extragenital vesicles were frequently seen (71%), most commonly 
on the lower back (37%). Postherpetic polyarthralgia, a rarely reported 
complication of genital herpes, was reported by 15% of the patients. 
Recurrent herpes in fi rst-degree relatives was reported by 42% of patients. 
Age, duration of clinical disease, severity of the fi rst clinical episode, or any 
other reported clinical manifestation – with the exception of neuralgias – did 
not associate with any measured immunologic variable.
Immunologic tests
Th e results of immunologic tests were then compared between the patients 
with genital herpes and the unselected control subjects. Total levels of plasma 
IgG, C3, C4, CH50, IgG1, and IgG3 were lower in the patients than in the 
control subjects (Table 4.5). Levels of IgM, IgA, IgG2, and IgG4 did not 
diff er between the groups. A decreasing linear trend in the levels of C3 (P 
= 0.016), CH50 (P = 0.023), IgG (P = 0.030), IgG1 (P < 0.001), and IgG3 (P 
= 0.003, Jonkcheere-Terpstra for all) was noted in the order: seronegative 
control subjects > seropositive control subjects > patients.
Table 4.5 Total plasma levels of complement-fi xing immunoglobulin subclasses 
G1 and G3 and complement studies in patients with frequent genital herpes 
recurrences and in control subjects.
Factor Patients 
(n = 52)
Controls 
(n = 150)
P1
IgG1, g/L (ref 4.9.-11.4 g/L) 5.96 (4.04-11.90) [4.05-11.07] 6.60 (2.88-13.30) [4.00-10.41] 0.004
IgG3, g/L (ref 0.2-1.1 g/L) 0.24 (0.05-0.61) [0.06-0.59] 0.32 (0.11-0.84) [0.13-0.67] 0.001
C3, g/L (ref 0.5-1.5 g/L) 0.91 (0.65-1.45) [0.66-1.39] 1.01 (0.49-1.58) [0.66-1.46] 0.002
C4, g/L (ref 0.15-0.5g/L) 0.17 (0.05-0.37) [0.06-0.36] 0.19 (0.04-0.34) [0.10-0.33] 0.040
CH50 IU/ml (ref 50-130 IU/ml) 93 (20-200) [25-187] 110 (30-200) [45-200] 0.005
NOTE. Data are median (range) [2.5th-97.5th percentile], unless otherwise specifi ed. CH50 was 
measured in serum, other parameters in plasma. CH50 = serum classical pathway hemolytic 
activity, values ≥ 200 counted as 200, ref = reference value. 1Mann-Whitney 2-tailed test. From 
Study III, ref.327, with permission from University of Chicago Press.
Of control subjects, 80 (53%) were HSV seropositive, and 19% were HSV-
2 seropositive. Th e frequencies of low levels of IgG1, IgG3 in patients and 
control subjects, as well as in the HSV seropositive and HSV seronegative 
control subjects are depicted in Table 4.6. 
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Table 4.6 Total plasma immunoglobulin levels associated with frequently active genital herpes 
simplex virus (HSV) type 2 infection in logistic regression analysis
Plasma 
Ig
level 
< 2 SD
Patients 
(n = 52)
All 
control subjects 
(n = 150)
HSV-seropositive 
control subjects 
(n = 80)
HSV-seronegative 
control subjects 
(n = 70)
No.(%) No.(%) OR (95%CI) P No.(%) OR (95%CI) P No.(%) OR (95%CI) P
IgG1 13 (25) 10 (7) 4.7 (1.9-11.5) 0.001 7 (9) 3.5 (1.3-9.4) 0.014 3 (4) 7.4 (2.0-27.8) 0.003
IgG3 18 (35) 21 (14) 3.4 (1.6-7.2) 0.001 12 (15) 3.0 (1.3-6.9) 0.010 8 (11) 4.1 (1.6-10.4) 0.003
IgG1 or 
IgG3 
28 (54) 28 (19) 5.1 (2.6-10.1) <0.001 19 (24) 3.7 (1.8-7.9) 0.001 9 (13) 7.9 (3.3-19.2) <0.001
Comparison of patients with control subjects and control subject subgroups with or without antibodies against 
herpes simplex HSV viruses type 1 or 2. CI = confi dence interval, OR = Odds ratio. From Study III, ref.327, with 
permission from University of Chicago Press.
Low total plasma IgG1 (4.7 [1.9-11.5] 0.001) and IgG3 (3.4 [1.6-7.2] 0.001) 
values were more common in the patients than in the control subjects. 
Diff erences remained in subgroup analyses. Th e biggest diff erence was 
seen in the frequencies of low IgG or IgG3 between patients and HSV-
seronegative control subjects (7.9 [3.3-19.2] < 0.001; Table 4.6). Th e levels 
of anti-HSV-2 subclass antibodies against gC-2 were not associated with 
frequent recurrences.
Genetic studies
In genetic studies, the G3mg,G1ma/a(x) haplotype was more common in 
patients than in seronegative control subjects (P = 0.047, χ2 test). In linear-
by-linear association analysis of diploid genomes, a trend appeared toward 
more common G3mg,G1ma/a(x) homozygosity in patients and G3mb,G1mf 
homozygosity in the HSV-seronegative control subjects (P = 0.056). Of the 
11 G3mg,G1ma/a(x) homozygous patients, 10 also had low IgG3 levels. 
Compared with the Finn90 historical control group A*32 (in 9 patient 
vs. 4 control genomes, P = 0.018), the haplotype B*15, DRB1*11 (4 vs. 
0, P = 0.017), and their combination A*32, B*15, DRB1*11 (3 vs. 0, P = 
0.048) were associated with frequent genital herpes. Th e haplotype A*2, 
B*15, DRB1*04 (0 vs. 10, P = 0.015), and its part B*15, DRB1*04 (1 vs. 
12, P = 0.036, Fisher’s exact 2-sided test without statistical correction for 
multiple comparisons for all) were more common in the control subjects. 
Th e frequencies of C4 nulls did not diff er between the groups. Th e numbers 
of C4 genes obtained by C4 allotyping and C4 genotyping, when the 2-bp 
insertion in exon 29 (codon 1213) of the C4A gene was counted as missing, 
were largely concordant (Table 4.7). In the testing of C4A gene numbers, 
discordant results were obtained in 2% of patients and 9% of control subjects, 
for C4B the corresponding frequencies were 4% and 5%. 
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Table 4.7 C4 gene numbers IV in immunophenotyping based on protein levels in 
serum compared with C4 gene numbers by real-time polymerase chain reaction. 
Data from Studies III and IV
Group C4  A  or  B 
number in 
phenotyping
C4A number 
in genotyping1
C4B number 
in genotyping
0 1 2 3 4 0 1 2 3
Severe genital 
herpes patients
(n = 52)
0 0 0 0 0 0 8 0 0 0
1 0 13 0 0 0 0 15 1 0
2 0 0 23 0 1 0 1 28 0
3 0 0 0 14 0 0 0 0 0
4 0 0 0 0 1 0 0 0 0
Unselected 
control subjects
(n = 150)
0 2 0 0 0 0 15 0 0 0
1 0 21 4 0 0 0 42 2 0
2 0 2 75 4 1 0 4 86 0
3 0 0 1 36 1 0 0 0 1
4 0 0 0 1 2 0 0 0 0
Severe chronic adult 
periodontitis patients
(n = 37)
0 0 0 0 0 0 3 0 0 0
1 0 8 0 1 0 0 16 0 0
2 0 0 13 0 0 0 0 17 0
3 0 0 0 13 0 0 1 0 0
4 0 0 0 0 2 0 0 0 0
Concordant results are highlighted. 12-bp insertion in exon 29 (codon1213) of the C4A gene 
counted as missing. 
Compared with the control subjects, C4 nulls were more frequent in patients 
without neuralgias (3.3 [1.1-10.4] 0.037) and without prolonged or chronic 
neuralgias (3.4 [1.3-9.3] 0.016) aft er adjustment for low IgG1 and IgG3. 
Within the patient group, C4 nulls were negatively associated with neuralgias 
(0.2 [0.06-0.81] 0.022) and prolonged or chronic neuralgias (0.2 [0.05-0.57] 
0.004). In forward stepwise logistic regression analysis, the frequencies of 
C4 defi ciencies and G3mg,G1ma/a(x) homozygosity were not signifi cantly 
diff erent between the patients and the control subjects.
Low IgG1 (4.9 [2.0-12.5] 0.001) and low IgG3 (3.6 [1.7-7.8] 0.001) 
were more frequent in the patients than in the control subjects (Table 4.8). 
Compared with seropositive control subjects, low IgG1 (4.2 [1.5-11.7] 0.007) 
and IgG3 (3.5 [1.5-8.3] 0.005) were more commonly found in the patients. 
In addition, low IgG1 (7.3 [1.9-28.2] 0.004) and low IgG3 (4.1 [1.5-10.6] 
0.005) were more frequent in patients than in seronegative control subjects. 
Only low IgG1 was more common when all infected persons (patients and 
seropositive control subjects) were compared with seronegative subjects 
(4.0 [1.1-13.9] 0.030; Table 4.8).
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Table 4.8 Total plasma immunoglobulin levels as risk factors for frequently active 
genital herpes, based on forward logistic regression analyses between patients 
with herpes simplex virus type 2 infection (n = 52), controls (n = 150), and control 
subgroups with (n = 80) or without (n = 70) antibodies against herpes simplex 
viruses type 1 or 2
Plasma 
levels
< 2SD
Patients vs. all control 
subjects
Patients vs. HSV-
seropositive control 
subjects
Patients vs. HSV-
seronegative control 
subjects
Patients and HSV-
seropositive control 
subjects vs. HSV-
seronegative control 
subjects
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
IgG1 4.9 (2.0-12.5) 0.001 4.2 (1.5-11.7) 0.007 7.3 (1.9-28.2) 0.004 4.0 (1.1-13.9) 0.030
IgG3 3.6 (1.7-7.8) 0.001 3.5 (1.5-8.3) 0.005 4.1 (1.5-10.6) 0.005 0.054
CI = confi dence interval, OR = odds ratio. From Study III, ref.327, with permission from University of 
Chicago Press.
8.3 Adult chronic or recurrent rhinosinusitis
According to the severity classifi cation methods we used, the recruited 48 
consecutive voluntary patients all suff ered from severe treatment-refractory 
chronic or recurrent rhinosinusitis (CRRS). Th e most common pathogens 
cultured from their sinus cavities were S. pneumoniae, H. infl uenzae, and M. 
catarrhalis. Repeatedly cultured S. aureus was more commonly found in patients 
with nasal polyposis than in those without it (P = 0.016, Fisher’s exact test). 
Subjects in the unselected group were on average 8.3 years younger 
than subjects in the other groups. CRRS patients had comorbidities more 
frequently than ARS patients (Table 4.9). Plasma and serum values in study 
groups are shown in Table 4.10.
Table 4.9 Comorbidities and clinical fi ndings in patients with chronic or recurrent 
rhinosinusitis (CRRS) compared with acute rhinosinusitis patients (ARS)
CRRS 
(n = 48)
no. (%)
ARS 
(n = 50)
no. (%)
Fisher’s
exact test
P-value
Any hypersensitivity 34 (71) 14 (28) < 0.001
Allergy 15 (31) 7 (14) 0.053
Nonallergic rhinitis 19 (40) 7 (14) 0.006
Nasal polyposis 29 (60) 3 (6) < 0.001
Bronchial asthma 27 (56) 4 (8) < 0.001
Nonsteroidal anti-infl ammatory drug hypersensitivity 14 (29) 0 (0) < 0.001
Current or previous smoking 13 (27) 29 (58) 0.002 
Septal deviation 10 (21) 2 (4) 0.014
Irritant rhinitis 6 (13) 5 (10) 0.471
Upper molar infection 1 (2) 15 (30) < 0.001
Nasal fractures 0 (0) 3 (6) 0.243
P-values < 0.05 are in bold type. Reproduced from Study II328, with permission from Blackwell 
Publishing.
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We searched for relevant diff erences, especially between the ARS and CRS 
patients. In multivariate logistic regression analysis of C4 defi ciencies, 
C4AQ0s were more common in the CRS than in the ARS patients (odds 
ratio [OR] 6.9; 95% confi dence interval [95% CI] [2.0-30.1]; P = 0.001) (Table 
4.3). In the CRRS patients, C4AQ0s (2.7 [1.3-5.6] 0.006) and any C4Q0s 
(3.7 [1.6-8.5] 0.003) were also more frequent than in the unselected group. 
Further, C4Q0s (3.9 [1.4-11.3] 0.005) were more common in the CRRS than 
in the healthy group, but in C4AQ0s (2.6 [0.9-7.5] 0.044) they did not reach 
signifi cance. We found no associations between C4AQ0s and any clinical 
comorbidities. When the American Rhinosinusitis Classifi cation, published 
aft er our study commenced (Table 3.3), was applied, C4AQ0s were not more 
common in either CRS or recurrent rhinosinusitis subgroup. C4AQ0 was 
less frequent in ARS patients than in the combined group, but the diff erence 
did not reach statistical signifi cance (P = 0.088, Fisher’s exact test).
M = male, F = female, P = plasma, S = serum, C = complement factor, Ig = immunoglobulin, 
1Kruskal-Wallis, 2Jonkcheere-Terpstra, 32-sample t test with Bonferroni correction for multiple 
comparisons, 4Fisher’s exact t test, 5Fisher’s exact test with Bonferroni correction, 6n= 46, 7CH50 = 
classical pathway hemolytic activity, values ≥ 200 counted as 200,hn= 47, CH50 was measured in 
serum, other parameters in plasma. P-values < 0.05 are in bold type. Reproduced from Study II328, 
with permission from Blackwell Publishing.
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Th e concentrations of C3, C4, IgA, IgM, IgG, IgG1, IgG2, IgG3, IgG4, 
and CH50 levels, frequencies of low values, and the results of statistical 
analyses between the groups are depicted in Table 4.10. Th ere were signifi cant 
diff erences in global P-values between the groups in plasma concentrations 
of C3, C4, IgG, IgG1, IgG2, IgG3, and CH50 levels. Levels of C3, C4, and 
CH50 had linear trends with the highest values in the ARS patients followed 
by CRRS, unselected, and healthy subjects. IgG and IgG2 levels had linear 
trends with the highest values in healthy subjects followed by unselected, 
ARS, and CRRS subjects. Plasma levels of C3, C4, CH50, and IgG2 were 
lower in the CRRS than in the ARS patients (Table 4.10).
Low IgG1, IgG2, IgG3, and IgG4 levels were common in all study groups. 
Global P-values between the groups reached signifi cance in low C4, IgA, 
IgG, IgG1, IgG2, and IgG3 values. Low IgA, IgG, IgG1, IgG2, IgG3, and IgG4 
were all more frequent in the CRRS patients than in the combined group 
subjects. However, only low IgA and low IgG1 were more frequent in CRRS 
than in ARS (Table 4.10). 
We then analyzed whether any combinations of low Ig class or subclass 
levels in plasma would more signifi cantly associate with CRRS than with ARS. 
Having a combination of low IgG4 with low IgG1 or IgG2 was signifi cantly 
more frequent in CRRS than in ARS patients (P = 0.030, Fisher’s exact t-test 
with Bonferroni correction). Th e same signifi cance was reached with low 
IgA (Table 4.10).
Th e relative contribution of low immunoglobulin levels and C4A nulls, 
taken into multiple logistic regression analysis as independent variables, 
were then studied. When CRRS patients were compared with the combined 
group, diff erences in C4AQ0 (2.89 [1.3-6.3] 0.007, low IgG1 (6.23 [2.7-14.5] 
0.001), low IgG2 (6.19 [1.8-21.0] 0.003), and low IgG3 (2.38 [1.04-5.4] 
0.039) remained signifi cant. When CRRS and ARS patients were compared, 
only C4AQ0 (7.65 [2.3-25.7] P = 0.001) and low IgG1 (3.6 [1.3-9.9] 0.013) 
remained signifi cantly more frequent in the CRRS patients. 
We then took all the questioned comorbidities (Table 4.11) and all 
the performed laboratory measurements into forward stepwise logistic 
regression analysis. In it, only four factors distinguished CRRS from ARS 
patients: nasal polyposis, asthma, C4AQ0, and low IgG4 together with IgG1 
or low IgG2 (Table 4.11). Having one of these factors diff erentiated a CRRS 
patient from an ARS patient with a sensitivity of 87.5% and specifi city of 
80%. Th e specifi city rose to 96% if two factors were present.
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Table 4.11 Clinical and immunologic risk factors for chronic or recurrent 
rhinosinusitis group (CRRS), based on forward logistic regression analysis with 
acute rhinosinusitis group (ARS) as control subjects
Risk factor OR (95% CI) P
Nasal polyposis 10.64 (2.5-45.7) 0.001
Bronchial asthma 8.87 (2.3-34.9) 0.002
Complement factor C4A null 5.84 (1.4-24.9) 0.017
Low immunoglobulin G4 with decreased G1 or G2 15.25 (1.4-166.8) 0.026
OR = odds ratio, CI = confi dence interval. Reproduced from Study II328, with permission from 
Blackwell Publishing.
8.4 Severe chronic adult periodontitis
According to the severity classifi cation methods we used, the recruited 37 
consecutive non-immunocompromised patients all suff ered from severe 
treatment refractory chronic adult periodontitis despite the regular (interval 
between visits: 5 +/- 1.5 SD [range 3-12] months) long-term treatment 
during their follow-up (15 +/- 5.1 [5-27] years). Th e patients were older (P 
< 0.001) and more oft en males (P = 0.004, Fisher’s exact 2-sided test) than 
the unselected control subjects. Of the 37 patients, 19 (51%) smoked.
Aft er age adjustment, the patients’ plasma concentrations of C3 were 
higher, and the CH50 levels lower than in the control subjects (Table 4.12). 
In control subjects, the levels of plasma C3, C4, and serum CH50 correlated 
with each other (P < 0.001 for all comparisons, Spearman’s rho). In patients, 
only the levels of C3 and C4 correlated with each other (P = 0.001, Spearman’s 
rho). 
Table 4.12 Diff erences between patients with severe adult chronic periodontitis and 
control subjects in complement levels
Parameter
g/L
Reference 
range
g/L
Patients 
(n = 37)
Control subjects 
(n = 150)
P
C3 0.5-1.5 1.22 (0.78-1.98) [1.12-1.30] 1.03 (0.49-1.58) [0.99-1.07] 0.001
C4 0.15-0.5 g/L 0.21 (0.11-0.48) [0.19-0.23] 0.20 (0.04-0.34) [0.19-0.21] 0.260
CH50 50-130 IU/ml 80 (25-200) [63-97] 116 (30-200) [109-123] <0.001
NOTE. Data are age-adjusted means (range) [95% confi dence interval], unless otherwise 
specifi ed. CH50 = classical pathway hemolytic activity, values ≥ 200 counted as 200. CH50 was 
measured in serum, other parameters in plasma. 1ANCOVA.
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In linear regression analysis, C4A gene numbers (P < 0.001), C4B gene 
numbers (P < 0.001), and age (P < 0.001), but not gender (P = 0.153) were 
associated with the level of plasma C4 in the study subjects. Each C4A gene 
raised the level of plasma C4 on average by 0.036 g/L, C4B gene by 0.044 
g/L, and each year of age by 0.001 g/L. No associations were found between 
C4 gene numbers and CH50 levels.
C4 gene numbers estimated by allotyping and genotyping were again 
largely concordant (Table 4.7). Frequencies of total C4A or C4B defi ciencies 
did not diff er between the groups. Having ≤1 C4A or C4B was not associated 
with the age of the subject, and was more frequent in patients than in control 
subjects (2.4 [1.1-5.5] 0.032). However, plasma C4 levels did not diff er 
between the groups.
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9. Discussion
9.1 Frequently recurring intraoral herpes caused by HSV-1
Due to the infrequent nature of HLA homozygosity and to the extreme rarity 
of frequently recurring intraoral herpes, the probability that consecutive 
patients suff ering this infection would, by coincidence, have the two combined 
seems minimal. HLA homozygosity is known to predispose to chronic viral 
infections and may limit the range of epitopes presented by infected cells 
and professional APCs67. Th is may lead to a less effi  cient immune response, 
already impaired by the various immune evasion mechanisms of HSV-1. 
HSV-1 is known to have immune evasion molecules that protect it from the 
HLA-mediated presentation of its antigens on the surface of the infected 
cell250. It also has eff ective immune evasion molecules against complement206. 
C4 isotype defi ciency may further contribute to the host’s susceptibility, 
because HSV-1, even more eff ectively than HSV-2, evades from the AP of 
complement105, 152, 206, 340, 364. 
Clinically, the patients suff ered from a highly debilitating disease. Th eir 
treatment with antiviral medication titrated to a high enough dose was highly 
eff ective. However, the treatment was complicated by its high cost. Th at the 
patients appear to suff er from an impairment of cell-mediated (HLA) or 
humoral (complement) immunity or both seems to support a decision to 
treat them actively. Due to the rarity of this disease form, it is unlikely that 
controlled treatment trials would become available soon. 
9.2 Frequently recurring genital herpes simplex type 2 
infection 
Compared with previous literature, male sex was found only infrequently 
(37%) in our highly symptomatic patients387. Radicular neuralgias in sacral or 
lumbar dermatomes or both were disturbingly common and had developed 
into chronic neuralgia in 12% of the patients (Table 4.4). 
For the fi rst time in literature, we found genetic polymorphisms of 
Ig genes associated with frequently recurring genital herpes in a well-
characterized patient population125. Of the 11 G3mg,G1ma/a(x) homozygous 
patients, 10 also had low IgG3 levels. Th is suggests that G3mg,G1ma/a(x) is a 
susceptibility haplotype, but only when it is present in conjunction with low 
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IgG3 (with which G3mg is associated)326. Both in vitro data on the function 
and allotype-specifi city of vFcR and genetic data from animal studies support 
this hypothesis21, 24, 246. Susceptibility to complicated or chronically active 
virus infection that is immunoglobulin allotype-specifi c has previously been 
suggested only in association with respiratory syncytial and hepatitis C virus 
infections, respectively29, 264.
Normal IgG1 levels were associated with HSV seronegativity. Since total 
plasma IgG1 and IgG3 levels were negatively associated with the disease or 
its activity or both, we may not yet know the epitope against which potential 
vaccines may need to be directed. Protective vaccines may also need to 
evoke, not only cellular immunity, but also IgG1- and IgG3-specifi c humoral 
immunity and ADCC90, 184. 
C4 nulls were negatively associated with neuralgias. It may thus be that 
the complement-mediated infl ammation evoked by recurrences is sometimes 
harmful to the host121. In frequently recurring genital herpes, neuralgic 
pain was surprisingly common and oft en the most distressing complication 
of the disease89, 91. It also interfered with the patient’s ability to work and 
seemed to have a tendency to become chronic. In animal models, antibody-
mediated immunity seems important in neuroprotection138, 229. In addition, 
the viral FcR formed by gE/I is required for axonal localization and cell-
to-cell spread279, 380. Antibody-mediated immunity may thus have a role 
in neuroprotection. However, no association between neuralgias and low 
antibody levels was found. Th e patient group studied was small, and low 
IgG1 and IgG3 levels were common in our patients. To study the role of 
antibodies in neuroprotection with suffi  cient statistical power would require 
a larger study. Th e eff ect of vaccines and antiviral medication on specifi c 
prevention of chronic neuralgia should be tested in the future. Whether 
eczema herpeticum could serve as an easy clinical marker of reduced 
antiherpetic immunity should also be tested in the future.
Due to the slow recruitment process, patients suff ering from frequently 
recurring oral-facial HSV-1 could not be studied. Whether the roles of 
diff erent arms of humoral immunity (antibodies, complement) in defense 
against HSV-1 and HSV-2 diff er could, therefore, not be addressed in this 
study. Patients with frequently active HSV-2, who suff er from a highly 
debilitating disease form that impairs self-esteem, every day activity, and 
sexual well-being, may oft en have a genetic predisposition to the disease. 
Th eir treatment with antiviral medication, with the treatment titrated to 
suffi  cient doses, was highly eff ective but complicated by the high cost of 
medication.
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9.3 Adult chronic or recurrent rhinosinusitis
Th e high frequency of low Ig subclass levels in the general population and 
in ARS patients potentially infl uences their use in the clinical practice27, 
192. Th e reference values of commercial tests used to measure IgG subclass 
levels are based on mostly unpublished data. Since the frequencies of 
especially low IgG1 and low IgG3 clearly exceeded the expected 2.5%, the 
usefulness of manufacturer’s reference values in the Finnish population may 
be limited. Th ough low IgG subclass levels were frequent in all our groups, 
their frequency seemed to be positively associated with the clinical severity 
of rhinosinusitis. Th ere were no clear cut-off  points which would have 
diff erentiated reliably between our study groups. Due to the complexity and 
redundancy of immunity, any “correct” reference values may be diffi  cult to 
determine and would require standardized methods and studies in clinically 
well-characterized and large populations262. 
Very little is previously known of the importance of complement-mediated 
immunity in defense against rhinosinusitis194, 199, 252, 288. In our study, the 
clinical (presumed) activity of sinus problems seemed to be associated with 
higher levels of the measured complement variables. Th us, defi ciencies in 
either or both arms of humoral immunity (complement and antibodies) 
may contribute to the etiopathogenesis of the disease. C4A defi ciency was 
more strongly associated with CRRS than any Ig value or combination of 
low Ig concentrations. It thus seems promising in patient assessment and 
needs to be tested further. Testing of subclass levels alone seems to be of 
limited value in the timely diagnosis and treatment of patients predisposed 
to chronic disease forms. We need immunologic parameters that would 
better predict end-organ damage in CRRS patients6, 69, 168.
Th e higher frequency of C4A nulls in CRRS than in ARS patients may 
be explained by its ability to regulate antibody production, by its function 
in defense against encapsulated pathogens or in the clearance of immune 
complexes, necrotic and late apoptotic cells presumably generated during 
ARS68, 84, 378. In addition, the associated full MHC haplotypes and either the 
existence of another functional gene in linkage disequilibrium with C4A 
nulls or of multiple functional polymorphisms in these MHC haplotypes 
may play a role168, 197. Despite the assumed role of C4B in defense against 
encapsulated pathogens, its frequency was, somewhat surprisingly, similar in 
the two patient groups. Comorbidities associated with hyper-infl ammation 
were common in patients with chronic forms of the disease, many of these 
(e.g. asthma, hypersensitivity) are known to have an immunologic basis. 
C4A, IgA, and IgG4 are thought to possess anti-infl ammatory functions2, 
38, 84, 97. Our fi ndings suggest that both factors impairing and enhancing 
immune responses need to be present simultaneously. Not only eff ective 
forms of infection prevention, but also anti-infl ammatory treatments may 
need to be clinically tested in rhinosinusitis patients. 
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9.4 Severe chronic adult periodontitis
Complement system appears important in the etiopathogenesis of chronic 
periodontitis. Plasma C3 concentrations were higher and CH50 levels lower 
in patients than in control subjects, but C4 concentrations did not diff er 
between the groups. Low CH50 levels have previously been reported15, 25, 
167, 233. Complement activation was not measured in our study. Th e levels of 
C4 and CH50 may refl ect a higher consumption of CP components together 
with AP (and CP) upregulation. C4 defi ciencies may predispose to severe 
chronic periodontitis. Th e combination of more frequent C4 defi ciencies in 
the patients but similar levels of C4 may also imply that either the numbers 
of C4A and C4B genes need to be balanced in order to protect against 
periodontitis, or that the surplus of C4 defi ciencies in patients was found 
by chance. 
Th e most common pathogen associated with periodontitis, Porphyromonas 
gingivalis, is known to be able to evade from and exploit complement283. 
C4 defi ciencies were more frequent in periodontitis patients, and they are 
known to be more frequent in atherosclerosis patients220, 354. Hypothetically, 
these diseases may share common susceptibility genes. In addition, an 
impaired defense against oral pathogens may predispose to atherosclerosis220, 
354. Quite likely, the predisposition to periodontitis depends on multiple 
polymorphisms of immunologically active genes present in an extended 
haplotype, and in linkage disequilibrium with each other349, 356. If genetic 
testing is attempted, to achieve good predictive value we would probably 
need to test multiple susceptibility genes317
9.5 General discussion: limitations and fi ndings of special 
interest in our studies
Th e prevalence of C4B defi ciency we found in the unselected group was 
the highest ever reported in any population. We conformed to the ethical 
regulations on genetic studies, and the control subjects were informed on 
the diseases we studied. Consequently, some of the control subjects in the 
unselected group may have suff ered from these diseases, and may have been 
more willing to participate because of this. We had no information on any 
diseases suff ered by the control subjects. Th is may have caused a selection 
bias: those aff ected may have been more willing to participate. Any such 
bias would, however, only diminish the diff erence in the prevalence of any 
defi ciency with an eff ect on the course of a disease. However, the frequencies 
of C4 defi ciencies or low Ig values did not diff er between the unselected 
group and the healthy blood donor group in Study II. 
In all our studies, the patients had more C4 null alleles (Table 4.3) and 
– when measured – also more IgG SCDs than the control subjects. Th is 
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did not reach signifi cance in the genital herpes study. To study whether C4 
defi ciencies are, in fact, overrepresented in herpes patients would require 
a larger study. Th e diff erence needed in the prevalences between groups of 
any studied clinical factor – to become potentially clinically relevant – is 
arbitrary, but should probably be larger than what was found in our study. 
Since immune evasion from complement by the closely related virus HSV-
1 is more eff ective than by HSV-2, our fi ndings may not be applicable to 
HSV-1.
In pilot case-control studies, reasonable numbers of recruited patients are 
small133. An association study is never able to prove any causal relationship 
between the factors studied88. In studies II and III, factors with statistically 
signifi cant diff erences in prevalence were commonly independent in logistic 
regression analyses. Susceptibility to common infectious diseases is likely to 
be polygenic. Linkage equilibrium frequently occurs in the human genome 
and in the genes aff ecting immunity. It is likely that multiple genes, acting 
in concert as haplotypes, have eff ects on disease susceptibility197. Th is 
phenomenon further constrains the interpretation of our fi ndings before 
further studies recruiting considerably larger numbers of study subjects are 
available. Multiple polymorphisms (e.g. in Toll-like receptor genes, cytokine 
genes) that are not in linkage disequilibrium may also, with the factors we 
studied, only together impart a clinically signifi cant genetic eff ect on disease 
susceptibility365.
Th e fi ndings in studies I and IV are interesting, but their interpretations 
are limited by the small numbers of patients studied and require further 
confi rmation. However, our fi ndings from the two larger studies seem 
particularly interesting. Our rhinosinusitis study was the fi rst study to 
compare the frequencies of low subclass levels in severely aff ected patients with 
patients having non-complicated disease forms or no disease. Th e methods 
and especially the reference values used in IgG subclass measurements 
vary greatly between manufacturers and clinical centers. Since subclass 
levels are commonly measured in clinical practice, these fi ndings may spur 
further studies on their clinical usefulness. Interestingly, the defi ciencies 
most strongly associated with chronic rhinosinusitis are also associated 
with not only impaired immune defense but also with hyper-infl ammation. 
Since the majority of patients coming for sinus operations benefi t from 
treatment, our fi ndings are likely to be applicable only to those with treatment 
refractory disease. Attempts to treat early with, for example, surgery or anti-
infl ammatory medication or both seem particularly attractive in patients 
found to have multiple subtle predisposing immunologic disturbances. If 
supported by further studies, the measurement of levels of plasma Ig classes, 
IgG subclass levels, and C4 null alleles together might become a useful tool 
in clinical practice.
We were also able to associate disease activity and severity of genital 
herpes with a functionally relevant genetic polymorphism encoding an 
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allotypic form of IgG121, 24, 206. Based on the results from basic immunology, 
herpes simplex virus type 1 is known to eff ectively evade from this allotypic 
IgG1206. Our fi ndings may spur further research directed to fi nd potentially 
important epitopes on HSV-2, against which vaccine-induced immunity 
would be eff ective184. It also encourages studies that would further test the 
ability of candidate vaccines to stimulate humoral immune responses against 
these epitopes184. Since these patients most likely have a genetic cause to a 
debilitating disease, this could have an eff ect on further clinical studies on 
disease management, on prevention of neurologic sequelae, and even on 
the right to receive reimbursable antiviral treatment.
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10. Conclusions 
1. Genetic complement factor C4A and C4B defi ciencies and low IgG subclass 
levels were common in the population. Th ere were no signifi cant diff erences 
in the frequencies of C4A and C4B defi ciencies or low IgG subclass levels 
between the general population and blood donors without a history of 
rhinosinusitis, even though low IgG subclass levels were somewhat more 
common in the general population. 
2. C4A defi ciencies, low IgG1 levels, and the combination of low IgG4 
together with low IgG1 or IgG2 were all more common in patients with 
chronic recurrent rhinosinusitis (CRRS) than in acute rhinosinusitis (ARS) 
patients.
3. Defi ciencies of C4 were also associated with chronic severe adult 
periodontitis. Low IgG subclass levels were associated with CRRS. Low 
IgG1 and IgG3 levels and the immunoglobulin heavy chain gene haplotype 
G3mg,G1ma/a(x) were associated with frequently recurring genital HSV-2 
infection. HLA-A*, -B*, and -DRB1* gene polymorphisms were associated 
with active genital herpes infection. HLA-A*, -B*, -C* and -DRB1* 
homozygosity, together with a total defi ciency of C4A or C4B isotype, may 
be associated with frequently recurring herpetic gingivostomatitis.
4. Genetic defi ciencies of C4 were negatively associated with radicular 
neuralgias in genital HSV-2 infection.
5. Th e new PCR-based quantitative analysis of C4A and C4B genes 
complemented the traditional C4A and C4B protein allotyping with 
reproducible results in patient analyses.
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11. Summary 
Th e present study addressed whether plasma concentrations of complement 
factors C3, C4, or immunoglobulins, serum CH50, or polymorphisms in 
the class I and II HLA genes, isotypes and gene numbers of C4, or allotypes 
of IgG1 and IgG3 heavy chain genes were associated with severe frequently 
recurring or chronic mucosal infections. Frequencies of low levels in IgG1, 
IgG2, IgG3 and IgG4 were also tested, for the fi rst time, from adult general 
population. According to strict clinical criteria, altogether 188 consecutive 
voluntary patients without a known immunodefi ciency and 198 control 
subjects were recruited. In the patients, other chronic or recurrent infections 
were infrequent.
Frequently recurring intraoral herpes simplex type 1 infections, a rare 
form of the disease, was associated with a total defi ciency of the C4A or C4B 
isotype, and with homozygosity in HLA -A*, -B*, -C*, and -DR* genes. 
Low plasma levels of IgG subclasses were common in the voluntary 
subjects from the general adult population. We also tested, for the fi rst time, 
the frequency of low subclass levels in acute rhinosinusitis. Low levels of IgA, 
IgG, IgG1, IgG2, IgG3, and IgG4 were all more frequent in patients with adult 
chronic or recurrent sinusitis than in presumably healthy control subjects. 
When patients having a chronic form of the disease were compared with those 
with an acute form, only low levels of IgG1 were more common in CRRS. 
Th e best immunologic parameter in diff erentiating between patients with 
complicated and uncomplicated forms of the disease was C4A defi ciency, 
and the combination of low plasma IgG4 together with either low IgG1 or 
IgG2 performed almost equally. Clinically, nasal polyposis and bronchial 
asthma were associated with complicated disease forms. C4A, IgA, and IgG4 
are known to possess anti-infl ammatory activity. Th eir lack, together with 
a concurrent subtly impaired immunity caused by low subclass levels, may 
predispose to chronic disease forms.
Frequently recurrent genital HSV-2 infections were associated with 
low levels of IgG1 and IgG3, present in 54% of the recruited patients. Th is 
association was partly allotype-dependent. According to previous studies, 
HSV eff ectively evades the allotype G1ma/ax of IgG1, whereas G3mg is 
associated with low IgG3. Th e G3mg,G1ma/ax haplotype, in association with 
low levels of IgG3, was more common in patients than in control subjects 
who lacked antibodies against herpes simplex viruses. Certain HLA genes 
were more common in patients than in control subjects. Having more than 
one C4A or C4B gene was associated with neuralgias caused by the virus. 
In severe chronic adult periodontitis, any C4A or C4B defi ciency combined 
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was associated with the disease. Lower levels of plasma C3 or C4 or both, 
and serum CH50 were found in herpes and periodontitis patients, when 
compared with control subjects. In rhinosinusitis, there was a linear trend 
with the highest levels found in the order: ARS > CRRS > general population 
> blood donors with no self-reported history of rhinosinusitis. Complement 
is involved in the defense against the tested mucosal infections. Th e new 
quantitative analysis of C4 genes and the conventional C4 allotyping method 
complemented each other.
Seemingly immunocompetent patients with chronic or recurrent 
mucosal infections frequently have subtle weaknesses in diff erent arms of 
immunity. Th eir susceptibility to chronic disease forms may be caused by 
these. Host’s subtly impaired immunity oft en seems to coincide with eff ective 
immune evasion from the same arms of immunity by the disease-causing 
pathogens. 
If subclass levels alone are tested without additional immunologic 
factors known to predispose to severe disease forms, their interpretation is 
diffi  cult and of limited value in early diagnosis and treatment. To prevent 
organ damage caused by frequent mucosal infections, early initiation of 
therapy would probably be required. Further easily applicable immunologic 
parameters are needed. 
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